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ABSTRACT OF THESIS 
The present study investigated the effects of four commonly used sugar alcohols (maltitol, myo-
inositol, sorbitol and erythritol) on intestinal glucose absorption and muscle glucose uptake as 
possible anti-hyperglycemic agents and their mechanisms of action using some ex vivo and in 
vivo experimental models.  
Data of the ex vivo study (experiment 1) showed that all sugar alcohol exhibited a 
concentration-dependent (2.5 – 20%) inhibitory effect on jejunal glucose absorption and 
enhancement of psoas muscle glucose uptake (with or without insulin) ex vivo. Maltitol showed 
the most potent inhibitory effect on intestinal glucose absorption (IC50 = 3.57 ± 1.18%) but poor 
muscle glucose uptake effect without insulin (GU50 = 111.12 ± 19.36) ex vivo. On the other hand, 
erythritol showed the most potent muscle glucose uptake effect with (GU50 = 2.02 ± 1.24%) or 
without insulin (GU50 = 6.91 ± 2.03%), but its inhibitory effect on intestinal glucose absorption 
ex vivo was not remarkable (IC50 = 55.90 ± 11.98%). Data of the in vivo glucose absorption study 
(experiment 2) revealed that excluding maltitol, a bolus tolerable dose of sorbitol (0.4 g/kg bw), 
myo-inositol (1 g/kg bw) and erythritol (1 g/kg bw) co-ingested with glucose (2 g/kg bw) 
significantly (p < 0.05) delayed gastric emptying, accelerated digesta transit and significantly (p 
< 0.05) reduced postprandial blood glucose increase as well as glucose absorption at the 
proximal quarter of the small intestine of normal and type 2 diabetic rats. Further in vivo glucose 
uptake study (experiment 3) arising from the outstanding ex vivo muscle glucose uptake 
potentials of erythritol revealed that a single bolus dose of erythritol (1 g/kg bw) appreciably 
improved glucose tolerance, insulin secretion, mRNA expression of muscle Glut-4 and IRS-1 as 
well as the activities of muscle and liver hexokinase, but suppressed the hepatic release of 
glucose in diabetic animals. 
Data of this study suggest that myo-inositol, sorbitol and erythritol, but not maltitol 
exhibited anti-hyperglycemic potentials, possibly via inhibiting intestinal glucose absorption and 
enhancing muscle glucose uptake. Hence, these agents may be further investigated to access their 
anti-hyperglycemic potentials to be used not only as sweeteners but also as supplements to the 






INTRODUCTION AND LITERATURE REVIEW 
 
1.1  General introduction and background 
Diabetes mellitus is a metabolic disorder caused by a defect in insulin secretion, insulin action, 
or both (Bastaki, 2005). Recent data from the International Diabetes Federation (IDF) reported 
that the global estimate of people with diabetes is about 415 million and this figure has been 
projected to become 642 million by 2040 (IDF, 2015). There are several types of diabetes, but 
among the two major types (type 1 and type 2), type 2 is more prevalent, accounting for more 
than 90% of all diabetes cases (Loghmani, 2005; Pratley, 2013). Type 2 diabetes (T2D) is 
described as a multifaceted and progressive disease that is linked to several metabolic defects 
and organ malfunction or damage (Pratley, 2013). The most prominent metabolic defects 
contributing to the pathogenesis and progression of T2D are impaired insulin secretion and 
insulin resistance in peripheral tissues, such as adipose, muscle and hepatic tissues (Pratley 
&Weyer, 2001; Kahn, 2003). Impaired insulin secretion is due to a progressive loss of pancreatic 
beta cell function and beta cell mass, which has been observed in the onset (pre-diabetes) and 
progression of T2D  (Pratley & Weyer, 2001; Kahn, 2003).  
Additionally, the interaction between several factors such as genetic, environmental and 
behavioural risk factors is strongly involved in the pathogenesis and progression of T2D 
(Olokoba et al., 2012; Wu et al., 2014). Behavioural risk factors are the most influential, which 
includes sedentary life style, routine consumption of high fat and high calorie diets as well as 
chronic consumption of refined and simple carbohydrates e.g. sucrose, fructose etc (Uusitupa, 
2002; Hu, 2003; Montonen et al., 2007). Several studies have consistently reported the role of 
sugar consumption in the development of T2D and metabolic syndrome (Elliottet al., 2002; 
Astrup et al., 2002; Hu & Malik, 2010; Stanhope, 2012). Accordingly, the use of sugar 
substitutes and non-nutritive sweeteners as part of diabetic and non-diabetic diets is increasingly 
gaining public endorsement in the management of diabetes, because they have minimal effect in 
increasing post-prandial blood glucose and caloric value compared to easily digestible simple 
carbohydrates such as glucose, sucrose and fructose (Talbot & Fisher, 1978; Brown et al., 2010). 
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Sugar substitutes are known for their sweetening ability and are usually used to replace 
regular table sugar in numerous edible products (Islam, 2011). They have negligible or reduced 
effect on blood glucose and insulin levels and also provide lower calorie compared to glucose 
and sucrose (Islam, 2011). Non-nutritive or artificial sweeteners like saccharin, aspartame, 
sucralose, neotame, ace-K etc are some of the sugar substitutes that are consumed by humans. 
They are characterized by an intense sweetening power ranging from 30-13000 times as well as a 
zero glycemic, insulinenic and caloric value compared to sucrose (O’Donnell & Kearsley, 2012; 
Fitch &Keim, 2012). 
Although non-nutritive sweeteners (NNS) are widely used in diabetic and non-diabetic 
diets with determined accepted daily intake (ADI), controversies regarding their safety has been 
documented (Tandel, 2011). This is because of some life threatening side effects such as 
carcinogenic or cancerous effects, migraines, genetic diseases, etc that may be associated with 
the chronic consumption of some of these NNS (Islam & Indarjit, 2012). Additionally, most of 
the time, it is not feasible to adhere to their determined ADIs, since NNS are used in many 
products consumed by people regularly. On the other hand, nutritive or reduced calorie 
sweeteners like sugar alcohols are non-synthetic and do not pose any life threatening side effects 
if consumed at tolerable dosages. The commonly used sugar alcohols are xylitol, erythritol, 
maltitol, isomalt, mannitol, myo-inositol, lactitol and sorbitol, which have a number of beneficial 
effects on health including dental protection (Van Loveren, 2004). They have lower caloric 
effect and glycemic response compared to glucose and sucrose (Livesey, 2003). They are used as 
sweeteners and additives in numerous dental and oral health products. Nevertheless, the 
beneficial effects of sugar alcohols are not limited to the above stated benefits. Data from several 
studies suggest that sugar alcohols may also possess anti-hyperglycemic potentials in normal and 
diabetic conditions (Ishikawa et al., 1996; Natah et al., 1997; Maeba et al., 2008; Islam and 
Indrajit, 2012; Kang et al., 2014; Chukwuma and Islam, 2015; Woelnerhanssen et al., 2016), 
which have not been completely elucidated so far. 
In a previous study, it has been reported that 14 days daily consumption of 20 g of 
erythritol significantly reduced blood glycated hemoglobin (HbA1c); relatively reduced blood 
glucose levels; and had no significant effects on serum lipids and renal function in subjects with 
non-insulin dependent diabetes mellitus (NIDDM) (Ishikawa et al., 1996). In other studies, 
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mannitol and lactitol has been reported to reduce hyperglycemia in healthy human subjects 
(Mӓkinen and Hӓmӓlӓinen, 1985; Natah et al., 1997). Furthermore, dietary myo-inositol 
significantly decreased blood glucose (Maeba et al., 2008) and also improved insulin sensitivity 
biomarkers in human subjects with metabolic syndrome (Giordano et al., 2011; Santamaria et 
al., 2012). Additionally, Moon et al. (1990) reported that dietary maltitol significantly reduced 
glycemic and insulin response compared to glucose in normoglycemic and diabetic subjects 
(Moon et al., 1990). In a more recent study, thein vitro α-glucosidase, α-amylase and sucrase 
inhibitory activities of some commonly used sugar alcohols was reported (Kang et al., 2014). 
TheJoint FAO/WHO Expert Committee on Food Additives (JECFA) has proposed that sorbitol 
may possess inhibitory effects on glucose absorption based on data from several studies (World 
Health Organization, 1985). In a very recent study, Chukwuma and Islam (2015) demonstrated 
the potency of xylitol on the inhibition of intestinal glucose absorption and enhancement of 
insulin-mediated muscle glucose uptake ex vivo and in normal and type 2 diabetic rats 
(Chukwuma and Islam, 2015). 
Despite the above-stated anti-hyperglycemic potentials of some commonly used sugar 
alcohols, further investigations are still required for most of them to elucidate their additional 
anti-hyperglycemic potency and the mechanisms of action. Therefore, the present study was 
conducted to investigate the effects of some selected and commonly used sugar alcohols on 
intestinal glucose absorption and muscle glucose uptake as a possible anti-hyperglycemic 
mechanism of action. 
 
1.2  Literature review 
1.2.1  Diabetes 
Diabetes has been a plague to man for more than 3000 years, which was initially characterized 
by the sweetness of the urine and blood of patients, first observed in ancient Indians (Ahmed, 
2002). As time progressed, the role of glucose metabolism and pancreas malfunction in the 
pathogenesis of diabetes was established (Ahmed, 2002; Piero et al., 2014). Presently, diabetes is 
defined as a multifaceted or heterogenous disorder that is peculiarly associated with abnormally 
high blood glucose due to endocrine and/or metabolic disorders (Lin & Sun, 2010). These 
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disorders lead to blurred vision, frequent hunger (polyphagia), weight loss, excessive urination 
(polyuria), increased thirst (polydipsia) and a compensatory increased fluid intake, which are the 
other clinical symptoms of diabetes other than hyperglycemia (Lin & Sun, 2010). Diabetes has 
been classified into several types based on the aetiology and clinical presentation. 
 
1.2.2  Types of diabetes 
There are several types of diabetes, which are classified based on their pathogenic processes. 
According to the American Diabetes Association (ADA), these include the auto-immune 
destruction of pancreatic beta cells, deficient insulin production or secretion and resistance of 
peripheral tissues to insulin action (ADA, 2004). These abnormalities may exist separately or co-
exists in patients having different diabetic conditions. The major types of diabetes are type 1 
diabetes (T1D), T2D and gestational diabetes. Other forms of diabetes-related endocrine or 
metabolic defects are closely associated with the pathophysiology of T1D and T2D. 
 
i) Type 1 diabetes or insulin-dependent diabetes mellitus 
This form of diabetes was formally referred to as insulin-dependent diabetes mellitus. It is 
caused by auto-immune destruction of the insulin-producing pancreatic beta cell, which causes 
insulin deficiency due to inadequate secretion of insulin by beta-cells (Atkinson & Eisenbarth, 
2001). Accordingly, patients with T1D may require exogenous insulin to compensate for 
depleted insulin secretion. Studies have shown that islet destruction by auto-antibodies is 
common among infants, who show early characteristic of islet auto-immunity as early as before 
the age of 2 years (Ziegler et al., 1999; Kimpimaki et al., 2002; Hummel et al., 2004). Hence, the 
name “juvenile-onset diabetes” was used to describe this form of diabetes. Several factors 
influence the development of T1D, including genetic, environmental and dietary factors, viral 





ii) Type 2 diabetes or non-insulindependent diabetes mellitus 
In the onset of T2D, peripheral tissues do not effectively respond to the insulin action in clearing 
of circulating blood glucose and pancreatic beta cells do not adequately secrete insulin hormone. 
Over time, type 2 diabetic patients experience persistent hyperglycemia due to partial pancreatic 
beta-cell dysfunction, impaired glucose tolerance and insulin resistance (Pratley & Weyer, 2001; 
Kahn, 2003). The inability of peripheral tissues to respond to insulin action is known as insulin 
resistance. 
 
iii) Gestational diabetes 
This is a type of hyperglycemia that is common to pregnant women, which is caused by glucose 
intolerance during the second to third trimester of their pregnancy (Buchanan and Xiang, 2005). 
Pregnancy causes a state of insulin resistance and hyperinsulinemia that may put pregnant 
women at risk of developing gestational diabetes (Buchanan &Xiang, 2005; Gilmartin et al., 
2008). Insulin resistance during pregnancy may be due to several reasons, including growth 
hormone alteration; secretion of cortisol, an insulin antagonist; increase in calorie intake and 
maternal adipose deposition; lactogen and insulinase secretion in the placenta (Gilmartin et al., 
2008). Between 2% to 5% of pregnant women encounter gestational diabetes, but varies 
according to the prevalence of type 2 diabetes (Xiong et al., 2001; Gilmartin et al., 2008). Risk 
factors of gestational diabetes include history of macrosomia (birth weight > 4000 g), polycystic 
ovarian syndrome, obesity, hypertension, persistent glucosuria, spontaneous abortions as well as 
a family history of diabetes (Xiong et al., 2001; Gilmartin et al., 2008). Supporting data have 
shown a correlation between child birth weight above the 90th percentile and increasing plasma 
glucose levels (HAPO study, 2008). 
 
iv) Other specific diabetes-related defects and causes 
There are other types of diabetes-related defects that could be associated with hyperglycemia. 
Some forms of diabetes are linked to a genetic defect of genes (e.g. glucokinase gene) and gene 
transcription factors (e.g. hepatocyte nuclear factor (HNF)-1α, HNF-4α, HNF-1β and insulin 
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promoter factor (IPF)-1), which are involved in glucose metabolism (ADA, 2004). These 
defected genes or transcription factors can be inherited in an autosomal dominant pattern. They 
usually occur at the onset of maturity in patients (mostly before 25 years of age).  A typical 
example is the defect that is associated with mutation on chromosome 7p of the glucokinase 
gene, which causes an altered insulin secretion and eventually, hyperglycemia (ADA, 2004). 
Another example is the mutation of insulin receptor genes, which adversely affect insulin action 
on peripheral tissues as well as cellular uptake of circulating glucose. 
Furthermore, pancreatic injuries and infections such as pancreatitis, trauma, viral 
infection, pancreatectomy and pancreatic carcinoma can damage the pancreas and eventually 
cause diabetes due to insufficient insulin secretion to regulate blood glucose. Additionally, 
exogenous substances such as drugs and chemicals may also induce diabetes by either impairing 
insulin secretion and action or acting as a toxin that can permanently damage pancreatic beta-cell 
(Blackburn & Wilson, 2006; Rehman et al., 2011; Tripathi & Verma, 2014). In some other 
instances, diabetes can be caused by genetic in-born error syndromes. For example, in Wolfram’s 
syndrome there is an autosomal recessive disorder that is linked to insulin-deficiency and 
absence of β-cells at autopsy, which causes diabetes insipidus (ADA, 2004). Finally, some 
hormones e.g. growth hormone, cortisol, glucagon, and epinephrine are known to be insulin 
antagonists, because they can antagonize the action of insulin (Lager, 1991) and consequently 
predispose victims to hyperglycemia. 
 
1.2.3 Prevalence of diabetes 
Diabetes is a serious threat to global public health, which has become a major cause of morbidity 
and mortality around the world including in the developed countries (Menke et al., 2015). The 
prevalence of this disease is tremendously increasing with population growth due to aging, 
urbanization, unhealthy eating habit, sedentary life style and increasing prevalence of obesity 
(Wild et al., 2004). About 171 million people of all age group worldwide (approximately 2.8%) 
were diagnosed to have diabetes in the year 2000, and this figure has been predicted to increase 
to about 336 million people (approximately 4.4% ) by the year 2030 (Wild et al., 2004). 
Demographic studies suggest that this increase is mainly in the proportion of people > 65 years 
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of age. As at 2015, the global figure of people living with diabetes between age 20 and 79 years 
was already about 415 million (meaning approximately 1 in every 11 adult is diabetic) (IDF, 
2015). The new projection of diabetes by the year 2040 is approximately 642 million (meaning 
approximately 1 in every 10 adult will be diabetic) (Table 1.1) (IDF, 2015). Additionally, the 
global health expenditure to treat diabetes and prevent complications was more than 600 billion 
USD in the year 2015, making diabetes a significant opposition to economic development and 
sustainable growth of healthcare systems (IDF, 2015). 
 
Table 1.1: Global percentage of people (20-79 years) living with diabetes in 2015 and projection 
for 2040 (IDF, 2015) 
 2015 2040 
Approximate number of people (million) 415 642 
Approximate global percentage of diabetes prevalence (%)  9 10 
   
 
 
Projections have shown that this increasing diabetes prevalence is becoming a serious 
health problem in Africa compared to other global regions. Although from 2011 to 2015 Africa 
has shown the lowest number of people (between age 20 and 79 years) living with diabetes 
compared to other global regions (IDF, 2011; 2013; 2015), the percentage increase (140.8%) by 
the year 2040 has been predicted to be the highest (Fig 1.1) (IDF, 2015). In South Africa for 
example, the number of adults between ages 20 to 79 years with diabetes in 2012 was 
approximately 6.3% , when  high prevalence has been reported among the black, coloured and 
Indian population (Amod et al., 2012; Erasmus et al., 2012), and about 50-85% of diabetic 




Figure 1.1: Global estimate of people (20-79 years) living with diabetes in 2015 and projections 
for 2040 (Adapted from IDF Diabetes Atlas, 2015). 
 
As mentioned above, T2D is the most prevalent type of diabetes; accounting for 90% - 
95% of all diabetic cases worldwide (Loghmani, 2005; Sheri et al., 2010). Additionally, T2D is 
strongly influenced by dietary related factors, such as unhealthy eating habits, which is a major 
problem in our present society. Our present study was therefore centered on T2D. Type 2 
diabetes (T2D) like other types of diabetes presents persistent hyperglycemia as a major 
diagnostic manifestation, which is exclusively due to a derangement in glucose metabolism 
(Aronoff et al., 2004). In order to understand the etiology and pathophysiology and management 
of type 2 diabetes, it is rational to first review and understand the normal physiological 
metabolism of carbohydrate and glucose. 
 
1.2.4 Carbohydrate metabolism and blood glucose regulation 
The major source of dietary glucose for humans is starch, which releases glucose upon complete 
digestion or hydrolysis. Glucose is majorly absorbed from the small intestine into circulation 
thus influencing postprandial blood glucose. Therefore, the degree of glucose absorption and the 
blood level of postprandial glucose can be influencing factors in hyperglycemia-related disorders 
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like diabetes, obesity and related metabolic diseases (Dhital et al., 2013). Glucose is completely 
and rapidly absorbed from the small intestine, but absorption capacity may be different for 
different intestinal segments. Previous studies suggested that the highest glucose absorption 
capacity is exhibited by the proximal (Rider et al., 1967) or mid small intestinal segment (Lavin, 
1976).  Another study conducted on female chicks suggested that the duodenum may account for 
most glucose absorbed (Riesenfeld et al., 1980). 
Furthermore, gastric emptying and digesta transit can also affect nutrient (including 
glucose) absorption from the small intestine (Islam and Indarjit, 2012). Gastric emptying rate 
means the rate at which nutrients or food is emptied from the stomach to the small intestine, 
while digesta transit rate is the rate at which digesta in the gut moves through the intestine. It has 
been previously reported that delayed gastric emptying and accelerated intestinal transit can 
result in reduced intestinal nutrient absorption (Salminen et al., 1984; Shafer et al., 1987). Anti-
diabetic drug like acarbose have also been suggested to reduce or control postprandial blood 
glucose by partly delaying gastric emptying (Ranganath et al., 1998). 
After absorption, glucose immediately circulates in the blood thus causing elevated blood 
glucose. Accordingly, the human normal physiology is equipped with several interrelated 
mechanisms to adequately normalize blood glucose level and regulate blood glucose homeostasis 
(Fig. 1.2). Ideally, blood glucose level or concentration is mainly determined by the amount of 
glucose entering into the blood and the counter-balancing of glucose removal from circulation. 
Three major metabolic processescontribute to blood glucose pool; dietary intestinal glucose 
absorption during fed state, glycogenolysis (hepatic glycogen release of glucose) and 
gluconeogenesis (glucose production primarily from lactate and amino acid precursors) during 
fasting state (Aronoff et al., 2004). On the other hand when blood glucose rises due to metabolic 
processes that contribute to systemic glucose pool, it is counter-balanced by two major metabolic 
processes that facilitates the clearance of circulating glucose: glycogenesis (hepatic glycogen 
synthesis from glucose for storage) and glucose uptake by peripheral tissues for metabolic 
functions (Aronoff et al., 2004). Glucagon hormone is the major hormone that up regulates 
metabolic processes like glycogenolysis and gluconeogenesis, which favours systemic glucose 
appearance. Insulin, on the other hand, is the major hormone that up regulates metabolic 
processes like glycogenesis and peripheral glucose uptake, which favours systemic glucose 
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disappearance (Aronoff et al., 2004). This bi-hormonal glucose homeostasis model functions to 
maintain a normal range of circulating glucose concentration. 
 
 
   (a)           (b) 
Figure 1.2: Normal regulation of glucose homeostasis. In a fed state (a): Insulin, amylin and 
GLP- suppresses glucagon secretion and action (1), which inhibits hepatic glucose production 
(2). Amylin and GLP-1 via a neural pathway (3) reduces gastric emptying rate (4). Insulin 
promotes circulating glucose disappearance (5) via glucose uptake in peripheral tissue (6) and 
hepatic glycogenesis (7). In the fasting state (b): Insulin suppression on glucagon is down 
regulated (1) and glucagon stimulates hepatic glycogen break down (glycogenolysis) (2). Insulin 
stimulates glucose uptake into peripheral tissues (muscle and adipose) (3). 
 
During fasting state (Fig. 1.2), circulating glucose is cleared at a constant rate. In order to 
counter-balance circulating glucose disappearance, the body is required to produce glucose 
endogenously. In the first 8 to 12 hours of fasting, glucagon released by the pancreatic alpha 
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cells stimulates hepatic glycogenolysis, which is the major or sole source of endogenous glucose. 
But after prolonged fasting, endogenous glucose is additionally made available by hepatic 
gluconeogenesis, which is also upregulated by glucagon hormone (Aronoff et al., 2004). After 
feeding (Fig. 1.2), blood glucose reaches its post-meal peak value, but gradually decreases with 
time and eventually returns to fasting level, due to circulating glucose clearance. Insulin is the 
major glucoregulatory hormone that is secreted by the pancreatic beta cells during fed state and 
when blood glucose elevates. Insulin hormone enhances circulating glucose removal by 
stimulating hepatic glycogenesis and storage of glycogen as well as glucose uptake in peripheral 
tissue (majorly skeletal muscle and adipose tissues), while suppressing the secretion and action 
of glucagon hormone (Gerich et al., 1974; Wallum et al., 1992; Gerich, 1993). Glucose entering 
peripheral tissues especially muscle and fat tissue is majorly metabolized at cellular level via an 
initial glycolytic process to provide chemical energy required for cellular function or used as a 
precursor for fatty acid synthesis (Aronoff et al., 2004). 
The insulin-mediated glucose uptake in peripheral tissues, especially muscle tissue is a 
complex signalling pathway that is made up of a cascade of enzymes and signalling factors at 
cellular or molecular level (Fig. 1.3). Glucose is the major endogenous stimulus of insulin 
secretion, which enters into the blood after secretion. Once insulin gets into circulation, it acts as 
a ligand that binds to the extracellular α-subunit of membrane-bound insulin receptor molecule 
(glycoprotein) to form an insulin receptor-ligand complex (Van Obberghen et al., 2001). Binding 
of insulin causes a conformational change on the intracellular catalytic domain (β-subunit) of 
insulin receptor molecule, which results in the activation of tyrosine kinase unit of the catalytic 
domain (Van Obberghen et al., 2001; Chang et al., 2004). Activated tyrosine kinase then 
phosphorylates the tyrosine unit of intracellular substrates such as the insulin receptor substrate 
family (IRS 1, 2, 3 and 4). Phosphorylated IRS family then display binding sites for numerous 
signalling partners, such as Phosphoinositide 3-kinase (PI3-K) and Mitogen-activated Protein 
Kinase (MAP-Kinase), which both play major roles in the metabolic function (glycogenesis, 
peripheral tissue glucose uptake and glucose oxidative metabolism) and mitogenic function (cell 
growth and gene expression regulation) of insulin respectively (Chang et al., 2004; González-






Figure 1.3: Cellular insulin signalling pathway and insulin-mediated glucose uptake (Adapted 
without permission from González-Sánchez & Serrano-Ríos, 2007). 
 
Phosphoinositide 3-kinase (PI3-K) is activated on binding to IRS-1 and initiates a 
downstream cascade of events leading to activation of Akt (a serine/threonine protein kinase 
identified as one of the downstream targets of activated PI3-K) (González-Sánchez & Serrano-
Ríos, 2007). Activated Akt induces the translocation of glucose transporter type 4 (Glut-4) to the 
plasma membrane and influx of glucose for glycogen synthesis, glycolysis, fatty acid synthesis 
etc (Lizcano & Alessi 2002; Chang et al., 2004; González-Sánchez & Serrano-Ríos, 2007). 
 
1.2.5 Etiology and pathophysiology of T2D 
In the premature stage and during the early progression of T2D (pre-diabetes), the action of 
insulin becomes abnormal, which is observed as the loss of timeous postprandial response of 
insulin (Kahn, 2000). At this stage, an individual may show blood glucose level that is higher 
than normal but not high enough to be classified as full-blown diabetes. Progressively, insulin 
resistance in peripheral tissues, coupled with partial pancreatic beta cell dysfunction as well as 
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reduced availability and potency of insulin contribute to the clinical features and manifestation of 
persistent or chronic hyperglycemia in T2D (Toft-Nielsen et al., 2001; DeFronzo, 2004). 
Insulin resistance can be described as a pathological condition in which cells do not 
adequately respond to the normal signalling and action of insulin hormone, which predisposes an 
individual to the development of T2D. Insulin resistance can manifest as failure of insulin to 
facilitate circulating glucose uptake in peripheral tissues for energy production via glycolysis and 
TCA cycle or glycogenesis. It can also manifest as failure to suppress the secretion and action of 
glucagon as well as metabolic processes (glycogenolysis and gluconeogenesis) that promotes 
circulating glucose appearance andhyperglycaemia (Olefsky & Nolan, 1995). Additionally, since 
insulin is also functional in the regulation of physiological fat metabolism, insulin resistance can 
also cause a defect in fat metabolism, which can be linked to the development of several 
diabetes-related metabolic disorders or complications such as obesity, hypertension, 
hyperlipidemia, atherosclerosis and metabolic syndrome (Kahn and Flier, 2000; Haag & 
Dippenaar, 2005; Rabol et al., 2011). 
Insulin resistance can occur at any stage of insulin signalling pathway starting from the 
binding of insulin to insulin receptor to the insulin-mediated Glut-4 translocation and cellular 
influx of glucose molecules (Olefsky & Nolan, 1995; Petersen & Shulman, 2006). A disorder in 
the insulin signalling will result inreduced insulin-induced glucose uptake in peripheral tissues 
and eventually, hyperglycemia. It has been previously reported that patients with non-insulin-
dependent diabetes mellitus possessed insulin receptors with diminished autophosphorylation 
(kinase) activity of the catalytic domain, which contributed to the severity of fasting 
hyperglycemia (Olefsky & Nolan, 1995). Additionally, the inhibition of insulin-stimulated IRS–
1 tyrosine phosphorylation and the subsequent suppression of IRS-1–mediated activation of PI3-
K can also result in reduced sensitivity of peripheral tissues to insulin action (Petersen and 
Shulman, 2006). 
As a result of insulin resistance in peripheral tissue, the pancreatic beta cells adopt a 
compensatory role (secretion and release of more insulin into the blood) to accommodate for the 
non-responsiveness of cells to insulin action. This will eventually lead to excessive levels of 





Figure 1.4: Schematic diagram showing the changes in beta-cell mass and insulin secretion 
accompanying progression of T2D (Adapted without permission from Souza et al., 2006). 
 
Hyperinsulinemia promotes elevated energy storage in adipocytes and formation of fatty 
tissues, which may increase risk of hypertension, obesity, dyslipidemia hypertriglyceridemia, and 
glucose intolerance, collectively referred to as metabolic syndrome (Modan et al., 1985; Shanik 
et al., 2008). Additionally, the compensatory role adopted by the pancreatic beta-cell due to 
insensitivity of cells to insulin action may gradually become exhaustive. Eventually, this 
adversely affects the pancreatic beta-cell function and physiology; a condition that is referred to 
as partial pancreatic beta-cell dysfunction (Fig. 1.4) (Cnop et al., 2005; Souza et al., 2006). 
In a previous study, Ogawa et al. (1992) demonstrated that insulin resistance, beta-cell 
dysfunction and impaired insulin secretion were inter-related in the development of T2D (Ogawa 
et al., 1992). Their study showed that despite the presence of insulin resistance in both diabetic 
and non-diabetic rats, the mass of the islet and insulin secretion of diabetic rats was lesser 
compared to non-diabetic rats, which suggested the presence of impaired insulin secretion in the 
diabetic animals due to beta cell derangement. Accordingly, they concluded the co-existence of 
insulin resistance and pancreatic beta-cell in the pathophysiology of T2D. 
Additionally, abnormal gastric emptying has been observed during type 1 or type 2 





1.2.6 Role of gastric emptying in the pathophysiology of T2D 
Gastric emptying is normally delayed in the fed state by the action of amylin and GLP-1 in order 
to regulate postprandial glycemia (Fig. 1.1). Although the prevalence is controversial, studies 
have suggested that gastric emptying is often accelerated, especially during the early stages of 
T2D (Phillips et al., 1991; Horowitz et al., 1996). In our recently published study, we observed 
that induction of T2D in rats significantly increased gastric emptying rate of normal rats 
(Chukwuma & Islam, 2015). Accordingly, we hypothesized that accelerated gastric emptying 
may partly contribute to the frequent hunger (polyphagia) that is observed during diabetes, 
because of the previously reported correlation between faster gastric emptying and reduced 
satiety or increased food intake in healthy male subjects (Zhu et al., 2013). Additionally, since 
the concentration of postprandial glucose and insulin secretion is related to gastric emptying rate 
(Horowitz et al., 1993), accelerated gastric emptying may translate into a faster increase of 
postprandial blood glucose concentration. This is mostly accompanied by apoorly timed insulin 
delivery, which may eventually aggravate or worsen postprandial hyperglycemia (Phillips et al., 
1991). 
 
1.2.7 Complications of T2D 
Due to uncontrolled hyperglycaemia, more than 50% people suffer from one or more diabetic 
complications including diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, 
diabetic neuropathy and diabetic food disease (Litwak et al., 2013). Most diabetic complications 
are responsible for the increasing morbidity and mortality associated with diabetes. Diabetic 
complications are broadly classified into acute and chronic complications. 
 
i) Acute complications 
The acute complications include diabetic ketoacidosis, nonketotic hyperglycemic coma as well 
as hypoglycaemia and hypoglycaemic reactions, which are basically due to metabolic and 
glucose level alterations (Henry, 1987). Diabetic ketoacidosis is due to insulin deficiency in the 
presence of hyperglycaemia, which leads to increase in lipolysis and ketone bodies production, 
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and eventually increase in blood acidity (blood pH ≤ 7.3) (Faich et al., 1983). Diabetic 
ketoacidosis can also lead to diabetic coma (Faich et al., 1983, Henry, 1987). 
Non-ketotic hyperglycemic coma is also called hyperosmolar hyperglycemic non-ketotic 
coma. It is also due to insulin deficiency in the presence of hyperglycemia, although the insulin 
deficiency is not enough to cause increased lipolysis and ketone bodies production. However, the 
presence of hyperglycemia causes elevated serum osmolality, which leads to polyuria, excessive 
dehydration, seizures and coma (Loewen & Haas, 1991). Most of the long-term or chronic 
diabetic complications are more detrimental than acute diabetic complications (Fowler, 2008). 
 
ii) Chronic complications 
Chronic diabetes complications are associated with direct and/or indirect severe hyperglycemic 
effect on the human vascular tree, which are the major causes of morbidity and mortality in 
diabetes. They can be sub-classified into the microvascular and macrovascular complications. 
 
(a) Microvascular complications 
Microvascular diabetic complications are associated with small vessels such as capillaries-related 
problems. Several theories have been suggested in an attempt to elucidate the pathophysiology of 
microvascular complications associated with T2D. The polyol pathway and oxidative stress are 
some of them (Fowler, 2008). 
The intracellular polyol pathway consists of an initial aldose reductase-catalyzed reaction 
that may be involved in the development of type 2 diabetic complications. Aldose reductase 
catalyzes the conversion of glucose to sorbitol. In hyperglycemic state, more sugar molecules 
flux through the polyol pathway, which causes accumulation of sorbitol in cells. Sorbitol 
accumulation in cells can result in osmotic stress, which has been hypothesized as an underlying 




Furthermore, hyperglycemia-induced oxidative stress has been implicated in the 
symptoms, progression and complications of T2D (Giugliano et al., 1996; Pourghassem-Gargari 
et al., 2011). Persistent hyperglycemia is responsible for elevated superoxide ion production, 
glucose oxidation, protein glycosylation, formation of advanced glycation end products (AGEs) 
and lipid peroxidation, which facilitate the production of pro-oxidants such as free radicals and 
reactive oxygen species (Wiernsperger, 2003). Oxidative stress sets in when the generated pro-
oxidants surpasses the body’s antioxidant defence system. Reactive oxygen species play a major 
role in cellular damage during oxidative stress, which contributes to diabetic microvascular 
complications. Animal studies have demonstrated that treatment with vitamin E, a known anti-
oxidant molecule may be useful in ameliorating diabetes-associated microvascular dysfunction 
(Kunisaki et al., 1995). 
The notable forms of diabetes-associated microvascular complications are called diabetic 
retinopathy, diabetic nephropathy and diabetic neuropathy. 
 Diabetic retinopathy 
Diabetic retinopathy may be the major cause of blindness in developing and developed 
countries (Fowler, 2008; Singh et al., 2008). It is characterized by the dysfunction of retina 
and/or the macula, which can lead to visual problem and eventually, partial or total blindness 
in type 2 diabetic patients. The loss of pericytes and microaneurysm formation are the 
predominant marker for diabetic retinopathy (Fowler, 2008; Singh et al., 2008). 
The pathogenesis of diabetic retinopathy is still not clear and remains a subject of debate. 
However, there are several theories which explain the pathophysiology of diabetic 
retinopathy. Sorbitol-related osmotic stress and electrolyte imbalance due to increased 
metabolic flux of the polyol pathway are important catalysts of retinal pericytes death and 
microaneurysm formation (Kubawara and Cogan, 1962; Fowler, 2008). Also, the normal 
hemodynamics of the retina can be altered due to distortion of the inner blood retinal barrier 
and extracellular fluid deposition (Williamson & Kilo, 1984; Ferris & Patz, 1984). 
Furthermore, AGEs and glycated proteins can also cause injury to pericytes leading to loss of 
pericytes. There are evidences in animal studies where AGEs was associated with the loss of 
pericytes and formation of microaneurysms (Fong et al., 2004). Additionally, growth factors 
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such as vascular endothelial growth factor (VEGF), growth hormone, and transforming 
growth factor β have also been suggested to participate significantly in the development of 
diabetic retinopathy. Notable increases in VEGF production have been reported in diabetic 
retinopathy (Aiello et al., 1995; Keenan et al., 2007), perhaps due to hypoxia. Additionally, 
previous studies have also reported that the progression of retinopathy was impaired in 
animal models due to suppression of VEGF production (Aiello et al., 1995). 
 
 Diabetic nephropathy 
Diabetic nephropathy is the leading cause of renal failure in majority of elderly people 
seeking kidney disease therapy (Parchwani & Upadhyah, 2012). It is characterized by 
persistent occurrence of increased urinary albumin excretion (microalbuminuria and 
macroalbuminuria) in diabetic patients, without manifestation of other renal disease 
symptoms (Gross et al., 2005). Early clinical diagnostic markers of diabetic nephropathy 
include microalbuminuria (30-300 mg/day), glomerular hyperfiltration, glomerular and renal 
hypertrophy, increased glomerular basement membrane thickness, microaneurysm formation 
and mesangial nodule formation (Kimmelsteil-Wilson bodies) (Gross et al., 2005, Fowler, 
2008). Without therapeutic intervention microalbuminuria in diabetic patients progresses into 
an advanced stage of overt diabetic nephropathy, characterized by proteinuria, 
macroalbuminuria (>300 mg/day), progressive deterioration in the rate of glomerular 
filtration and creatinine clearance as well as glomerulosclerosis (Gross et al., 2005, Fowler, 
2008; Parchwani & Upadhyah, 2012). 
Genetic factor, race and gender susceptibility, high-protein diet, smoking, aging, 
hypertension, hyperglycemia and hyperfiltration have been identified as notable risk factors 
in the development and progression of diabetic nephropathy (Ayodele et al., 2004). However, 
theories put forward suggest that growth factor and cytokines; hemodynamic factors such as 
Angiotensin II and Endothelin; protein glycosylation; AGEs formation; polyol and protein 
kinase C pathways are involved in the underlying mechanisms behind the pathophysiology of 




 Diabetic neuropathy 
According to the American Diabetes Association (ADA), diabetic neuropathy is described as 
the occurrence of clinical symptoms of peripheral nerve dysfunction in diabetic individuals 
without the presence of other nondiabetes-related peripheral nerve dysfunction (ADA, 2007). 
Like other diabetes-associated microvascular complications, the risk of developing diabetic 
neuropathy is a function of the intensity and persistence of hyperglycemia, although genetic 
susceptibility is also a risk factor. 
Although the actual nature of injury to the peripheral nerves by 
hyperglycemia and the underlying pathogenic mechanisms still remains unclear, 
several theoretical mechanisms have been put forward to explain the pathogenesis and 
pathophysiology of T2D-associated neuropathy (Head, 2006; Fowler, 2008). These include 
accumulation of polyol due to increase of metabolic flux of the polyol pathway; oxidative 
stress and AGEs-mediated peripheral nerve injury; increased activity of protein kinase C 
pathways; and reduced levels of neurotrophic agents (Boulton et al., 2005; Ziegler, 2008; 
Fowler, 2008). Peripheral neuropathy in diabetes may present in different forms, including 
sensory, focal/multifocal, and autonomic neuropathies. These may lead to morbidities such as 
amputations due to foot ulceration or injury, loss of ankle reflex, gastroparesis, anhidrosis, 
bladder dysfunction, erectile dysfunction, myocardial ischemia and eventually death (Abbott 
et ., 2002; Maser et al., 2003; Boulton et al., 2005). 
 
(b) Macrovascular complications 
These are complications associated with large vessels like arteries and veins, which are mostly, 
linked to cardiovascular events in type 2 diabetic individuals. Cardiovascular disorders (CVDs) 
are the leading cause of mortalities in patients with T2D. Data from previous investigations 
showed that the risk of developing CVDs, excluding other traditional CVDs risk factors like 
aging, smoking, dyslipidemia, hypertension and obesity is four times higher in type 2 diabetic 




The principal pathophysiological mechanisms of diabetic macrovascular complications, 
especially CVDs have been postulated to grossly involve the pathogenic processes of 
atherosclerosis (Fowler, 2008). Atherosclerosis is characterized by a severe inflammation and 
injury to the arterial wall in the peripheral or coronary vascular system. This is due to the 
deposition of fatty material on the arterial inner walls, which causes the lumen of arteries all over 
the body to narrow down (Insull, 2009). Fatty particles or deposits in the arterial endothelial 
walls may undergo Angiotensin-induced oxidation, while monocytes infiltrate arterial wall to 
form macrophages after differentiating. Macrophages formation causes T-lymphocyte-associated 
proliferation of arterial wall smooth muscles, which eventually lead to an acute vascular 
infarction (Maser et al., 2003). 
Furthermore, hyperglycemia-induced free radical formation in arterial platelets can 
impair the generation of nitric oxide (an important vasodilator), which promotes atheroma 
formation and arterial platelet aggregation and adhesion. This condition, in the presence of 
impaired fibrinolysis, can further aggravate the risk of cardiovascular events in T2D individuals 
(Fowler, 2008). 
 
1.2.8 Management of T2D 
Dietary and lifestyle modifications are commonly recommended for people with T2D, especially 
in less severe cases and for long term management programs. However, pharmacological agents 
are usually introduced when dietary and lifestyle modifications are not effective in controlling 
hyperglycemia, especially in chronic or later stage of T2D. 
 
i) Use of therapeutic drugs 
The major rationale behind the use of pharmacological agents in the management of T2D sterns 
from the severity of hyperglycemia in patients. Pharmacological agents or therapeutic drugs for 
the management of T2D act promptly to control re-occurring incidences of abnormal high blood 
glucose in chronic T2D conditions. There are several pharmacological agents currently available 
for the management of T2D, which are sub-divided into different classes depending on the 
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mechanism of action employed to ameliorate hyperglycemia (Tsang, 2012). In this section, the 
mode of action and side effects of some anti-diabetic drugs/therapies like biguanides, 
sulfonylureas, thiazolidinedione, alpha glucosidase inhibitors, dipeptidyl-peptidase (DPP) IV 
inhibitors and incretin-based therapies are discussed (Fig. 1.5). 
 
(a) Biguanides 
Although the mechanism of action is not completely known, it has been reported that biguanides 
lower blood glucose by suppressing hepatic glucose production (especially gluconeogenic 
processes), while enhancing circulating glucose uptake in peripheral tissue and decreasing 
intestinal glucose absorption (Collier et al., 2006). Metformin is the most recent and most 
frequently used biguanide in the market, commonly used by overweight and obese patients with 
T2D. Previous studies have suggested that metformin suppresses gluconeogenesis via the 
activation of AMP-activated protein kinase, which is a key regulatory enzyme involved in the 
expression of genes that regulate gluconeogenesis (Kim et al., 2008). Additionally, metformin 
has also been reported to increase fatty acid oxidation and decreases plasma lipid levels 
(DeFronzo et al., 1991; Collier et al., 2006), which can enhance weight loss in obese and lean 
individuals with non-insulin-dependent diabetes mellitus (DeFronzo et al., 1991). However, 
metformin medication in some individuals is associated with some gastrointestinal side effects 
such as nausea, abdominal spasm, diarrhea and bloating (Bailey and Turner, 1996). Metformin 
medication can also cause lactic acidosis, especially in elderly diabetic individual suffering from 
renal impairment; hence these individuals are advised to use metformin with caution (Misbin et 
al., 1998; Collier et al., 2006). 
 
(b) Sulfonylureas 
Current drugs belonging to this class of anti-diabetic agents include gliclazide, glibenclamide, 
glipizide and glimepiride, with glibenclamide being the most popular. They lower blood glucose 
by stimulating endogenous insulin secretion in the pancreas and improving beta cell functions 
(Koski, 2004; Chiniwala & Jabbour, 2011; Tsang, 2012). Sulfonylureas bind strongly to beta 
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cells via membrane-specific receptors, which signal the release of insulin from secretory 
granules within the beta cells (Tsang, 2012). However, direct induction of insulin secretion by 
beta cells regardless of blood glucose levels can increase the risk of hypoglycemia, which is a the 
major adverse effect of sulfonylureas medication (van Staa et al., 1997; Chiniwala and Jabbour, 
2011). Elderly patients have an increased risk of 38% in developing sulfonylureas-associated 
hypoglycemia compared to younger patients (van Staa et al., 1997). 
 
 
Figure 1.5: Diagram showing some current anti-diabetic drugs, their mechanisms of action and 
side effects. (Adapted and modified from Cheng & Fantus, 2005) 
 
(c) Thiazolidinedione 
Thiazolidinediones are earliest anti-diabetic drugs that were produced to tackle the problem of 




because they enhance insulin sensitivity in peripheral tissues. Thiazolidinediones improve insulin 
sensitivity via a basal route that indirectly involvesthe regulation of lipid metabolism by 
peroxisomes proliferator-activated receptor gamma (PPAR-γ) (Yki-Järvinen, 2004; Hammarstedt 
et al., 2005). Peroxisomes proliferator-activated receptor gamma (PPAR-γ) is a transcription 
factor that is involved in the insulin-dependent regulation of carbohydrate and lipid metabolism. 
Thiazolidinediones act as a ligand that strongly binds to (PPAR-γ), thus activating it. Activated 
PPAR-γ upregulates insulin-mediated glucose uptake in the muscle and fat tissues; expression of 
adipocyte insulin-sensitizing hormone; and adipocyte differentiation, while suppressing lypolytic 
processes (Yki-Järvinen, 2004; Hammarstedt et al., 2005). 
The major classes of thiazolidinediones are pioglitazone and rosiglitazone. However, 
rosiglitazone has been recommended for restriction by the Food and Drug Administration (FDA) 
due to some reported associated cardiovascular events (Yoon et al., 2006). On the other hand, 
pioglitazone is not associated with hypoglycemic effects and can be well tolerated by elderly 
patients. However, several side effects such as anaemia, edema, fluid retention, weight gain and 
congestive heart failure have been reported to be associated with pioglitazone medication. Thus, 
pioglitazone should be avoided by type 2 diabetic patients and elderly people with congestive 
heart failure, hepatic impairments and patients with class III-IV heart failure (Inzucchi, 2002). 
 
(d) Alpha glucosidase inhibitors 
Alpha glucosidase inhibitors inhibit the action of carbohydrates digestive enzymes such as alpha 
glucosidase and alpha amylase on carbohydrate breakdown, thereby limiting postprandial 
glucose absorption in the small intestine (Patel et al., 2012). This class of anti-diabetic 
pharmacological agents is therefore most effective in controlling postprandial hyperglycemia. 
Studies suggest that alpha glucosidases inhibitors are carbohydrate analogues, which inhibit the 
action of carbohydrate digestive enzymes in a competitive fashion (Horii et al., 1986; kim et al., 
1999). 
Acarbose, voglibose and miglitol are the examples of some the commonly used alpha 
glucosidase inhibitors, although acarbose is the most popular one. Besides suppressing 
carbohydrate breakdown, studies have shown that acarbose may also exert glycemic control by 
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delaying gastric emptying, which may reduce small intestinal glucose absorption (Ranganath et 
al., 1998). However, the use of alpha glucosidase inhibitorsis limited, due to frequent incidences 
of gastrointestinal side effects such as diarrhea, bloating and flatulence (Cheng & Fantus, 2005). 
 
(e) Dipeptidyl-peptidase (DPP) IV inhibitors 
This class of anti-diabetic drugs inhibits dipeptidyl peptidase (DPP) IV, which is an antagonist of 
incretin hormones like glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic 
polypeptide (Pratley and Salsali, 2007). Incretin hormones promote beta cell mass, suppress 
glucagon secretion, delay gastric emptying and induce satiety (Pratley and Salsali, 2007). 
Accordingly, the action of DPP IV inhibitors preserves the activity of incretin hormones, thereby 
enhancing postprandial glycemic control. Sitagliptin is the first DPP IV inhibitor that was 
introduced into the market in 2006, followed by vildagliptin, saxagliptin, linagliptin and 
alogliptin. These drugs are well tolerated and have low risk of causing hypoglycemia. However, 
side effects like headache, nausea, hypersensitivity, skin reactions and nasopharyngitis have been 
reported with DPP IV inhibitor medication (Gallwitz, 2013). Additionally they are relatively 
expensive compared to other commonly used oral hypoglycemic drugs .e.g metformin. 
 
(f) Incretin-based therapies 
These are analogues or agonists of incretin hormone, which mimic the action GLP-1, thereby by 
enhancing incretin-based glycemic control (Stonehouse et al., 2012). Examples include 
exenatide and liraglutide. Incretin-based therapies present no severe risk of hypoglycemia, but 
may present mild gastrointestinal disturbances (Garber, 2011). Incretin-based therapies may also 
be useful in cardiovascular and hepatic health (Stonehouse et al., 2011). However, very little is 






ii) Exercise and physical activities 
Exercise and physical activities play a significant role in the management of T2D because they 
improve carbohydrate and lipid metabolism, assist in glycemic and weight gain control and 
ameliorate lipid-induced insulin resistance associated with obesity, T2D and metabolic syndrome 
(Winnick et al., 2008; Colberg et al., 2010).  Previous studies have presented consistent evidence 
on the therapeutic effect of both acute and chronic exercise on T2D individuals. For instance, 
aerobic exercise, which is the most popular type of physical exercise, has been reported to 
improve insulin sensitivity in patients starting from the first week of exercise (Winnick et al., 
2008). Other studies have demonstrated that physical exercise reduces total and LDL-cholesterol 
but increases HDL-cholesterol (Kadoglou et al., 2007); and is also useful in the prevention and 
management of weight gain and T2D-related complications such as hypertension and 
cardiovascular events (Sigal et al., 2006). 
 
iii) Dietary management 
Detrimental positive energy balance and weight gain resulting from unhealthy dietary habits is a 
major contributor to overweight or obesity, which can increase the risk of developing serious 
health problems, including T2D, cardiovascular diseases, hypertension and metabolic syndrome 
(Artham et al., 2009). Accordingly dietary adjustment is one of the first therapeutic 
recommendations in the managements of T2D. According to the Society for Endocrinology, 
Metabolism and Diabetes of South Africa (SEMDSA) guidelines for the management of T2D, 
type 2 diabetic patients should consume less saturated fat and also reduce the intake of high-
calorie sugars like sucrose to about 10% of total energy intake per day (Amod et al., 2012). This 
is because despite the fact that sugar consumption will aggravate hyperglycemia in patients, 
chronic consumption has been consistently shown to be strongly associated with detrimental 
health outcomes such as elevated food intake, body weight gain and visceral adiposity (Astrup et 
al., 2002; Hu & Malik, 2010; Stanhope et al., 2011;); reduced insulin sensitivity and lipid 
dysregulation (Thorburn et al., 1989; Elliott et al., 2002); and the risk of developing T2D, 
obesity, metabolic syndrome and cardiovascular diseases (Schulze et al., 2004; Montonen et al., 
2007; Bantle, 2009; Stanhope, 2012). 
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Major dietary adjustments in diabetics that has recently gained global acceptance is the 
use of sugar substitutes such as non-nutritive and nutritive (reduced-calorie) sweeteners to 
replace sugar in diabetic diets (Talbot & Fisher, 1978; Brown et al., 2010), because they are 
known to have little or no glycemic or caloric value compared to sucrose; thus, are useful for 
glycemic control in diabetics. 
 
1.2.9 Non-nutritive and nutritive sweeteners 
Sweetener is the common name for sugar replacers or sugar substitute. They are basically used in 
place or together with table sugar (sucrose). Their sweetness range from slightly less sweet to 
several thousand times sweeter than sucrose and are broadly classified as either non-nutritive or 
nutritive (reduced-calorie) sweetener (Fitch & Keim, 2012). 
 
i) Non-nutritive sweeteners (NNSs) 
As the name imply, these sweeteners do not provide the body with any sort of nutrition. In fact 
they cause a zero caloric effect upon consumption. Their sweetening power range from about 30 
– 13000 times higher than sucrose, and as such, are also referred to as intense sweeteners 
(O’Donnell & Kearsley, 2012; Fitch & Keim, 2012). They are used in relatively smaller amounts 
compared to reduced-calorie sweeteners, due to their intense sweetening ability. At high 
amounts, they exhibit a sweetness profile that is characterized by an unpleasant after taste. Non-
nutritive sweeteners are sometimes referred to as artificial sweeteners because of their synthetic 
origin, except for some high potency natural sweeteners like stevia, thaumatin, mogrosides, 
brazzein and monatin, which are derived from plants (Lindley, 2012). The commonly used NNSs 
include saccharin, aspartame, sucralose, acesulfame potassium (Ace-K), cyclamate, neotame and 
stevia. Although artificial sweeteners are widely used in several products and as table top 
sweeteners, with endorsement from different food regulatory bodies, it is often difficult to obtain 
or verify a universal regulatory status regarding the use of these sweeteners. This is due to the 
continuously changing food regulatory processes, which is subject to different interpretations by 




Saccharin is the oldest NNSs, which was accidentally discoveredin 1897 by Constantine 
Fahlberg, while working in the laboratory of Ira Remsem, Hopkins University, United States 
(DuBois, 2012). It is a heterocyclic white crystalline compound (Fig. 1.6), which is about 300 
times sweeter than sucrose (Fitch &Keim, 2012). It is highly absorbed but not metabolized in the 
body; hence has a zero caloric effect (DuBois, 2012). Absorbed saccharin is excreted in the 
urine. Saccharin has been approved by the United States FDA for general use except in meat and 
poultry, with an ADI of 15 mg/kg bw (Fitch & Keim, 2012). 
 
 
Figure 1.6: Chemical structures of some non-nutritive sweeteners (structures adapted without 
permission from O’Donnell & Kearsley, 2012). 
 
(b) Cyclamate 
Cyclamate is a white crystalline sodium or calcium salt of cyclohexylsulfamic acid (cyclamic 
acid) (Fig. 1.6). The sweetening property of Cyclamate was first reportedin 1944 by Sveda and 
Audrieth at the University of Illinois (DuBois, 2012). Sodium cyclamte is about 30 to 50 times 
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sweeter than sucrose (Fitch & Keim, 2012; DuBois, 2012). As a result of its low sweetening 
power and bitter-salty off taste, sodium cyclamate is often used with other non-nutritive 
sweetenersin blended combination. Cyclamate is not metabolized in human tissue but can be 
converted to cyclohexylamine, cyclohexanol and cyclohexane-1,2-diol by the action of large 
intestinal microflora of some individuals (Bopp & Price, 2001). Absorbed cyclamate and 
cyclamate metabolite are completely excreted in the urine, post consumption. Cyclamate has 
gained approval for use in beverages and drink and as a table top sweetener in more than 50 
countries but not in the United States (Fitch & Keim, 2012). The ADI for cyclamate approved by 
JECFA is11.0 mg/kg bw (DuBois, 2012). 
 
(c) Aspartame 
Aspartame is a white crystalline ester of two amino acids, l-phenylalanine and l-aspartic acid, 
joined by a methyl-ester link (Fig. 1.6). It was discovered by Schlatter in 1965 in the laboratories 
of G.D. Searle (O’Donnell, 2012). Aspartame was first introduced to the US market in 1981 as 
“NutraSweet”, which became a house-hold brand name by the late 80’s and early 90’s. 
Aspartame is about 160 to 220 time sweeter than sucrose and characterized by a sweet clean 
taste, which can improve the synergistic effect with other sweeteners or flavours (Fitch & Keim, 
2012; O’Donnell, 2012). 
As a dipeptide molecule, aspartame is metabolized or hydrolyzed in the body by digestive 
peptidases into methanol and its constituent amino acids, l-phenylalanine and l-aspartic acid. 
Amino acids are absorbed in the intestines to become part of protein metabolism in the body, 
while methanol is excreted (Ranney & Opperman, 1979; Harper, 1984). Although methanol 
metabolite may be potentially harmful at toxic levels (200–500 mg/kg body weight), the amount 
of methanol resulting from aspartame metabolism is relatively very small and harmless 
compared to the toxic levels (Stegink et al., 1981). 
Aspartame is used as a table top sweetener and in several products like yoghurts, 
confectionaries, beverages, but not suitable for baking, because it is not heat stable. Major food 
regulatory bodies have established an ADI of 40-50 mg/kg bw for aspartame, but have restricted 
the use of aspartame for people suffering from phenylketonuria (Fitch & Keim, 2012; 
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O’Donnell, 2012). This is because sufferers of this disease are deficient of the enzyme 
phenylalanine hydroxylase, and therefore cannot physiologically metabolize phenylalanine into 
tyrosine. Accumulation of phenylalanine may result in mental retardation (Ranney & Opperman, 
1979; Harper, 1984). 
 
(d) Neotame 
Neotame is an aspartame derivative that was born out of a collaborative research between the 
French research group, Tinti and Nofre of Claude Barnard University France and The Nutra 
Sweet Company (Nofre & Tinti, 2000). The purpose of the collaborative research was to develop 
a novel sweetener with better physical and organoleptic properties as well as lesser production 
cost compared to aspartame. By 1991 the discovery of an n-[n-(3,3-dimethylbutyl)-l-aspartyl]-l-
phenylalanine-1-methyl ester (Fig. 1.6), which was later named neotame was reported 
(O’Donnell, 2012). Neotame is about 7000 to 13000 times sweeter than sucrose and it is 
characterized by a clean sweet taste, similar to sucrose (Fitch & Keim, 2012; O’Donnell, 2012). 
It is partially absorbed in the intestine and de-esterified in the body, but does not release 
phenylalnine or toxic amount of methanol; hence, is suitable for people suffering from 
phenylketonuria (O’Donnell, 2012). Both absorbed and de-esterified neotame are excreted in the 
urine and feces. Noetame has been approved by the US FDA as a general use sweetener with an 
ADI of 18 mg/kg bw, but not suitable in meat and poultry (Fitch & Keim, 2012). 
 
(e) Acesulfame potassium (Ace-K) 
Acesulfame potassium (Ace-K) is a colourless monoclinic crystalline potassium salt of 
Acesulfame (a dihydro-oxathiazinone dioxides) (Fig. 1.6), which was accidentally discovered by 
Clauß and Jensen in 1967 (Clauß&Jensen, 1973). Ace-K is about 200 times sweeter than sucrose 
and is characterized by a sweetness profile that does not remain longer than the original taste of 
the food it sweetens (Klug & Lipinski, 2012; Fitch &Keim, 2012). It is partially absorbed but not 
metabolized in the body, hence both absorbed and non-absorbed Ace-K completely excreted in 
the urine and feces. The US FDA has approved an ADI of 15 mg/kg bw for Ace-K (Fitch & 
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Keim, 2012). Ace-K is used as a table top sweetener, as blended combination with other 




Sucraloseis a white powder-like sweetener, derived from sucrose by the replacement of some 
hydroxyl groups with chlorine to produce a halogenated sugar (Fig. 1.6) (Molinary and Quinlan, 
2012). The research leading to the discovery of sucralose started in the 1970’s by Tate & Lyle, 
PLC (Fitch & Keim, 2012). Sucralose is about 600 times sweeter than sucrose and it suitable for 
baking due to its heat stability (Molinary and Quinlan, 2012). Although sucralose is a sucrose 
derivative, it is partly absorbed but not metabolized in the body. Hence both absorbed and 
unabsorbed sucralose are excreted in the urine or feaces (Roberts et al., 2000). Sucralose was 




Steviais composed of steviol glycosides-rebaudioside A and stevioside, which are sweet organic 
compounds, extracted from the leaves of the plant Stevia rebaudiana Bertoni (Kinghorn & 
Soejarto, 1991). Stevia is about 250 times sweeter than sucrose, but characterized by a clean taste 
that can be bitter at higher quantities (Goyal et al., 2010). Stevia is rarely metabolized or 
absorbed in human, because the β-glycosidic linkages in steviol glycosides cannot be hydrolyzed 
by human digestive enzymes. However, microbial fermentation can occur in the large intestine to 
release steviol, which can be absorbed and excreted in the urine as steviol glucuronide, a 
conjugate of glucoronic acid (Wheeler et al., 2008). Stevia has been approved by the US FDA as 
a general use sweetenerand an ADI of 4 mg/kg bw has been determined by JECFA (Fitch & 
Keim, 2012). 
Despite, the endorsement of these NNSs by several food regulatory bodies, the several 
life threatening side effects that have been previously reported to be associated with some of 
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them may still remain a major concern for chronic consumers (Whitehouse et al., 2008). 
Additionally, though it may be safer at ADI dose or lower, most of the consumers are unaware of 
this. Accordingly, it may not be always possible to adhere to the ADIs, since NNSs are being 
used in the thousands of food products. 
 
ii) Nutritive or reduced-calorie sweeteners 
Considered as an alternative for sugars inobese and diabetics diets, nutritive or reduced-calories 
weeteners can be described as sweetening agents that can add calorie when ingested, but 
relatively lesser compared to sucrose, glucose or other sugars (Fitch & Keim, 2012). They are 
generally referred to as low glycemic index sweeteners, because they do not increase 
postprandial glucose level as much as sugars (Livesey, 2003). Most reduced-calorie sweeteners 
possess relatively less or similar sweetness compared to sucrose or glucose, hence they are used 
to replace the bulk or volume of sugar in foods (Fitch & Keim, 2012). There are several 
examples of reduced-calorie sweeteners, but for the purpose of this study the discussion will be 
limited to a class of reduced-calorie sweeteners known as sugar alcohols or polyols. 
 
1.2.10 Sugar alcohols 
Sugar alcohol is a class of reduced-calorie sweeteners mostly derived from simple carbohydrate 
like monosaccharides and disaccharides by catalytic hydrogenation of their carbohydrate 
precursors. They possess multiple hydroxyl functional groups without aldehyde (-CHO) or 
ketone (=CO) functional group that are present in their carbohydrate precursors, and also occur 
naturally in numerous fruits and vegetables or in the body as metabolites of carbohydrate 
metabolism (O’Donnell & Kearsley, 2012). Sugar alcohols possess lesser or about similar 
sweetness compared to sucrose. Their sweetness profile is characterized by a pleasant cooling 
effect that is void of a bitter or unpleasant after taste. Almost all sugar alcohols are sparingly 
metabolized and absorbed in the intestine, hence they provide lesser calorie and cause lesser 
blood glucose rise or insulin response compared to equivalent amount of sugars like sucrose or 
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glucose (O’Donnell & Kearsley, 2012). However, the glycemic responses of sugar alcohols are 
different, due to their varying digestibility, absorption capacity and metabolism (Table 1.2). 
 










































        
Sucrose 68 45 4 100 ND 90 ~125 
Erythritol 0 2 0 70 90 <2 ~125 
Xylitol 12 11 2.4 95 50 <2 ~50 
Mannitol 0 0 2.4 50 25 25 ~20 
Isomalt 9 6 2.4 40 10 <2 ~50 
Lactitol 5 4 2.4 40 2 <2 ~20 
Maltitol 45 27 2.4 90 40 <2 ~96 
Sorbitol 9 11 2.4 50 25 <2 ~50 
Myo-inositol ND ND ND 50** ND ND ND 
aRelative glucose response (RGR) and relative insulin response (RIR) as percentage of glucose and insulin responses 
of oral glucose equivalence (values adapted from Livesey, 2012).  bValues adapted from Flambeau et al., 2012. 
cValues adapted from Sadler and Stowell, 2012, except for myo-inositol (**). dValues adapted from Livesey, 2003. 
ND: Not determined. 
 
Absorbed portion of most sugar alcohols are metabolized to become part of carbohydrate 
metabolism, while the remaining portion are fermented in the large intestine by microflora to 
produce short-chain fatty acids, which are absorbed and metabolized to produce energy. 
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Additionally, carbon dioxide plus some organic gases are also released, which together with 
short-chain fatty acids contribute to common gastrointestinal side effects such as bloating, 
nausea, flatulence and osmotic diarrhea associated with excessive sugar alcohol consumption 
(O’Donnell & Kearsley, 2012). However, the intensity of gastrointestinal side effects of sugar 
alcohols is different for each sugar alcohol and in different individuals, partly due to the different 
gastrointestinal tolerance of different people and the varying digestibility and absorption capacity 
of different sugar alcohols (livesey, 2003; O’Donnell & Kearsley, 2012) (Table 1.2).The 
Academy of Nutrition and Dietetics reported that up to 10 or 15 g/day of most sugar alcohols can 
be tolerated (Fitch and Keim, 2012). Furthermore, the organoleptic and physico-chemical 
properties also vary from one sugar alcohol to another. The chemical and metabolic properties of 




Xylitol is a five carbon crystalline sugar alcohol (Fig. 1.7) that is derived from the catalytic 
hydrogenation of its precursor, xylose (Zacharis, 2012). It however occurs naturally in numerous 
fruits and vegetables at levels less than 1% (Washuett et al., 1973) and also produced 
physiologically in human as part of hepatic carbohydrate metabolism at levels of about 5-15 g 
per day (Touster, 1974). Xylitol has about similar sweetness as sucrose (Table 1.2) and a taste 
characterized by a refreshing cooling sensation. Upon ingestion, about 50% is absorbed in the 
intestine (Table 1.2), while the remaining is fermented in the large intestine by colonic 
microflora to produce some gases and short chain fatty acids (Livesey, 2012). Absorbed xylitol is 
mostly metabolized in the liver to become part of normal carbohydrate and glucose metabolism 
via the glucoronic acid-pentose phosphate shunt of the pentose phosphate pathway (Touster, 
1974), while less than 2% is excreted in the urine (Livesey, 2003). The relative glycemic 
response (RGR) and relative insulin response (RIR) of xylitol (compared to sucrose equivalent) 
are about 12 and 11 (sucrose: 68 and 45) respectively (Table 1.2). 
Xylitol possesses a better gastrointestinal tolerance compared to somesugar alcohols like 
mannitol and lactitol due to its lower laxative threshold (Table 1.2) (Flambeau et al., 2012), 
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although this may vary among different individuals. Nevertheless, there are evidences that the 
gastrointestinal tolerance of xylitol may increase with regular consumption (Sakallioğlu et al., 
2014). Xylitol has been approved by the US FDA as food additive for special dietary purposes 
and as a table top sweetener (Fitch and Keim, 2012). It is widely used in several products such as 
pharmaceuticals, chewing gum, oral mouth wash, candies confectionaries etc. Notable beneficial 
properties associated with xylitol consumption include low glycemic response (Livesey, 2012), 




Figure 1.7: Chemical structures of some sugar alcohols (structures adapted without permission 
from O’Donnell & Kearsley, 2012). 
 
ii) Sorbitol and mannitol 
Sorbitol and mannitol were the foremost sugar alcohols to be discovered and commercially made 
available. They are both white crystalline hexanols that share structural similarities except for the 
orientation of the hydroxyl group at carbon position “C2” (Fig 1.7) (Deis & Kearsley, 2012). 
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Sorbitol and mannitol occur naturally in appreciable amounts, more than most sugar alcohols. 
Sorbitol is found in a wide range of fruits and berries, while mannitol is found in most plants and 
sea weeds (Deis & Kearsley, 2012). Commercially, both sorbitol and mannitol are produced by 
the catalytic hydrogenation of simple reducing sugars. Hydrogenation of dextrose (aldose-sugar) 
yields sorbitol, while hydrogenation of fructose (ketose-sugar) derived from starch or sugar 
produces mannitol and sorbitol in varying proportions depending on the starting material (starch 
or sugar) (Deis & Kearsley, 2012). 
Both sorbitol and mannitol are approximately 50% as sweet as sucrose and exhibit 
similar absorption capacities, which is about 25% of the amount ingested (Table 1.2).However, 
sorbitol is more extensively metabolized in the body than mannitol via carbohydrate metabolic 
pathways in the liver; hence, only negligible amounts (< 2%) are excreted in the urine (Livesey, 
2003). On the other hand, mannitol is almost completely excreted in the urine after absorption 
(Livesey, 2003). Accordingly, sorbitol has a RGR of 10, while mannitol has a RGR of 0 (Table 
1.2). 
Like most sugar alcohols, sorbitol and mannitol cause gastrointestinal side effects when 
consumed excessively, due to microfloral fermentation of unabsorbed portions in the large 
intestine. They are less tolerable compared to most sugar alcohols, but sorbitol is more tolerable 
than mannitol (Table 1.2). In fact, mannitol is known to be one of the least tolerated sugar 
alcohols. While 40 g of sorbitol per day may not cause any side effects, consumption of more 
than 20 g per day of mannitol can result in severe gastrointestinal symptoms (Deis & Kearsley, 
2012). However, both sugar alcohols have been approved by US FDA as food additives, but with 
warnings on the risk of laxativeside effects (Fitch and Keim, 2012). Sorbitol and mannitol are 
used in several products, such as pharmaceuticals, candies, confectionaries, chewing gum etc, 
but sorbitol is more frequently and widely used, because it is more tolerable than mannitol. Other 
notable health benefits of sorbitol include prevention of caries incidence (Burt, 2006). 
 
iii) Maltitol 
Maltitol powder is a white disaccharide sugar alcohol that is composed of glucose and sorbitol 
moiety (Fig. 1.7). It is commercially produced by the catalytic hydrogenation of maltose sugar. 
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Maltitol syrup on the other hand is a hydrogenated starch hydrolysate, commercially produced 
from maize starch, maltose syrup or glucose syrup by catalytic hydrogenation (Flambeau et al., 
2012). Maltitol syrup is predominantly composed of maltitol and small amounts of sorbitol and 
hydrogenated gluco-oligosaccharide. Maltitol is about 90% as sweet as sucrose (Table 1.2). 
About 40% of ingested maltitol is absorbed in the intestine (Livesey, 2003). However, 
absorbed and unabsorbed maltitol can be hydrolyzed by physiological disaccharidase to give 
glucose and sorbitol (Lian-Loh et al., 1982; Zunft et al., 1983). Glucose is rapidly absorbed in 
the intestine, while sorbitol is passively absorbed and/or fermented (sorbitol) in the large 
intestine by colonic bacteria. Hence, sorbitol is found in the urine after maltitol consumption 
(Lian-Loh et al., 1982; Zunft et al., 1983). Additionally, the glucose resulting from maltitol 
hydrolysis majorly contributes to its higher RGR and RIR compared to most sugar alcohols 
(Table 1.2). Unabsorbed maltitol or sorbitol is responsible for gastrointestinal side effects due to 
colonic bacterial fermentation. However, maltitol is better tolerated compared to than most 
commonly used sugar alcohols (Table 1.2), which might be due to its higher molecular weight 
and glucose-sorbitol moiety composition (Flambeau et al., 2012). Maltitol has been determined 
to be safe for consumption by JECFA. In Europe however, there are specific legal requirements, 
which limits the use of maltitol to mostly confectionery, baked goods, ice cream, desserts and 
fruit preparations (Flambeau et al., 2012). 
 
iv) Isomalt 
Isomalt is a white crystalline sugar alcohol that is composed of disaccharide sugar alcohols with 
glucose-mannitol and glucose-sorbitol moieties (Fig. 1.7). Commercially, isomalt is produced by 
catalytic hydrogenation of isomaltulose derived from bacterial fermentation of sucrose sugar 
(Sentko & Willibald-Ettle, 2012). Isomalt is about 40% as sweet as sucrose and poorly digested 
or absorbed in the intestine (about 10% of ingested amount) compared to most sugar alcohols 
(Table 1.2). Like maltitol, isomalt can be hydrolyzed by intestinal disaccharidases, but to a lesser 
degree (Nilsson and Jägerstad, 1987). Hydrolysis of isomalt produces glucose, which is rapidly 
absorbed, as well as mannitol and sorbitol, which are partly absorbed and partly fermented. 
However the RGR of isomalt is lower than maltitol (Table 1.2), which is due to the lower degree 
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of enzymatic hydrolysis. Furthermore, although isomalt has same molecular weight as maltitol, it 
is less tolerable than maltitol (Table 1.2), which is due to its lower degree of enzymatic 
hydrolysis compared to maltitol. Up to 50 g per day of isomalt in spread doses is tolerable in 
humans (Sentko & Willibald-Ettle, 2012). Isomalt has been approved by JECFA and US FDA 
for use as a table top sweetener and in several products like pharmaceuticals, candies, breakfast 
cereals, fruit spreads, baked products, chewing gums, chocolates etc (Sentko & Willibald-Ettle, 
2012). Health-related beneficial effects associated with isomalt include, glycemic control 
(Livesey G, 2003) and oral health care benefits (Featherstone, 1994). 
 
v) Lactitol 
Lactitol is a white crystalline disaccharide sugar alcohol that is composed of sorbitol and 
galactose moiety (Fig. 1.7). It is commercially produced by the catalytic hydrogenation of 
lactose (milk sugar) (van Velthuijsen, 1979). Lactitol is about 40% as sweet as sucrose andthe 
least absorbed polyol in the intestine (about 2% of the ingested amount) (Table 1.2). The 
remaining portion is fermented in the colon to produce some gases and short chain fatty acids. 
Studies have shown that lactitol is slowly hydrolyzed by intestinal disaccharidase (galactosidase) 
at a rate that is one-tenth the activity of galactosidase on lactose (van Velthuijsen, 1979). Due to 
the relatively slow absorption and metabolism of lactitol, it exhibits lesser RGR and RIR 
compared to most othersugar alcohols (Table 1.2). Lactitol possesses approximately similar 
laxative threshold as mannitol, which are both the least tolerated sugar alcohols (Flambeau et al., 
2012) (Table 1.2). Studies have shown that consumption of 20 g lactitol caused gastrointestinal 
symptoms such as colic, flatulence, borborygmi, and bloating (Lee & Storey, 1999).Lactose mal-
absorbers are more susceptible than normal lactose absorbers (Soontornchai et al., 1999). The 
use of lactitol has been approved by different regulatory bodies in different countries, but with 
warnings on its laxative effects. It is used in the production of pharmaceutical products, desserts, 





vi) Erythritol (non-caloric sugar alcohol) 
Erythritol is a white crystalline four carbon sugar alcohols (Fig. 1.7) that occurs in many fruits 
and vegetables. Commercially, erythritol is produced by yeast fermentation of a dextrose- or 
sucrose-rich solution (de Cock, 2012). It is about 70% as sweet as sucrose and also the most 
absorbed sugar alcohol in the intestine, which is about 90% of the amount ingested (Table 1.2). 
However, absorbed erythritol is not metabolized in the body but completely excreted unchanged 
in the urine (O’Donnell & Kearsley, 2012). Accordingly, it has no caloric, glycemic and 
insulinaemic effects, unlike other commonly used sugar alcohols (Table 1.2). Additionally, since 
erythritol is almost completely absorbed in the intestine, it rarely causes undesirable 
gastrointestinal side effects. It is better tolerated than other sugar alcohols (Table 1.2), even at 
ingested amounts that are two to four times higher than other sugar alcohols (de Cock, 2012). 
Erythritol has been endorsed by both JECFA and the US FDA as a safe general use sweetener 
(de Cock, 2012; Fitch and Keim, 2012). It is widely used as a table-top sweetener and in 
products like candies, bakery products, confectionaries, chewing gums, chocolates etc. Health 
benefits associated with erythritol include glycemic control, oral health care (Mäkinen et al., 
2005) and anti-oxidant effects (den Hartog et al., 2010). 
 
vii) Myo-inositol 
Myo-inositol is a white crystalline cyclic sugar alcohol that is an isomer of glucose (Fig. 1.7). It 
belongs to the group of stereoisomers collectively called inositol (1,2,3,4,5,6-cyclohexanehexol 
or simply cyclohexanehexol). However, myo-inositol is the main inositol stereoisomer in the 
human body (comprising over 90% of cellular inositol) and the most consumed or supplemented 
inositol stereoisomer (Chung & Kwon, 1999; McLaurin et al., 2000). Myo-inosiol alsooccurs 
naturally in several plants, mostly in citrusfruits and grains (Rex & Darnell, 1980; Lee & Coates, 
2007). Commercially, it is produced from hydrolysis of crude phytate (US FDA, 2015). In 
human, myo-inositol is synthesized from glucose-6-phosphate by enzyme-catalyzed 
isomerization and dephosphorylation, which mostly occur in the kidney (Parthasarathy et al., 
2006). However, dietary myo-inositol is obtained from myo-inositol supplement and phytic acid 
(inositol hexaphosphate), a storage form of myo-inositol in fruits and grains (Rex & Darnell, 
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1980). In the intestine, inositol hexaphosphateis hydrolyzed by phytase to release myo-inositol 
(Lam et al., 2006). 
Myo-inositol is about 48 to 50% as sweet as sucrose and is absorbed in the intestine. 
Majority of ingested myo-inositol are absorbed in the intestine, while the remaining is fermented 
in the colon. Absorbed myo-inositol is used as a precursor for inositol phospholipid synthesis 
and as a part of cell membrane phospholipids, while excess inositol is metabolized via the 
glucuronic acid – pentose phosphate pathway (Lam et al., 2006). Myo-inositol has been reported 
to cause mild gastrointestinal symptoms, with 18 g per day being the maximum tolerable dose 
(Lam et al., 2006). Myo-inositol has been approved by the US FDA to be used as a food 
supplement and for special dietary purposes, including manufacturing of beverages, candies and 
infant milk (US FDA, 2015). Dietary supplementation of myo-inositol has been reported to show 
promising beneficial effects in the treatment of polycystic ovary syndrome (Ciotta et al., 2011), 
fertility and menstrual problems (Artini et al., 2013) as well as neurological disorders (Palatnik 
et al., 2001). 
The lower glycemic response of sugar alcohols compared to sucrose (Table 1.2) is an 
important quality that makes them useful in glycemic control, especially in diabetics. However, 
advances in research have further suggested that sugar alcohols may also possess anti-
hyperglycemic potential and may be useful in the management of diabetes and its related 
complications. In line with the aim of this study, the anti-hyperglycemic potencies of some 
commonly used sugar alcohol are discussed below. 
 
1.2.11  Anti-hyperglycemic potentials of some commonly usedsugar alcohols 
Xylitol is the most studied polyol that has shown promising anti-hyperglycemic and anti-diabetic 
potentials. Previous studies conducted by Islam and co-authors have consistently shown that  
10% xylitol solution as a replacement of drinking water significantly reduced (p< 0 .05) NFBG 
levels in normal ratsand also improved glucose toleranceand pancreatic beta-cell histology in 
diabetic rats (Islam, 2011, Islam & Indrajit, 2012; Rahman & Islam, 2014). In normoglycemic 
human subjects, 50 g xylitol in 300 mL of water supplied via nasogastric tube sparingly 
increased plasma glucose, but significantly increased GLP-1 hormone compared to glucose 
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administration (Woelnerhanssen et al., 2016). Accordingly, it was concluded that xylitol may be 
useful in the control of postprandial blood glucose rise. Consistent with these data, Kang et al. 
(2014) and Chukwuma & Islam (2015) reported the significant in vitro inhibitory effects of 
xylitol on alpha glucosidase and alpha amylase activities, while other animal studies provided 
evidences on the inhibitory effect of xylitol on intestinal glucose absorption in sit u(Frejnagel et 
al., 2003) and in normal and diabetic animals (Chukwuma & Islam, 2015). Chukwuma & Islam 
(2015) later concluded that the inhibitory effect of xylitol on intestinal glucose absorption may 
be influenced by the delayed gastric emptying, concomitantly observed in the xylitol fed diabetic 
animals of their study (Chukwuma & Islam, 2015). Additionally the potency of xylitol to 
ameliorate insulin resistance has also been demonstrated in diabetic rats with NEFA-induced 
insulin resistance (Kishore et al., 2012), while data from other ex vivo  and in vivo studies 
suggests the potency of xylitol to improve diabetes-induced insulin depletion (Rahman and 
Islam, 2014) and enhance insulin-mediated muscle glucose uptake (Chukwuma and Islam, 2015). 
Maltitol is the most absorbed and metabolized disaccharide sugar alcohol (Table 1.2). 
Nevertheless, its effect on glucose and insulin response is lower than sucrose in both normal and 
non-insulin dependent diabetic patients. In normal subjects, a single oral dose of 50 g maltitol 
resulted in significantly lower glycemic and insulin responses compared to same amount of 
glucose or sucrose (Secchi et al., 1986; Matsuo, 2003). In non-insulin dependent diabetes 
subjects, single oral administration of 30 g or 50 g maltitol also exerted lower effects on glucose 
and insulin response compared to glucose or sucrose (Moon et al., 1990, Vessby et al., 1990). In 
fact, 50 g of maltitol caused a peak mean blood glucose that was only about 30% compared to 50 
g glucose (Moon et al., 1990), which suggests the potency of maltitol in glycemic control during 
diabetes. Furthermore, the anti-hyperglycemic potential of maltitol has been demonstrated in 
overweight subject, who showed improved blood glucose, insulin and lipidemic response as well 
as increased satiety after consumption of maltitol-containing low calorie muffins compared to 
subjects fed with conventional sugar-sweetened muffins (Quilez et al., 2007). Data suggests that 
maltitol may be useful in the management of obesity-related diabetes. Additionally, in vitro 
studies showed that maltitol exhibited significant inhibition on alpha glucosidase and alpha 
amylase activities (Kang et al., 2014), thus may have clinical benefits to diabetics via reducing 
carbohydrate digestion, glucose absorption and postprandial hyperglycemia. 
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The in vitro and clinical anti-hyperglycemic potentials of myo-inostol have been 
demonstrated in a number of previous studies, when most data from different studies suggests 
the potency of myo-inositol supplement in improving insulin resistance and enhancing insulin-
mediated peripheral glucose uptake. In humans, myo-inositol participates in glucose metabolism 
via its metabolites such as P-type inositol phosphoglycans (Saltiel, 1990; Shashkin et al., 1997). 
P-type inositol phosphoglycans are markers of insulin-mediated glucose uptake, which are 
involved in the upregulation of glycolysis via activation of pyruvate dehydrogenase complex 
(Kunjara et al., 1999; McLean et al., 2008). In previousstudies, it has been reported that both 6 
months (Giordano et al., 2011) and 1 year (Santamaria et al., 2012) supplementation of 2000 mg 
myo-inositol (twice daily) was associated with the improvement of biomarkers of glucose 
metabolism and insulin sensitivity in postmenopausal women with metabolic syndrome. In 
another study, Dang et al. (2010) reported that oral administration of 1000 mg/kg myo-inositol 
facilitated cellular Glut-4 translocation 30 min after the ingestion in mice (Dang et al., 2010). In 
fact, 1 mM of myo-inositol and/or several inositol metabolites have been reported to be as 
effective as 100 nM insulin in stimulating Glut-4 translocation to the cell membrane in vitro 
(Yap et al., 2007), suggesting the potency of myo-inositol to improve insulin resistance and 
enhance peripheral insulin sensitivity. Accordingly, dietary myo-inositol has been shown to exert 
hypoglycemic effects in experimental animal (Dang et al., 2010) and human subjects with 
metabolic syndrome (Maeba et al., 2008). 
Sorbitol is believed to be the most widely used polyol and several studies have 
demonstrated that sorbitol may be useful in glycemic control. Previous studies have reported the 
glycogenic effects of oral or parenteral sorbitol in rats (Stetten & Stetten, 1951), which suggests 
the possibility of sorbitol to enhance clearance of excess blood glucose towards glycogen 
synthesis. In humans, 35 g of orally administered sorbitol caused significantly lower mean peak 
increment of plasma glucose compared to sucrose or fructose in both normal and diabetic 
subjects (Akgün & Ertel, 1980). Furthermore, based on the data from several absorption studies, 
JECFA proposed that sorbitol may possess the potency to inhibit intestinal glucose absorption 
(World Health Organization, 1985), and consequently control postprandial blood glucose 
elevation. However, mechanism behind this effect of sorbitol is still not clear. Recently, it was 
reported that sorbitol plus some commonly used polyols exhibited appreciable inhibitory effects 
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on alpha glucosidase and alpha amylase activities in vitro (Kang et al., 2014), which further 
confirms the potency of sorbitol to control postprandial glucose elevation. 
Several studies have demonstrated the glycemic control effect of erythritol. In a previous 
study, Bornet et al. (1996) reported that in healthy human subjects, the mean levels of plasma 
glucose and insulin remained unaffected up to 3 hours after a single oral administration of 1 g/kg 
bw of erythritol (Bornet et al., 1996). In diabetic rats, 10 days oral administration of 100 to 400 
mg/kg bw of erythritol significantly reduced glucose level as well as oxidative stress markers 
like protein glycosylation and lipid peroxidation in the serum, liver and kidney (Yokozawa et al., 
2002). Supporting clinical data in type 2 diabetic human subjects showed that 14 days oral 
administration of 20 g erythritol continuously reduced serum glucose and glycated hemoglobin 
(HbA1c), which suggests the potency of erythritol in ameliorating diabetes (Ishikawa et al., 
1996). Furthermore, Flint et al. (2014) reported that short term (4 weeks) oral administration of 
erythritol (30 g/day) improved arterialendothelial function in T2D subjects (Flint et al., 2014), 
which suggests that erythritol may be useful in the management of diabetes-related 
microvascular complications. A most recent study showed that single dose of 75 g erythritol in 
300 mL of water supplied via nasogastric tube modulated gut hormone (GPL-1) and also delayed 
gastric emptying in lean and obese normoglycemic subjects (Woelnerhanssen et al., 2016). 
Glucose level was also not significantly affected in this study, which suggests that erythritol 
could be useful in the control of postprandial glucose elevation and physiological glucose 
homeostasis. 
 
1.2.12  Study rationale 
Considering the above discussions, it is obvious to see that some commonly used sugar alcohols 
exhibit considerable glycemic control and anti-hyperglycemic potentials. The anti-
hyperglycemic effects of xylitol and its potency in glycemic control via reducing intestinal 
glucose absorption and enhancing insulin-mediate glucose uptake have been widely investigated 
and demonstrated (refer to section 1.2.11). However, the possible anti-hyperglycemic 




1.2.13  Aim and objectives 
The aim of this study was to further elucidate the possible sites and modes of action underlying 
the anti-hyperglycemic potentials of some selected commonly used sugar alcohols (maltitol, 
myo-inositol, sorbitol and erythritol). The research objectives included the following: 
1. Ex vivo study (experiment 1): 
 Investigating the effects of increasing concentrations of selected sugar alcohols on 
glucose absorption in isolated rat small intestine. 
 Investigating the effects of increasing concentrations of selected polyols on 
glucose uptake in isolated rat psoas muscle. 
 
2. In vivo study (experiment 2 and 3): 
 Experiment 2: Investigating the effects of a single bolusdose of selected sugar 
alcohols (maltitol, myo-inositol, sorbitol and erythritol) on gastric emptying, 
intestinal glucose absorption and digesta transit rate in both normal and type 2 
diabetic rats. 
 Experiment 3: Investigating the molecular mechanisms behind the insulin-
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MATERIALS AND METHODS 
2.1 Materials 
2.1.1  Chemicals and reagents 
Streptozotocin, di-basic sodium phosphate, citric acid,sodium acetate,3-(N-morpholino) 
propanesulfonic acid (MOPS), acarbose, maltitol, sorbitol, adenosine 5′-triphosphate disodium 
salt hydrate (ATP), D-mannitol, phosphorus standard solution, 1st Strand cDNA Synthesis Kit 
for RT-PCR-AMV andammonium molybdatetetrahydrate were purchased from Sigma Aldrich, 
South Africa. Mono-basic sodium phosphate, sodium hydroxide, sodium bicarbonate, sodium 
chloride, potassium chloride, calcium chloride di-hydrate, mono-basic potassium phosphate, 
magnesium sulphate, sodium hydrogen carbonate, phenol red, sodium citrate, glucose-6-
phosphate dehydrogenase, D-glucose 6-phosphate sodium salt, ferrous sulphateheptahydrate, 
trichloacetic acid (TCA), chloroform, sulphuric acid, isopropanol, ethanol, magnesium chloride, 
sodium hydroxide, disodium EDTA and myo-inositol were purchased from Merck, South Africa. 
Triethanolamine hydrochloride, diethylpyrocarbonate (DEPC), formamide, agarose, 
bromophenol blue, ethidum bromide and nicotinamide adenine dinucleotide phosphate (NADP+) 
were purchased from Inqaba Biotech Company Ltd, South Africa. Glucose and fructose were 
purchased from Associated Chemical Enterprise (ACE), South Africa, while metformin and 
Novo rapid insulin were purchased from a local pharmacy store (Pharmed) in Durban, South 
Africa. Erythritol was purchased from Jungbunzlauer, South Africa.Insulin ELISA kit was 
purchased from Mercodia AB, Uppsala, Sweden. iTaqTM Universal SYBR Green Supermix and 
50x Tris/Acetic Acid/EDTA (TAE) buffer (pH, 8.0) were purchased from Bio-Rad Laboratories, 
Inc., South Africa, while 1kb Plus DNA ladder was purchased from Thermo Scientific, South 






2.1.2  Equipments 
Steri-Cult CO2 incubator (Labotec, South Africa), Automated Chemistry Analyzer 
(LabmaxPlenno, Labtest Inc., Lagoa Santa, Brazil), Glucometer (Glucoplus Inc., Saint-Laurent, 
Quebec, Canada), Ultra Turrax Tube Drive  Work Station Homogenizer (IKA-Works, Staufenim 
Breisgau, Germany), HettichMikro 200 Microcentrifuge (Hettich Lab Technology, Tuttlingen, 
Germany), Synergy HTX Multi-mode Reader (BioTek Instruments Inc, Winooski, USA), UV 
mini 1240 Spectrophotometer (Shimadzu Corporation, Kyoto, Japan), IKA TP 18/10 Utra-
Turrax Homogenizer (IKA-Works, Staufenim Breisgau, Germany), Microfuge 20R Centrifuge 
(Beckman Coulter, Inc., Germany), CFX96 TouchTM Real-Time System (Bio-Rad Laboratories 
Inc., Hercules, Carlifonia), G:BOX F3 Gel Doc Imaging System (Syngen Laboratory Equipment 
Supplier, Cambridge, UK), NanoDrop 2000c UV-Vis Spectrophotometer (Thermo Scientific, 
Wilmington, USA), Eppendorf™ 5810R Centrifuge (Fisher Scientific, UK) and Jenway PFP7 
Flame Photometer (Jenway Ltd., Felsted, UK), Ecotron Incubation Shaker (Infrost HT, 
Switzerland). 
 
2.2 Methods and experimental design 
 
Figure 2.1: Experimental design of study 
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2.2.1 Experiment 1: Ex vivo study 
Experiment 1 was conducted to determine the effect of increasing concentrations (2% -20%) 
maltitol, myo-inositol, sorbitol and erythritol on glucose absorption in isolated rat jejunum and 
glucose uptake in isolated rat psoas muscle. The schematic experimental design for this section 
of the study is presented in Fig. 2.1. 
 
i) Animals  
Twenty adult male Sprague-Dawley (SD) rats(five rats for each sugar alcohol: maltitol, myo-
inositol,sorbitol and erythritol)with mean body weight 183.20 ± 7.42 g were procured from the 
Biomedical Resource Unit (BRU) located at the Westville Campus of the University of 
KwaZulu-Natal, Durban, South Africa. The animals were fasted over-night (12 h) and 
euthanized by halothane anesthesia. Then the abdominal wall was dissected and the whole 
gastrointestinal tract (GIT) was collected immediately. Also the entire psoas muscle was 
collected immediately without causing any damage to the psoas muscle tissue. Intestines and 
psoas muscle tissues were immediately used for glucose absorption and glucose uptake study, 
respectively. All animal procedures were carried out according to the rules and regulations of the 
Animal Research Ethics Committee of the University of KwaZulu-Natal, Durban, South Africa 
(Ethical approval number: 092/14/Animal). 
 
ii) Measurement of glucose absorption in isolated rat jejunum 
This was measured by monitoring the time-dependent reduction of glucose concentration in an 
incubation solution containing 5 cm of freshly isolated rat jejunum and different concentrations 
(2.5% to 20%) of maltitol, myo-inositol, sorbitol and erythritol using methods reported 
previously (Hassan et al., 2010; Algandaby et al., 2010), with slight modification. Briefly, a 5 
cm of jejunal segment from the isolated rat GIT was first inverted to expose the villi and then 
incubated (Steri-Cult CO2 incubator, Labotec, South Africa) in 8 ml of Krebs buffer (118 mM 
NaCl, 5 mM KCl, 1.328 mM CaCl2·2H2O, 1.2 mM KH2PO4, 1.2 mM MgSO4 and 25 mM 
NaHCO3) containing 11.1 mM (199.98 mg/dl) glucose and separately increasing concentrations 
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(2.5% to 20%) of maltitol, sorbitol, myo-inositol and erythritol. Incubation condition was at 5% 
CO2, 95% oxygen and 37°C. Glucose with Krebs buffer, but without maltitol, myo-inositol, 
sorbitol and erythritol was used as a control for respective sugar alcohol. Glucose concentrations 
were measured by using an Automated Chemistry Analyzer (LabmaxPlenno, Labtest Inc., Lagoa 
Santa, Brazil) in all solutions before and after a 2 h incubation period. The intestinal glucose 
absorption was calculated as the amount of glucose (mg) absorbed per cm of rat jejunum using 
the following formula: 
𝐼𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑎𝑙 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 𝑎𝑏𝑠𝑜𝑟𝑝𝑡𝑖𝑜𝑛 (𝑝𝑒𝑟 𝑐𝑚 𝑜𝑓 𝑗𝑒𝑗𝑢𝑛𝑢𝑚) =
(𝐺𝐶1 − 𝐺𝐶2)
𝑙𝑒𝑛𝑔𝑡ℎ 𝑜𝑓 𝑗𝑒𝑗𝑢𝑛𝑢𝑚 𝑖𝑛 𝑐𝑚
(𝐸𝑞. 2.1) 
Where, GC1 and GC2 are glucose concentrations (mg/dl) before and after the incubation, 
respectively. 
Percentage glucose absorption inhibition to determine the IC50 value was calculated as follows: 
𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛(%) =
(∆𝐺𝐶 𝑓𝑜𝑟 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − ∆𝐺𝐶 𝑓𝑜𝑟 𝑠𝑎𝑚𝑝𝑙𝑒)
∆𝐺𝐶 𝑓𝑜𝑟 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
  𝑥 100        (𝐸𝑞. 2.2) 
Where ∆GC = GC1 – GC2. 
 
iii) Type of muscle tissue fiber and viability assay 
Rat psoas muscle (hip flexor) is composed of type I and type II (IIA, IIX and IIB) muscle fibres, 
with more than 95% composition of type II, predominantly IIB (> 60%) (Eng et al., 2008), thus 
was suitable for this ex vivo study.The viability of isolated psoas muscle tissue during 1 hour 
incubation period was confirmed according to previously described methods (Best, 2008; 
Pichugin et al., 2006). These include estimating cellular ATP concentrations and cellular K+/Na+ 
ratio of freshly isolated muscle tissue and 1 hour after the incubation at rest in Kreb’s buffer 
under similar experimental incubation conditions as used for ex vivo muscle glucose uptake 
study. ATP concentration (µM) was measured in tissue homogenate using CellTiter-Glo® 
Luminescent Cell Viability Assay kit (Promega Corporation, Madison, USA). Briefly, a 0.5 g of 
muscle tissue was homogenized in 5 ml of ice cold PBS and centrifuged at 12,000 g for 5 min at 
4°C. Thereafter, 90 µl of supernatant or ATP standard solution (3 to 30 µM) was mixed with 90 
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µl of ATP assay reagent and incubated for 10 min at 25°C. Luminescence was measured 
(Synergy HTX Multi-mode reader, BioTek Instruments Inc, Winooski, USA) and tissue ATP 
concentration (µM) was calculated from an ATP standard curve.  
On the other hand cellular K+/Na+ ratio in muscle tissue was measured according to a 
previously reported method with slight modifications (Pichugin et al., 2006). Briefly, a 0.5 g of 
tissue (reduced into tiny portions of approximately 1 mm thick) was first washed twice in 10 ml 
of 0.3 M D-mannitol solution by a 2 min gentle agitation to remove ions from the extracellular 
spaces of the tiny slices. Thereafter, the washed tissue was incubated in 20 ml of 3% w/v 
trichloroacetic acid (TCA) for 24 h to rupture cells of tissue and release intracellular ions. The 
K+ and Na+ concentrations (ppm) were measured in the TCA supernatant using a flame 
photometer (Jenway PFP7 Flame Photometer, Jenway Ltd., Felsted, UK). 
 
iv) Measurement of glucose uptake in isolated rat psoas muscles 
The effect of maltitol, myo-inositol, sorbitol and erythritol on glucose uptake in isolated rat psoas 
muscles was determined according to procedures modified from previously reported methods 
(Hassan et al. 2010; Algandaby et al. 2010), by monitoring the glucose concentration change in 
an incubation solution containing 0.5 g of freshly isolated rat psoas muscle and different 
concentrations (2.5% to 20%) of maltitol, myo-inositol, sorbitol and erythritol. Briefly, a 0.5 g of 
isolated rat psoas muscle was incubated in 8 ml of Krebs buffer containing 11.1 mM (199.98 
mg/dl) glucose and increasing concentrations (2.5% to 20%) of maltitol, myo-inositol and 
erythritolor 2 mg/ml metformin (as positive control) with and without 200 mU/ml insulin. 
Incubation condition was at 5% CO2, 95% oxygen and 37°C. Glucose with Krebs buffer, but 
without maltitol, myo-inositol, sorbitol and erythritol was used as a control. Glucose 
concentration was measured in all incubated solutions before and after 1 h incubation and the 
muscle glucose uptake was calculated as the amount of glucose (mg) absorbed per gram of rat 
psoas muscle using the following formula: 
𝑀𝑢𝑠𝑐𝑙𝑒 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 𝑢𝑝𝑡𝑎𝑘𝑒 (𝑝𝑒𝑟 𝑔𝑟𝑎𝑚 𝑜𝑓 𝑚𝑢𝑠𝑐𝑙𝑒 𝑡𝑖𝑠𝑠𝑢𝑒)
=
(𝐺𝐶1 − 𝐺𝐶2)
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑚𝑢𝑠𝑐𝑙𝑒 𝑡𝑖𝑠𝑠𝑢𝑒 𝑖𝑛 𝑔𝑟𝑎𝑚
                    (𝐸𝑞. 2.3) 
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Where, GC1 and GC2 are glucose concentrations (mg/dl) before and after the incubation, 
respectively. 
Percentage glucose uptake used to determine the concentration of sorbitol required to cause 50% 
increase of muscle glucose uptake (GU50), with or without insulin was calculated as per 
following formula: 
% 𝑖𝑛𝑐𝑟𝑒𝑎𝑠𝑒 𝑖𝑛 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 𝑢𝑝𝑡𝑎𝑘𝑒 =  
(∆𝐺𝐶 𝑓𝑜𝑟 𝑠𝑎𝑚𝑝𝑙𝑒 − ∆𝐺𝐶 𝑓𝑜𝑟 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
∆𝐺𝐶 𝑓𝑜𝑟 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
  𝑥 100    (𝐸𝑞. 2.4) 
Where ∆GC = GC1 – GC2 
 
2.2.2 Experiment 2: In vivointestinal glucose absorption study 
Experiment 2 was conducted to determine theacute effect of a bolus tolerable dose of maltitol, 
myo-inositol, sorbitol and erythritol on intestinal glucose absorption, gastric emptying, digesta 
transit and postprandial blood glucose increase in a normal and T2D rat model. The schematic 
experimental design for this section of the study is presented in Fig. 2.2. 
 
i) Animals and grouping 
Sixty-six seven weeksold male SD rats with mean body weight 182.32 ± 9.44 g were procured 
from the Biomedical Resource Unit located at the Westville Campus of the University of 
KwaZulu-Natal, Durban, South Africa. Animals were randomly divided into eleven (11) groups, 
with six animals in eachgroup. The groups were namely: normal control (NC), normal maltitol 
(NML), normal myo-inositol (NMI), normal sorbitol (NSO), normal erythritol (NER), diabetic 
control (DBC), diabetic maltitol (DML), diabetic myo-inositol (DMI), diabetic sorbitol (DSO), 
diabetic erythritol (DER) and diabetic acarbose (DBA). All animals were fed with a commercial 
rat pellet diet and were maintained according to the rules and regulations of the Experimental 
Animal Ethics Committee of the University of KwaZulu-Natal, South Africa during the entire 




Figure 2.2: Experimental design ofexperiment 2 (in vivo intestinal glucose absorption study) 
 
ii) Induction of T2D 
Insulin resistance and partial pancreatic β-cell dysfunction are the two major etiological and 
pathophysiological characteristics of T2D. In order to induce T2D, we adopted the methods 
reported previously (Wilson & Islam, 2012). Briefly, a 10% fructose solution was supplied in the 
form of drinking water for first two weeks to the animals in diabetic groups (DBC, DML, DMY, 
DSO, DER and DBA) to induce insulin resistance, while the animals in the non diabetic groups 
(NC, NML, NMY, NSO and NER) were supplied with normal drinking water. Thereafter, 
animals in diabetic groups were injected with a single dose (i.p.) of streptozotocin (40 mg/kg bw) 
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dissolved in citrate buffer (pH 4.5) to induce partial pancreatic β-cell dysfunction, whereas the 
animals in the non diabetic groups were injected with citrate buffer only. One week after the 
streptozotocin injection, non-fasting blood glucose levels of all animals was measured using a 
portable Glucometer (Glucoplus Inc., Saint-Laurent, Quebec, Canada), and rats with blood 
glucose level >300 mg/dl were considered as diabetic, and used for the study, while those with 
blood glucose levels < 300 mg/dl were excluded from the study. 
 
iii) Feeding and sampling 
After the confirmation of diabetes, all animals were fasted overnight (16 h) with free access to 
drinking water only and then fasting blood glucose (mg/dl) was measured using a portable 
glucometer (Glucoplus Inc., Saint-Laurent, Quebec, Canada). Thereafter, animals in each group 
were orally administered the following as a bolus dose containing 0.05% phenol red (PR) as a 
recovery marker: 
 Normal control (NC) group  : 2g/kg bw glucose 
 Normal maltitol (NML) group : 2 g/kg bw glucose  +  0.6 g/kg bw maltitol 
 Normal myo-inositol (NMI) group : 2 g/kg bw glucose  +  1 g/kg bw myo-inositol 
 Normal sorbitol (NSO) group  : 2 g/kg bw glucose  +   0.4 g/kg bw sorbitol 
 Normal erythritol (NER) group : 2 g/kg bw glucose  +  1 g/kg bw erythritol 
 Diabetic control (DBC) group : 2 g/kg bw glucose 
 Diabetic maltitol (DML) group : 2 g/kg bw glucose  +  0.6 g/kg bw maltitol 
 Diabetic myo-inositol (DMI) group : 2 g/kg bw glucose  +  1 g/kg bw myo-inositol 
 Diabetic sorbitol (DSO) group : 2 g/kg bw glucose  +   0.4 g/kg bw sorbitol 
 Diabetic erythritol (DER) group : 2 g/kg bw glucose  +  1 g/kg bw erythritol 
 Diabetic acarbose (DBA) group : 2 g/kg bw glucose  +   100 g/kg bw acarbose 
Oral bolus dose of sugar alcohols was chosen considering their gastrointestinal tolerance after 
ingestion (Livesey, 2003; Flambeau et al., 2012). 
Exactly 1h after the ingestion and without access to food or drinking water, animals were 
sacrificed using halothane anaesthesia and blood sample (using cardiac puncture) as well as the 
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entire GIT of each animal was quickly collected. Glucose concentration was measured in the 
blood samples using an Automated Chemistry Analyzer (LabmaxPlenno, Labtest, Lagoa Santa, 
Brazil). The GIT from each animal was frozen immediately in liquid nitrogen to prevent the 
movement of the contents, and then preserved immediately at -30oC for further analysis. 
 
iv) Sample preparation and analysis 
Each gastrointestinal tract (GIT) was thawed and divided into eight segments: stomach; 1st, 2nd, 
3rd, and 4th quarters of small intestine; cecum; proximal and distal half of the colon. Content 
weight of each segment was determined by subtracting the weight of the segment without 
content from the respective weight of the segment with content. Contents and tissues were 
collected and individually homogenized in ice cold normal saline (Ultra Turrax Tube Drive  
Work Station homogenizer, IKA Laboratory equipment, Staufen, Germany) and centrifuged 
twice at 15,000 rpm for 30 min (HettichMikro 200 microcentrifuge, Hettich Lab Technology, 
Tuttlingen, Germany) as reported previously (Chukwuma& Islam, 2015). Phenol red (PR) 
concentration was determined spectrophotometrically (Synergy HTX Multi-mode reader, BioTek 
Instruments Inc, Winooski, USA) with bile acid correction in the supernatants of contents and 
tissue segments according to a previously published method with slight modifications (French et 
al., 1968). Briefly, 30 µl of supernatant or phenol red standard (concentrations 0.0038% - 
0.00025%) was mixed with 210 µl of 0.1 M dibasic sodium phosphate solution (pH 10.5). Then 
the optical density at 420 nm was subtracted from the optical density at 620 nm (for bile acid 
correction) to obtain the final optical density. The concentration of PR was calculated from the 
standard curve. Glucose concentration in the intestinal contents was measured using an 
Automated Chemistry Analyzer (LabmaxPlenno, Labtest Inc., Lagoa Santa, Brazil) using 
commercial assay kits. 
 
v) Calculations 











 𝑋 𝐻𝑜𝑚𝑜𝑔𝑒𝑛𝑖𝑧𝑎𝑡𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑚𝐿)   (𝐸𝑞. 2.5) 






 𝑋 𝐻𝑜𝑚𝑜𝑔𝑒𝑛𝑖𝑧𝑎𝑡𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑚𝐿) (𝐸𝑞. 2.6) 
Where, 1 mg/dl ≡ 0.00001 g/ml and 1% w/v ≡ 0.01 g/ml 
The calculated glucose (g) and PR recovered (g) were  used as indexes to calculate 
gastric emptying, glucose absorption index (GAI) and digesta transit according to previously 
described methods (Chukwuma& Islam, 2015). 
Gastric emptying, denoting the degree of emptying of stomach content was calculated 
using the following formula: 
𝐺𝑎𝑠𝑡𝑟𝑖𝑐 𝑒𝑚𝑝𝑡𝑦𝑖𝑛𝑔 (%) =  
𝐴 − 𝐵
𝐴
 𝑋 100                 (𝐸𝑞. 2.7) 
Where, “A” is the total amount of PR (g) recovered from GIT; and “B” is the total amount of PR 
(g) recovered from the stomach. 
Glucose absorption index (GAI) denotes the degree of glucose absorption in each 
segment of GIT. It is the percentage amount of the glucose absorbed passing through a given 
segment of GIT, and was calculated using the following formula: 





 𝑋 100        (𝐸𝑞.  2.8) 
Where, “a” is the amount of glucose (g) recovered from that segment; “b” is the amount of 
phenol red (g) recovered from the same segment; “c” is the amount of glucose (g) given to 




Digesta transit in a particular segment of the intestine is the ratio of the amount of content 
leaving that segment to the amount reaching the same segment. It was calculated in percentage 
using the following formula: 
𝐷𝑖𝑔𝑒𝑠𝑡𝑎 𝑡𝑟𝑎𝑛𝑠𝑖𝑡 𝑖𝑛 𝑎 𝑔𝑖𝑣𝑒𝑛 𝑠𝑒𝑔𝑚𝑒𝑛𝑡 (%) =  
𝑎
𝑏
 𝑋 100                 (𝐸𝑞.  2.9) 
Where “a” is the amount of phenol red (g) recovered from that particular segment of the GIT to 
the distal colon excluding the amount of phenol red (g) recovered from that particular segment 
and “b” is the amount of phenol red (g) recovered from that particular segment of the GIT to the 
distal colon. 
 
2.2.3 Experiment 3: In vivo muscle glucose uptake study 
Experiment 3 was conducted to determine the acute effect of a bolus erythritol treatment on 
glucose tolerance, insulin secretion, liver and muscle gluconeogenic and glycolytic enzyme 
activities and mRNA expression of Glut-4 and IRS-1 in a normal and T2D rat models. The 
schematic experimental design for this section of the study is presented in Fig. 2.3. 
 
i) Animals and grouping 
Sixteen seven weeks old male SD rats with mean body weight 191.93 ± 13.60 g were procured 
from the Biomedical Resource Unit located at the Westville Campus of the University of 
KwaZulu-Natal, Durban, South Africa. Animals were randomly divided into four groups, with 
four animals in each group. The groups were namely: normal control (NC), normal erythritol 
(NER), diabetic control (DBC) and diabetic erythritol (DER). All animals were fed with a 
commercial rat pellet diet and were maintained according to the rules and regulations of the 
Experimental Animal Ethics Committee of the University of KwaZulu-Natal, South Africa 




Figure 2.3: Experimental design ofexperiment 3 (in vivo muscle glucose uptake study) 
 
ii) Induction of T2D 
Type 2 diabetes was induced and confirmed in the DBC and DER groups using similar methods 




iii) Animal treatments 
A week after induction of diabetes, all animals were fasted overnight (16 h) with free access to 
drinking water only. After fasting, animals in the NER and DER groups were oral administered 
with 1 g/kg bwerythritol as a bolus dose. On the other hand, the animals in the NC and DBC 
groups were orally administered with equivalent volume of drinking water. 
 
iv) Oral glucose tolerance test (OGTT) and sampling 
Exactly 30 min after oral erythritol dosing, a 1 h oral glucose tolerance test (OGTT) was carried 
out on all animals. To perform this test, a single dose of glucose solution (2 g/kg bw) was orally 
administered to each animal and thereafter blood glucose was measured at 0 (just before glucose 
ingestion), 30 and 60 min after the glucose ingestion using a portable glucometer (Glucoplus 
Inc., Saint-Laurent, Quebec, Canada). Immediately after OGGT, all animals were euthanized 
using halothane anesthesia. Blood was collected by cardiac puncture into sterile plain tubes to 
obtain the serum, while psoas muscle and liver tissues were collected and preserved at -30oC for 
further analysis. Muscle tissue for gene expression studies was preserved in RNA later at 2oC to 
8oC, while the remaining liver and muscle tissues for enzyme assays were preserved at –30°C. 
 
v)       Sample preparation 
The blood was centrifuged (Eppendorf™ 5810R Centrifuge, Fisher Scientific, UK) at 3000 rpm 
for 15 min at 4°C to obtain the serum, which was preserved at –30°C for subsequent analysis. 
Liver and muscle tissue homogenates for enzyme assay were prepared according to a previously 
described method (Ngubane et al., 2011) with slight modifications. Briefly, a 0.5 g of tissue 
sample (liver or muscle) was homogenized (IKA TP 18/10 Utra-Turrax Homogenizer, IKA-
Works, StaufenimBreisgau, Germany) in 5 ml of ice-cold homogenization buffer (50 mMTris-
HCl buffer containing 100 mMKCl, 1 mM EDTA, pH 7.6). Homogenate was centrifuged 
(Microfuge 20R Centrifuge, Beckman Coulter, Inc., Germany) at 12,000 x g for 1 min at 4°C 
and supernatant was stored at -30°C for further analysis. 
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vi) Measurement of serum insulin concentration 
Serum insulin concentration was measured by an enzyme-linked immunosorbent assay (ELISA) 
method in a plate reader (Synergy HTX Multi-mode reader, BioTek Instruments Inc, Winooski, 
USA)using an ultrasensitive rat insulin ELISA kit (Mercodia, Uppsala, Sweden) according to the 
supplied protocols from the company. Briefly, 25 µl of serum or insulin standards (0.02, 0.05, 
0.15, 0.40 and 1.00 µg/L) and 100 µl of 1X peroxidase-anti-insulin conjugate solution were 
measured into supplied mouse monoclonal anti-insulin coated wells. Mixture was incubated at 
250 rpm (Ecotron Incubation Shaker, Infrost HT, Switzerland) for 3 h at room temperature. 
Thereafter wells were washed 6 times with 700 µl of a 1X wash buffer solution. A 200 µl of 
Tetramethylbenzidine (TMB) substrate was then added. Reaction was stopped by a 50 µl stop 
solution after 15 min of incubation at room temperature and absorbance was read at 450 nm in a 
plate reader (Synergy HTX Multi-mode reader, BioTek Instruments Inc, Winooski, USA). 
Serum insulin concentration was calculated from insulin standard curve and expressed in 
µIU/ml. 
 
vii) Measurement of protein concentration in tissue homogenates 
The total protein concentration in tissue supernatant was measured using an automated chemistry 
analyzer (LabmaxPlenno, Labtest Co. Ltd., Lagoa Santa, Brazil) with commercial assaykits from 
the same company according to the biuret method of protein quantification. 
 
viii) Determination of liverglucokinase and muscle hexokinase activities 
Hexokinase activity was measured by spectrophotometrically monitoring (340 nm) the NADP+-
dependent oxidation of glucose-6 phoshate (a product of hexokinase activity) according to a 







Figure 2.4: Schematic diagram showing the principle of tissue hexokinase assay 
 
Briefly, a 0.5 ml of 50mMtriethanolamine buffer (pH 7.6), 0.5 ml of 555 mM D-glucose, 
0.05 ml of 19 mM ATP, 0.1 ml of 100mM MgCl2, 0.1 ml of 14mM NADP⁺ and 0.02 ml of 125 
U/ml glucose-6-phosphate dehydrogenase were mixed in a clean test tube and equilibrated to 
25°C. Thereafter, a 0.025 ml of tissue homogenate (diluted to 15 mg/ml protein) or 0.025 ml of 
deionized water (for Blank) was added and immediately mixed by inversion. The increase in 
absorbance at 340 nm (UV mini 1240 spectrophotometer, Shimadzu Corporation, Kyoto, Japan) 
was immediately recorded for approximately 5 min and the reaction rate (ɸ) was calculated by 
dividing the increase in absorbance by the duration of time in minutes. The specific enzyme 
activity was calculated using the following formula: 






𝜀 ∗ 𝑆𝑉 ∗ 𝑃𝐶
    (𝐸𝑞. 2.10) 
Where,   
ɸtest and ɸblank= Reaction rates of sample and blank respectively; RV = Reaction volume (ml); DF 
= Dilution factor; ε = 6.22, which is the millimolar extinction coefficient of NADPH at 340 nm; 
SV = Sample volume (ml); PC = 15 mg/ml, which is the protein concentration of sample used 
for assay. 




ix) Determination of liver glucose-6-phosphatase activity 
Glucose-6-phospatase activity was determined by spectrophotometric quantification of glucose-6 
phospatase-catalyzed inorganic phosphate (Pi) production from glucose-6-phospate substrate per 
unit time according to previously described methods (Taussky & Shorr, 1953; Nordlie & Arion, 
1966) with slight modifications as described below. 
 
 
Figure 2.5: Schematic diagram showing the principle of tissue glucose-6 phosphataseassay 
 
Briefly, a 0.15 ml of 100 mM bis-tris buffer (pH 6.5) and 0.05 ml of 200 mM glucose-6-
phosphate solution were mixed in two separate microtubes, namely test and blank mixtures and 
then incubated for 5 min at 37°C. Thereafter, a 0.01 ml of liver homogenate (15 mg/ml protein) 
was first added to the test mixture. After 5 min incubation at 37°C, 0.045 ml of 20% TCA was 
added to both test and blank mixtures, followed by 0.01 ml of liver homogenate (15 mg/ml 
protein) to blank mixture only. Aliquots (0.125 ml) of supernatants (4000 rpm for 10 min) from 
both test and blank mixtures or phosphorus standard solutions (65, 130, 195, 260 and 325 µM) 
were then mixed with equal volume of Taussky-Shorr Colour Reagent (0.5 M sulfuric acid, 1% 
ammonium molybdatetetrahydrate and 5% ferrous sulfate heptahydrate) in a 96 well plate and 
incubated at 25°C for 5 min. The absorbance at 660 nm (Synergy HTX Multi-mode reader, 
BioTek Instruments Inc, Winooski, USA) of the blank mixture was first subtracted from the test 
mixture to eliminate the Pi(s) produced by other glucose-6-phophatase catalyzed reactions. The 
amount (µmole) of Pi librated form glucose-6phosphate was calculated from phosphorus 
standard curve. The specific activity of enzyme was calculated using the following formula: 
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𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑒𝑛𝑧𝑦𝑚𝑒 𝑎𝑐𝑡𝑖𝑣𝑡𝑦 (𝑈𝑛𝑖𝑡 𝑝𝑒𝑟𝑚 𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛) =  
(𝑃𝑖 𝑖𝑛 µ𝑚𝑜𝑙𝑒)(𝑅𝑉)(𝐷𝐹)
𝑇 ∗ 𝑆𝑉 1 ∗ 𝑃𝐶 ∗ 𝑆𝑉 2
       (𝐸𝑞. 2.11) 
Where,   
RV= Reaction volume (mL) of enzyme reaction; DF = Dilution factor; SV 1 = Sample volume 
(mL) of enzyme reaction; SV 2= Sample volume (mL) of Pi quantification reaction; PC = 15 
mg/mL, which is the protein concentration of sample; T = Incubation time (min) of enzyme 
reaction. 
One unit of enzyme activity ≡ 1 µmol/min, which will liberate 1 μmole of Pi per min at pH 7.6 at 
37°C. 
 
x) Tissue RNA extraction 
Total RNA in muscle tissue was extracted using the tri reagent extraction method according to a 
previously described protocol (Rio et al., 2010) with slight modifications. Briefly, muscle tissue 
(approximately 0.1 g) was homogenized (IKA TP 18/10 Utra-Turrax Homogenizer, IKA-Works, 
StaufenimBreisgau, Germany) in 1 ml of ice‐cold TRIzol® buffer. Immediately, 0.2 ml of 
chloroform was added and mixture was vortexed briefly and allowed to stand for 10 min at 25°C 
before centrifuging at 12,000 x g for 15 min at 4°C. The aqueous phase of the supernatant was 
then transferred into a fresh tube and RNA was precipitated with 0.5 ml of isopropanol at room 
temperature for 10 min and thereafter pelleted at 12,000 x g for 10 min at 4°C (Microfuge 20R 
Centrifuge, Beckman Coulter, Inc., Germany). The RNA pellet was washed once with 1 ml of 
75% ethanol at 7,500 x g for 5 min at 4°C, properly air-dried and then dissolved in 0.05 ml of 
ice-cold diethylpyrocarbonate (DEPC) treated water for immediate cDNA synthesis. RNA 
integrity was confirmed on a 2% agarose gel (containing 0.7 M formaldehyde) using autoclaved 
1x MOPS running buffer (10x MOPS buffer: 0.2 M MOPS, 10 mM disodium EDTA and 50 mM 
sodium acetate, pH 7.0). Total RNA concentration and purity was determined using a NanoDrop 





xi) cDNA synthesis from total RNA 
Approximately 1 µg of total RNA was used for cDNA synthesis using a commercial cDNA 
synthesis kit (1st Strand cDNA Synthesis Kit for RT-PCR-AMV, Roche, Germany) according to 
protocols from the kit manufacturer. Reaction mixture contained 2 µL of reaction buffer (100 
mM Tris-base and 500 mMKCl, pH 8.3), 4 µL of 25 mM MgCl2, 2 µL of deoxynucleotide mix 
(contained 10 mM each of dATP, dCTP, dTTP, dGTP), 2 µL of 1.6 µg/µL p(dN)6 Random 
primer, 1 µL of 50 U/µL RNase inhibitor, 1 µL of 16 U/µL Avian Myeloblastosis Virus (AMV) 
Reverse Transcriptase and varying volumes of RNase-free water and total RNA to make a final 
volume of 20 µL containing approximately 1 µg of total RNA. Mixture was vortexed and 
centrifuged briefly and thereafter incubated at room temperature for 10 min and at 42oC for 60 
min consecutively. Mixture was then stored at -20oC and later used for Real-Time PCR (qPCR) 
(CFX96 TouchTM Real-Time System, Bio-Rad Laboratories Inc., Hercules, Carlifonia). 
 
xii) Semi-quantitative determination of mRNA expression 
Semi-quantitative determination of mRNA expression of target genes by Real-Time PCR 
(qPCR) was carried out in a CFX96 TouchTM Real-Time System (Bio-Rad Laboratories Inc., 
Hercules, Carlifonia) using the iTaqTM Universal SYBR Green Supermix (Bio-Rad Laboratories, 
Inc., South Africa) and synthesized forward and reversed primers for both the genes of interest 
(Glut-4 and IRS-1 of the insulin signaling pathway) and reference gene (β-Actin) (Table 2.1) 
(Araujo    et al., 2004; Im et al., 2006) according to manufacturer’s instructions. Reaction 
mixture contained 10 µl of supermix, 1 µl each of 0.5 µM forward and reverse primers and 1 µl 
50 ng/µl cDNA for (for quantification) or 0.04 to 50 ng/µl cDNA (for determination of qPCR 
efficiency, also known as “E” value). The qPCR was carried out using the following 
“PrimePCR” program conditions: initial cDNA denaturation at 95°C for 2 min; 39 cycles (95°C 
for 5 sec denaturation and 54°C for 30 sec annealing); 95°C for 5 sec; and a melt curve from 65 
to 95°C at 5°C increment per 5 sec. The computed efficiencies (E) (Supplementary data 4) 
(Pfaffl, 2001) and single melt peaks (Supplementary data5) were used as indexes for validating 
the quality of qPCR. The qPCR efficiency (E) was calculated from a qPCR standard curve 
(Supplementary data 4) using the following formula (Pfaffl, 2001). 
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𝐸 = 10[−1/𝑠𝑙𝑜𝑝𝑒]                (𝐸𝑞.  2.12) 
% 𝐸 = (𝐸 − 1)  ×   100                     (𝐸𝑞.  2.13) 
Where, E = qPCR efficiency and   % E = qPCR percentage efficiency. 
 





Forward primer Reverse primer 
Expected 
product/amplicon size* 
     
β-Actin NM_031144.3 5’- ATG AAG 
ATC CTG ACC 
GAG CGT G-3’ 
5’-CTT GCT 
GAT CCA CAT 
CTG CTG G-3’ 
510 bp 
Glut-4 NM_012751.1 5’-AGA GTC TAA 
AGC GCC T-3’ 
5’-CCG AGA 
CCA ACG TGA 
A-3’ 
297 bp 
IRS-1 NM_012969.1 5’- ACC CAC TCC 
TAT CCC G-3’ 
5’-CCC TAC 
TCC GTT TGT 
CC-3’ 
375 bp 
* Expected product/amplicon sizes and primer specificity of qPCR were determined in silico using SnapGene 3.2.1, 
windows version software (Supplementary data 1, 2 & 3). 
 
The mRNA expression of the genes of interest was first normalized against the reference 
gene and thereafter the expression of the treated groups was expressed as fold change from their 
respective control groups using the following previously reported formulae (Schmittgen & 
Livak, 2008). 
𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 𝑑𝑢𝑒 𝑡𝑜 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 =
2−(∆𝐶𝑞)  𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑔𝑟𝑜𝑢𝑝
2−(∆𝐶𝑞)  𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑟𝑜𝑢𝑝




Cq = Quantitation Cycle, which is the number of cycles required for the fluorescent signal from 
starting cDNA to be detected or exceeds background level during a qPCR assay. 
∆Cq = Cq of gene of interest – Cq of reference gene. 
The qPCR products for both the genes of interest (Glut-4 and IRS-1) and reference gene 
(β-Actin) were subjected to a 2% agarose gel electrophoresis at 60 volts for 2 h and then 
visualized by ethidium bromide staining in a G:BOX F3 gel doc imaging system (Syngen 
Laboratory equipment supplier, Cambridge, UK). Product sizes were estimated from a 1 kb Plus 
DNA ladder. 
 
2.3 Statistical analysis 
Data are presented as mean ± SD of either 3–5 replicates of determination for ex vivo study 
(experiment 1);  5-6 animals for in vivo intestinal glucose absorption study (experiment 2); and 
4 animals for in vivo muscle glucose uptake study (experiment 3). All data were analyzed with a 
statistical software package (IBM SPSS, version 21 and 23) using Tukey’s HSD multiple range 
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Preface: The effect of maltitol on intestinal glucose absorption and muscle glucose uptake was 
investigated in this article using ex vivo and in vivo experimental models. The article has already 







This study investigated the effects of maltitol on intestinal glucose absorption and muscle 
glucose uptake using ex vivo and in vivo experimental models. The ex vivo experiment was 
conducted in isolated jejunum and psoas muscle from normal rats. The in vivo study investigated 
the effects of a single bolus dose of maltitol on gastric emptying, intestinal glucose absorption 
and digesta transit in normal and type 2 diabetic rats. Maltitol inhibited glucose absorption in 
isolated rat jejunum and increased glucose uptake in isolated rat psoas muscle in the presence of 
insulin but not in the absence of insulin. In contrast, maltitol did not significantly (p>0.05) alter 
small intestinal glucose absorption or blood glucose levels as well as gastric emptying and 
digesta transit in normal or type 2 diabetic rats. The results suggest that maltitol may not be a 




Global estimation of diabetes mellitus has revealed that approximately 415 million people were 
affected with the disease in 2015, and by 2040, this figure would become 642 million 
(International Diabetes Federation, 2015). Type 2 diabetes (T2D) is the most common form of 
diabetes mellitus. It is characterized by insulin resistance and pancreatic beta-cell failure, which 
leads to decrease glucose transport into the muscle and fat cells as well as increased 
gluconeogenesis and endogenous glucose production in the liver, causing hyperglycemia 
(Olokoba et al., 2012). T2D is a result of complex interaction between several factors such as 
genetic, environmental and behavioral risk factors (Olokoba et al., 2012; Wu et al., 2014). 
However, the most influential factors are the behavioral risk factors such as sedentary life style, 
consumption of high fat and high calorie diets as well as refined and simple carbohydrates like 
sucrose and fructose among others (Thorburn et al., 1989; Elliott et al., 2002; Astrup et al., 2002; 
Hu, 2003; Stanhope et al., 2011). Thorburn et al. (1989) reported that normal rats that consumed 
diet containing 35% of energy as fructose displayed reduced glucose disposal as well as reduced 
action of insulin in the liver and most peripheral tissue. Additionally, Stanhope et al. (2011) 
reported that postprandial triglycerides, LDL-cholesterol, and apolipoprotein-B in young male 
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and female adults were markedly increased after 12 days consumption of fructose and high 
fructose corn syrup that was equivalent to 25% of total dietary energy. Furthermore, in human 
subjects, 10 weeks consumption of sucrose equivalent to 28% of dietary energy increased food 
intake, body weight, body fat mass, and blood pressure compared to non-sucrose sweetener 
(Astrup et al. 2002). Hence, there has been a growing acceptance of the use of sugar substitutes 
as alternative sweetening agents in both non-diabetic and diabetic diets. 
Sugar alcohol is one of the classes of sugar substitute that have gained popularity, 
especially for overweight, obese and diabetic individuals due to their lower caloric value and 
glycemic response compared to glucose and sucrose as well as minimal or no side effects 
(Livesey 2003, 2012; Islam & Indarjit, 2012; Fitch & Keim, 2012). Maltitol is one of the few 
commonly used disaccharide sugar alcohol formed from the catalytic hydrogenation of maltose 
to produce an alpha-l, 4 glucose-sorbitol linked polyol (Kearsley & Deis, 2012). Like most sugar 
alcohols, maltitol is poorly absorbed in the small intestine and also has a lower glycemic (35 
versus 68) and insulinemic index (27 versus 45), lower caloric value (2.4 versus 4 kcal/g) and 
sweetening strength (about 90%) compared to sucrose (Kearsley & Deis, 2012; Livesey, 2012). 
The oral health benefit of maltitol has been recognized in several in vitro and animal 
studies (Izumitani et al., 1989; Ooshima et al., 1992) as well as clinical trials (Li et al., 2010; 
Keukenmeester et al., 2014). However, the health benefit of maltitol is not limited to dental 
protection. Data from previous studies suggest that maltitol may also possess appreciable anti-
hyperglycemic potentials (Matsuo, 2003; Quílez et al., 2007). This is because a single oral 
administration of 50 g maltitol in healthy subjects resulted in significantly lower glycemic and 
insulin responses compared to the administration of same amount of glucose or sucrose (Secchi 
et al., 1986; Matsuo, 2003). It has been also reported that the consumption of 30 or 50 g maltitol 
as a single oral dose resulted in lower glucose and insulin response compared to the consumption 
of equivalent amount of maltose or glucose by diabetic subjects (Mimura et al., 1972; Vessby et 
al., 1990). Furthermore, overweight subjects fed with maltitol-sweetened muffins containing low 
fat, low calories and high-amylose cornstarch showed reduced blood glucose level, insulin and 
lipidemic responses, but increased satiety compared to those fed with conventional sugar-
sweetened muffin (Quílez et al., 2007). Additionally, two previous studies reported that a single 
oral administration of maltitol: sorbitol mixture (60:7) (Wheeler et al., 1990) or 50 g of maltitol 
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(Moon et al., 1990) caused significantly lower blood glucose and insulin responses compared to 
the administration of same amount of glucose in both normal and diabetic subjects. 
In a more recent study, Kang et al. (2014) reported the in vitro alpha glucosidase, alpha 
amylase, and sucrase inhibitory activities of maltitol, which suggests that maltitol may be useful 
in controlling carbohydrate digestion and postprandial hyperglycemia. However, contrary to this, 
Matsuo (2003) reported that maltitol does not inhibit intestinal alpha glucosidase, sucrase, or 
maltase activities when a single oral dose of a mixture of maltitol and sucrose (25:25 g) or 
sucrose (50 g) or maltitol (50 g) was given to healthy human subjects. Based on the results of 
above-mentioned studies, we hypothesized that maltitol may show hypoglycemic response via 
other mechanisms such as inhibiting intestinal glucose absorption and/or increasing muscle 
glucose uptake rather than inhibiting intestinal carbohydrate digesting enzyme activities. 
Therefore, this study was conducted to examine whether maltitol causes anti-
hyperglycemic effects via inhibition of intestinal glucose absorption and/or increasing muscle 
glucose uptake by using ex vivo experimental model as well as normal and T2D models of rats. 
 
3.3 Materials and methods 
Please refer to chapter 2, sub-sections 2.2.1 and2.2.2, pages 66-74 for detailed material and 
methods of this article. 
 
3.4 Results 
3.4.1 Ex vivo study (experiment 1) 
Effects of maltiol on intestinal glucose absorption and muscle glucose uptake 
Data for the effects of maltiol on intestinal glucose absorption and muscle glucose uptake are 
presented in Fig. 3.1 and 3.2 as well as Table 3.1. Incubation of jejunal tissue with all the tested 
concentrations of maltitol significantly inhibited glucose absorption (p<0.05) in a concentration-
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dependent manner compared to the control (Fig. 3.1). The computed IC50 value for inhibiting 
glucose absorption by maltitol was 3.57 ± 1.18%. 
 
 
Figure 3.1: Effect of maltitol on glucose absorption in isolated rat jejunum. Data are presented 
as mean ± SD of triplicate analysis. abcDifferent letters presented above the bars are significantly 
different from each other (p<0.05; Tukey’s HSD post-hoc test, IBM, SPSS version 21). 
 
On the other hand, in the presence of insulin, maltitol increased glucose uptake in the 
isolated rat psoas muscle in a concentration dependent manner (Fig. 3.2). The glucose uptake at 
20% maltitol concentration was significantly higher (p<0.05) than the control, but significantly 
lower (p<0.05) than a 2 mg/mL metformin containing sample, while glucose uptake at 2.5, 5 and 
10% maltitol concentrations did not show significant differences compared to either the control 
or a 20% maltitol containing sample (Fig. 3.2).The computed GU50 value of maltitol was 7.31 ± 
2.08% when treated with insulin (Table 3.1). However, in the absence of insulin, glucose uptake 
at all maltitol concentrations was significantly lower (p<0.05) than a 2 mg/mL metformin 
containing sample, but did not show any significant difference compared to the control (Fig. 
3.2). The GU50 value was 111.12 ± 19.36% (Table 3.1), which is significantly higher than the 










































Figure 3.2: Effect of maltitol on glucose uptake with or without insulin in isolated rat psoas 
muscle. Data are presented as mean ± SD of triplicate analysis. abc & xyDifferent letters presented 
above the bars for with or without insulin are significantly different from each other (p<0.05; 
Tukey’s HSD post-hoc test, IBM, SPSS version 21). 
 
Table 3.1: GU50 values of percentage glucose uptake increase of maltitol in isolated psoas 
muscle, with and without insulin 
 With insulin (200mU/mL) Without insulin 
GU50 (%) 7.31 ± 2.08
a 111.12 ± 19.36b 
Data are presented as mean ± SD of triplicates of analysis. abValues with different superscript letters are significantly 
different from each other (p < 0.05; T-test, IBM, SPSS, version 21).GU50: concentration (%w/v) of maltitol required 
to cause 50% increase of muscle glucose uptake. 
 
Furthermore, 1 h incubation of psoas muscle tissue did not significantly affect the cellular 
ATP concentration and K+/ Na+ ratio compared to fresh tissue which was used for the muscle 







































With insulin (200 mU/mL) Without insulin
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Table 3.2: Verification of psoas muscle tissue viability after 1 h of incubation in ex vivo muscle 
glucose uptake study 
 Psoas muscle tissue viability indexes 
 ATP level (µM)  K+/Na+ ratio viability index 
   K+ conc. (ppm) Na+ conc. (ppm) K+/Na+ ratio 
      
Freshly isolated 
tissue 




18.92 ± 2.63  9.53 ± 0.46 1.18 ± 0.10 8.12 ± 0.99 
**Tissue incubation condition was similar to ex vivo experimental condition (5% CO2, 95% oxygen and 37 °C). 
ppm: concentration in part per million. 
 
3.4.2. In vivointestinal glucose absorption study (experiment 2) 
Effects of maltitol on gastric emptying, glucose absorption index, digesta transit and blood 
glucose level 
The data for the effects of maltitol on gastric emptying, glucose absorption index and blood 
glucose level are presented in Fig. 3.3 to 3.5 and Table 3.3. Gastric emptying was significantly 
increased (p<0.05) after induction of diabetes. Treatment with maltitol did not significantly 
affect the gastric emptying in normal and diabetic animals, while acarbose treatments 








Figure 3.3: Effects of maltitol on gastric emptying in different animal groups at the end of a 1 h 
experimental period. Data are presented as mean ± SD of 5–6 animals. abcDifferent letters 
presented above the bars are significantly different from each other group of animals, 
*significantly different from NC group and #significantly different from DBC group (p<0.05; 
Tukey’s HSD post-hoc test, IBM, SPSS version 21). NC: normal control; NML: normal maltitol; 
DBC: diabetic control; DML: diabetic maltitol; DBA: diabetic acarbose. 
 
Furthermore, administration of maltitol did not significantly (p>0.05) affect the glucose 
absorption index GAI in the different intestinal segments of both normal and diabetic animals, 
while ingestion of acarbose significantly reduced (p<0.05) GAI in the 1st qtr of the small 
intestine, cecum and proximal colon of diabetic animals (Fig. 3.4). Additionally, ingestion of 
maltitol did not significantly lower postprandial blood glucose increase in both normal and 
diabetic animals, while ingestion of acarbose significantly (p<0.05) decreased postprandial blood 






































Figure 3.4: Effect of maltitol on glucose absorption index (GAI) in the different GIT segments 
of different animal groups at the end of a 1 h experimental period. Data are presented as mean ± 
SD of five to six animals. abDifferent letters presented above the bars for a given segment are 
significantly different from each other group of animals, *significantly different from NC group 
and #significantly different from DBC group (p<0.05; Tukey’s HSD post-hoc test, IBM, SPSS 
version 21). NC: normal control; NML: normal maltitol; DBC: diabetic control; DML: diabetic 
maltitol; DBA: diabetic acarbose. 
 
 
Figure 3.5: Effects of maltitol on final blood glucose concentration and blood glucose increase 
in animals after 1 h of the dose administration. Data are presented as mean ± SD of six animals. 
abc& yzDifferent letters presented above the bars are significantly different from each other group 
of animals, *significantly different from NC group and #significantly different from DBC group 
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The data for the effects of maltitol on intestinal digesta transit also revealed that maltitol 
or acarbose treatment did not significantly affect digesta transit percentage in the 1st to 3rd qtrs 
of the small intestine in normal or diabetic animals (Table 3.3). However, from the 4th qtr of the 
small intestine to the proximal colon, maltitol treatment significantly increased (p<0.05) digesta 
transit in normal animals. In diabetic animals, maltitol was able to significantly increase (p<0.05) 
digesta transit in the cecum only, while acarbose treatment significantly increased (p<0.05) 
digesta transit in the cecum and proximal colon (Table 3.3). 
 
Table 3.3: Effect of maltitol ondigesta transit in the different segments of the intestinal tract 
during 1 h experimental period 
Group 1stqtr 2ndqtr 3rdqtr 4thqtr Cecum Prox. Colon 
 Small intestine  Large Intestine 
  Digesta Transit (%)   
NC 95.26 ± 4.01 89.36 ± 4.58 70.27 ± 12.07a 48.53 ± 4.10a 23.68 ± 5.63a 36.81  ± 9.21a 
NML 94.74 ± 4.15 86.75 ± 4.53 76.13 ± 3.34b* 73.23 ±3.53b* 35.35± 2.91b* 57.58 ±7.77b* 
DBC 90.97 ± 0.08 87.86 ± 1.59 76.55  ± 5.16b 72.01 ±7.04b 37.56 ± 3.58b 49.69  ± 0.90b 
DML 89.91 ± 7.57 84.27 ± 7.34 73.77 ± 2.86b 73.90±3.36b 52.14 ± 5.69c# 54.54 ± 2.61b 
DBA 93.85 ± 4.72 87.01 ± 5.29 79.48  ± 6.09b 71.76 ±5.38b 65.26 ± 5.25d# 87.63  ± 3.07c# 
Data are presented as mean ± SD of five to six animals. abcdDifferent superscript letters presented in each column for 
a given segment are significantly different from each other group of animals, *significantly different from NC group 
and #significantly different from DBC group (p<0.05; Tukey’s HSD post-hoc test, IBM, SPSS version 21). NC: 
normal control; NML: normal maltitol; DBC: diabetic control; DML: diabetic maltitol; DBA: diabetic acarbose. 
 
3.5 Discussion 
Dietary sugar alcohols are known for their several health benefits in both normoglycemic and 
diabetic individuals (Livesey, 2003; Livesey 2012; Van Loveren, 2004). Maltitol is one of the 
few disaccharide sugar alcohols that are commonly used in various food products. However, the 
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effect of maltitol on intestinal glucose absorption and muscle glucose uptake has not been fully 
elucidated. In this study, we found that maltitol inhibits intestinal glucose absorption and 
increases insulin-mediated muscle glucose uptake under ex vivo condition but not in normal and 
type 2 diabetic rats, when co-ingested with glucose. 
Dietary glucose is rapidly absorbed from the small intestine. However, in vitro studies 
have suggested that the proximal (Rider et al., 1967) or mid-small intestine (part of the 
duodenum and jejunum) (Lavin, 1976) exhibited the highest glucose absorption. Hence, the 
jejunal segment of rat intestine was used to study glucose absorption in the ex vivo experiment. 
Also, it is a known fact that osmotic pressure can influence intestinal water and glucose 
absorption. A previous in vitro study suggested that decreasing osmolality resulted in enhanced 
absorption of luminal water and glucose in isolated rat duodenum (Daum et al., 1978). In our ex 
vivo absorption study, the peak value of 5.20 ± 0.72 mg/cm jejunum of glucose absorption was 
observed which was reduced to 3.00 ± 0.35 mg/cm jejunum in the presence of 2.5% maltitol 
(Fig. 3.1). Additionally, the inhibitory effect of maltitol on the jejunal glucose absorption was 
concentration-dependent reaching the lowest value of 1.20 ± 0.20 mg/cm jejunum at 20% 
maltitol concentration. These findings suggest a concentration-dependent inhibitory effect of 
maltitol on jejunal glucose absorption under ex vivo condition, which may be partly due to the 
increasing osmolarity (388.48–896.68 mOsm/l) effect of increasing maltitol concentrations (2.5–
10%).  
However, unlike the significant ex vivo inhibitory effect of maltitol on jejunal glucose 
absorption, a single oral administration of maltitol, co-ingested with glucose, did not 
significantly affect or reduce the glucose absorption index in the intestinal segments (Fig. 3.4). 
This effect equally translates into the observed insignificant effect on postprandial blood glucose 
level (Fig. 3.5) of normoglycemic and diabetic animals. This observation under in vivo condition 
may be linked to the hydrolysis of maltitol by disaccharidases of the small intestinal mucosa as 
demonstrated in several previous studies (Kamoi, 1975; Rennhard & Bianchine, 1975; Lian-Loh 
et al., 1982). Interestingly, our ex vivo and in vivo observations seem to further explain the 
apparent discrepancy on the reported effects of maltitol on alpha glucosidase and alpha amylase 
which varied from in vitro (Kang et al., 2014) to in vivo experimental conditions (Matsuo, 2003). 
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Gastric emptying and digesta transit rates of GIT largely influence the absorption of 
nutrient in the small intestine. Previous studies have reported that delayed gastric emptying and 
accelerated digesta transit can contribute to reduce intestinal nutrient absorption as well as food 
intake (Salminen et al., 1984; Shafer et al., 1987), which is believed to be a mode of action of 
acarbose in controlling postprandial blood glucose rise in diabetic patients (Ranganath et al., 
1998). In our in vivo absorption study, single oral dose of maltitol did not significantly influence 
gastric emptying in normal or diabetic animals (Fig. 3.3), which may be partly responsible for 
the insignificant effect of maltitol on small intestinal glucose absorption (Fig. 3.4). However, 
maltitol accelerated the digesta transit in the cecum of diabetic rats but not in other segments 
(Table 3.3), which could not affect the overall intestinal glucose absorption since most of the 
glucose absorption occur in the 1st qtr to mid-small intestine (Rider et al., 1967; Lavin, 1976). 
The uptake of circulating glucose by cells, for either storage or energy metabolism is a 
major mechanism of the body to maintain glucose homeostasis when there is rise in blood 
glucose due to dietary glucose absorption, glycogen breakdown and gluconeogenesis (Aronoff et 
al., 2004). Insulin is the major regulatory hormone that stimulates clearance of circulating 
glucose via an insulin-mediated cellular uptake of glucose (Aronoff et al., 2004). Although in 
some previous studies it has been reported that hyperosmolarity increases muscle glucose uptake 
via modulating AMP-Kinase and/or inhibiting the endocytosis of glucose transporter type 4 
(Gual et al., 2003), this may not be the case in our ex vivo study. The data from our ex vivo study 
(Table 3.1 and Fig. 3.2) revealed that although maltitol exhibited insulin-mediated glucose 
uptake (GU50 = 7.31 ± 2.08%), it did not show any appreciable glucose uptake effect without 
insulin in isolated rat psoas muscle (GU50 = 111.12 ± 19.36%). This observation could suggest, at 
least in ex vivo condition, that maltitol may potentiate an insulin-mediated glucose uptake in 
muscles, when increasing osmolarity (388.48–896.68 mOsm/l) due to increasing maltitol 
concentrations may not be an influencing factor in this regard. 
In summary, maltitol showed significant inhibitory effects on small intestinal glucose 
absorption and could increase insulin-mediated muscle glucose uptake ex vivo but did not 
possess appreciable inhibitory effect on intestinal glucose absorption or postprandial blood 
glucose level in normal or diabetic animals, when co-ingested with glucose, which may be linked 
to its hydrolysis by intestinal disaccharidases. Thus, maltitol may not be a useful dietary 
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supplement to ameliorate hyperglycemia via reducing intestinal glucose absorption or enhancing 
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The present study investigated the effects of myo-inositol on muscle glucose uptake and 
intestinal glucose absorption ex vivo as well as in normal and type 2 diabetes model of rats. In 
the ex vivo study, both intestinal glucose absorption and muscle glucose uptake were studied in 
isolated rat jejunum and psoas muscle respectively in the presence of increasing concentrations 
(2.5 % to 20 %) of myo-inositol. In the in vivo study, the effect of a single bolus dose (1 g/kg 
bw) of oral myo-inositol on intestinal glucose absorption, blood glucose, gastric emptying and 
digesta transit was investigated in normal and type 2 diabetic rats after 1 h of co-administration 
with 2 g/kg bw glucose, when phenol red was used as a recovery marker. Myo-inositol inhibited 
intestinal glucose absorption (IC50 = 28.23 ± 6.01 %) and increased muscle glucose uptake, with 
(GU50 = 2.68 ± 0.75 %) or without (GU50 = 8.61 ± 0.55 %) insulin. Additionally, oral myo-
inositol not only inhibited duodenal glucose absorption and reduced blood glucose increase, but 
also delayed gastric emptying and accelerated digesta transit in both normal and diabetic 
animals. Results of this study suggest that dietary myo-inositol inhibits intestinal glucose 
absorption both in ex vivo and in normal or diabetic rats and also promotes muscle glucose 
uptake in ex vivo condition. Hence, myo-inositol may be further investigated as a possible anti-
hyperglycemic dietary supplement for diabetic foods and food products. 
 
4.2 Introduction 
Recent data indicate that about 415 million people have diabetes worldwide and this figure is 
likely to increase to about 642 million by 2040 (International Diabetes Federation, 2015). 
Among the two major types of diabetes (type 1 and type 2), type 2 is the most prevalent one, 
accounting for more than 90 % of all diabetic cases (Loghmani, 2005). Type 2 diabetes (T2D) is 
a heterogeneous disorder characterized by insulin resistance followed by partial pancreatic β-cell 
dysfunction (Partley, 2013), leading to persistent hyperglycaemia. The chronic hyperglycaemia 
is strongly influenced by sedentary life style, high fat and high calorie diets as well as routine 
consumption of refined and simple sugars (Uusitupa, 2002; Hu, 2003; Montonen et al., 2007; 
Stanhope et al., 2011). Hence, among other therapeutic approaches, reducing the consumption of 
high calorie and high glycaemic index foods as well as increasing intake of agents that delay 
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post-prandial hyperglycaemia are rapidly gaining public endorsement (Bessesen, 2001; Livesey, 
2003; Brown et al., 2010). Recently, there has been a growing interest in the search for 
nutraceuticals such as sugar alcohols that possess lower calorific value and glycaemic index 
compared to sucrose and could have the potentials to delay the postprandial blood glucose rise 
(Livesey, 2003; Brown et al., 2010). 
Myo-inositol is one of the rarely used sugar alcohols, which has structural resemblance to 
glucose and it is present in a wide variety of foods and food products at low concentrations 
(Clements & Darnell, 1980). It belongs to the group of stereoisomers collectively called inositol 
(1,2,3,4,5,6-cyclohexanehexol or simply cyclohexanehexol) (Chung & Kwon, 1999). Inositol 
comprises of nine different stereoisomers but myo-inositol is the body’s main stereoisomer 
(comprising over 90 % of cellular inositol) (Chung & Kwon, 1999; McLaurin et al., 2000). 
However, D-chiro-inositol has been reported as another important stereoisomer of myo-inositol 
in fat, muscle and liver tissues (Facchinetti et al., 2015). The action of inositol epimerase 
determines the physiological distribution of myoinositol and D-chiro-inositol, which also 
influences their distinct physiological functions (Heimark et al., 2014; Unfer et al., 2014; 
Facchinetti et al., 2015). 
Myo-inositol is associated with glucose transporters activation and glucose utilization, 
while D-chiro-inositol is majorly involved in the synthesis of glycogen in the liver, fat and 
muscle tissues (Heimark et al., 2014). A number of recent studies reported that these two 
inositols consistently improved glucose metabolic markers, insulin resistance and dyslipidaemia 
in post postmenopausal women with metabolic syndrome (Giordano et al., 2011; Nordio & 
Proietti, 2012; Minozzi et al., 2013), when their combination normalized the risks of metabolic 
diseases better than myo-inositol alone in overweight patients with polycystic ovary syndrome 
(PCOS) (Nordio & Proietti, 2012; Minozzi et al., 2013). From the results of a recent 
international consensus conference, myo-inositol and D-chiroinositol have been reported as the 
second messenger of insulin in several insulin dependent processes such as metabolic syndrome 
and PCOS (Facchinetti et al., 2015). It has been also reported that although these two isomers of 
inositol have distinct effects, a number of observations required further intensive investigation. 
Additionally, myo-inositol supplementation has been reported to modulate lipid and 
glucose metabolism, which are closely associated with T2D (Onomi & Katayama, 1997; Yap et 
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al., 2007; Maeba et al., 2008; Dang et al., 2010). Daily administration of 5 or 10 g/ day of myo-
inositol for a week significantly reduced LDL-cholesterols and apo-lipoprotein B in subjects with 
lifestyle-related diseases such as obesity and hyperlipidemia (Maeba et al., 2008). In the same 
study, significant reduction of blood glucose level, particularly in the metabolic syndrome 
subjects, suggests the hypoglycaemic potential of myo-inositol. Additionally, Dang et al. (2010) 
reported that oral administration of a single dose of 1000 mg/kg myo-inositol caused an acute 
hypoglycaemic effect when administered with 2 g/kg bw glucose, and was also responsible for 
Glut-4 translocation, which was observed 30 min after the ingestion time (Dang et al., 2010). In 
fact, 1 mM of myo-inositol and/or several inositol metabolites have been reported to be as 
effective as 100 nM insulin in stimulating Glut-4 translocation to the cell membrane, in vitro 
(Yap et al., 2007), which may be partly associated with the improved insulin sensitivity and 
hypoglycemic effects of dietary myo-inositol. 
In spite of the above-mentioned studies, the direct effect of dietary myo-inositol on 
muscle glucose uptake is still not clear, and there are currently no studies to ascertain the effect 
of dietary myo-inositol on intestinal glucose absorption. Hence, the present study was conducted 
to examine the effects of myo-inositol on muscle glucose uptake and intestinal glucose 
absorption in isolated rat’s psoas muscle and jejunum, respectively (ex vivo) and in normal and 
type 2 diabetes model of rats (in vivo). 
 
4.3 Materials and methods 
Please refer to chapter 2, sub-sections 2.2.1 and 2.2.2, pages 66-74 for detailed material and 









4.4.1 Ex vivo study (experiment 1) 
Effects of myo-inositol on intestinal glucose absorption and muscle glucose uptake 
Data for the effects of myo-inositol on intestinal glucose absorption and muscle glucose uptake 
are presented in Fig. 4.1 and 4.2 as well as Table 4.1. Myo-inositol exhibited a concentration-
dependent effect on rat jejunal glucose absorption ex vivo (Fig. 4.1) with an IC50 = 28.30 ± 6.01 
%. Incubation of jejunal tissue in 10 % and 20 % myo-inositol significantly (p < 0.05) reduced 
glucose absorption compared to the control. However, the effects of 2.5 % and 5 % myo-inositol 
on the jejunal glucose absorption were not significantly (p > 0.05) different compared to the 
control (Fig. 4.1). 
 
 
Figure 4.1: Effect of myo-inositol on glucose absorption in isolated rat jejunum. Data are 
presented as mean ± SD of five replicates of analysis. abDifferent letters presented above the bars 
are significantly different from each other (p < 0.05; Tukey’s HSD multiple range post-hoc test, 













































Furthermore, glucose uptake at 10 % and 20 % concentrations of myo-inositol was 
significantly higher (p < 0.05) than the control, when glucose uptake at 2.5 % and 5 % of myo-
inositol containing sample did not show any significant difference compared to the control with 
or without insulin (Fig. 4.2). A 2 mg/mL metformin significantly increased (p < 0.05) muscle 
glucose uptake than all myo-inositol containing samples with or without insulin. The computed 
GU50 values for the increased glucose uptake in the isolated rat psoas muscle by myo-inositol 
(2.5 % - 20 %) were 2.68 ± 0.75 %, with insulin and 8.61 ± 0.55 %, without insulin (Table 4.1), 




Figure 4.2: Effect of myo-inositol on glucose uptake with or without insulin in isolated rat psoas 
muscle. Data are presented as mean ±SD of triplicate analysis. a-d or w-z Different letters presented 
above the bars for with or without insulin are significantly different from each other (p < 0.05; 




















































with insulin (200mU/mL) without insulin
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Table 4.1: Percentage GU50 values of glucose uptake increase of myo-inositol in isolated psoas 
muscle, with and without insulin 
 With insulin (200mU/mL) Without insulin 
GU50 (%)* 2.68 ± 0.75
a 8.61 ± 0.55b 
Data are presented as mean ± SD of triplicate analysis. abValues with different superscript letters are significantly 
different from each other (p < 0.05; Tukey’s HSD multiple range post-hoc test, IBM, SPSS version 21).*GU50: 
Concentration (% as w/v) of myo-inositol required to cause 50% increase of muscle glucose uptake. 
 
Additionally, muscle tissue viability studies confirmed that 1 h incubation of psoas 
muscle tissue did not significantly affect the viability of the tissue (Please refer to Table 3.2 in 
chapter 3, sub-section 3.4.1, section 3.4, page 92 for supporting data). 
 
4.4.2 In vivo intestinal glucoseabsorption study (experiment 2) 
Effects of myo-inositol on gastric emptying, glucose absorption index, digesta transit and 
blood glucose level 
The data for the effects of myo-inositol on gastric emptying, glucose absorption index and blood 
glucose level are presented in Fig. 4.3 to 4.5 and Table 4.2. Gastric emptying significantly 
increased (p < 0.05) after the induction of diabetes, while myo-inositol and acarbose treatments 
significantly reduced (p < 0.05) gastric emptying in diabetic animals. Treatment with myo-
inositol did not significantly affect gastric emptying in normal animals (Fig. 4.3).  
Furthermore, Ingestion of myo-inositol significantly reduced (p < 0.05) GAI in the 1st qtr 
of the small intestine in both normal and diabetic animals, while similar effects were observed in 
the 2nd and 3rd qtrs of the small intestine of normal animals. Ingestion of acarbose significantly 
reduced (p < 0.05) GAI in the 1st qtr of the small intestine, cecum as well as proximal colon of 
diabetic animals, while no significant difference in GAI was observed in the other intestinal 





Figure 4.3: Effect of myo-inositol on gastric emptying in different animal groups at the end of a 
1 h experimental period. Data are presented as mean ± SD of 5–6 animals. abcDifferent letters 
presented above the bars are significantly different from each other group of animals, 
*significantly different from NC group and #significantly different from DBC group (p<0.05; 
Tukey’s HSD post-hoc test, IBM, SPSS version 21). NC, normal control; NMI, normal myo-
inositol; DBC, diabetic control; DMI, diabetic myo-inositol; DBA, diabetic acarbose. 
 
 
Figure 4.4: Effect of myo-inositol on glucose absorption index (GAI) in the different GIT 
segments of different animal groups at the end of a 1 h experimental period. Data are presented 
as mean ± SD of five to six animals. abDifferent letters presented above the bars for a given 
segment are significantly different from each other group of animals, *significantly different 
from NC group and #significantly different from DBC group (p<0.05; Tukey’s HSD post-hoc 
test, IBM, SPSS version 21). NC, normal control; NMI, normal myo-inositol; DBC, diabetic 
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Although the data were not significantly different in normal animals, single oral dose of 
myo-inositol and acarbose significantly reduced (p < 0.05) the increment of blood glucose 1 h 
after the dose administration (Fig. 4.5). 
 
 
Figure 4.5: Effects of myo-inositol on final blood glucose concentrations and blood glucose 
increase in animals after 1 h of the dose administration. Data are presented as mean ± SD of six 
animals. abc& xyzDifferent letters presented above the bars are significantly different from each 
other group of animals,*significantly different from NC group and #significantly different from 
DBC group (p<0.05; Tukey’s HSD multiple range post-hoc test, IBM, SPSS version 21). NC, 
normal control; NMI, normal myo-inositol; DBC, diabetic control; DMI, diabetic myo-inositol; 
DBA, diabetic acarbose. 
 
Although not significantly different (p > 0.05), myoinositol treatment increased digesta 
transit in the 1st, 3rd and 4th qtrs of the small intestine of diabetic animals as well as in the 2nd 
qtr of the small intestine of normal animals (Table 4.2). However, both myo-inositol and 
acarbose treatments significantly increased (p < 0.05) digesta transit in the cecum and proximal 
colon of the diabetic animals. On the other hand, myoinositol treatment significantly increased (p 
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Table 4.2: Effect of myo-inositol on digesta transit in the different segments of the intestinal 
tract during 1 h experimental period 
Group 1stqtr 2ndqtr 3rdqtr 4thqtr Cecum Prox. colon 
 Small intestine  Large intestine 
                               Digesta transit (%)   
NC 95.26 ± 4.01ab 89.36 ± 4.58 70.27 ± 12.07a 48.53 ± 4.10a 23.68 ± 5.63a 36.81  ± 9.21a 
NMI 95.52 ± 1.13a 92.97 ± 2.37 88.84 ± 1.71b* 80.92 ±3.53b* 78.13± 7.57b* 68.42  ± 6.73b* 
DBC 90.97 ± 0.08b 87.86 ± 1.59 76.55  ± 5.16ab 72.01 ±7.04b 37.56 ± 3.58c 49.69  ± 0.90c 
DMI 95.22 ± 2.72ab 87.40 ± 5.89 85.67 ± 1.16ab 82.88±3.94b 51.98 ± 1.34d# 55.03  ± 3.43b# 
DBA 93.85 ± 4.72ab 87.01 ± 5.29 79.48  ± 6.09ab 71.76 ±5.38b 65.26 ± 5.25b# 87.63  ± 3.07d# 
Data are presented as mean ± SD of five to six animals. abcdDifferent superscript letters presented in each column for 
a given segment are significantly different from each other group of animals, *significantly different from NC group 
and #significantly different from DBC group (p<0.05; Tukey’s HSD post-hoc test, IBM, SPSS version 21). NC, 




Myo-inositol is a sugar alcohol that is used as a supplement in various foods and food products. 
Studies have suggested that myo-inositol may be effective in ameliorating diabetes, obesity and 
metabolic syndrome related abnormalities via improving insulin action as well as glucose and 
lipid metabolism (Onomi & Katayama, 1997; Yap et al., 2007; Maeba et al., 2008; Dang et al., 
2010; Giordano et al., 2011; Facchinetti et al., 2015). In the present study, it was observed that 
myo-inositol inhibited intestinal glucose absorption in isolated rat jejunum and in the proximal 
small intestine of normal and diabetic rats, while it dose-dependently increased glucose uptake in 
isolated rats psoas muscle (Figs. 4.1, 4.2 & 4.4), which may be possible mechanisms of its anti-
hyperglycemic potential. 
In glucose metabolism, insulin enhances the clearance of circulating glucose for either 
storage or energy production in cells, which ensures blood glucose homeostasis (Aronoff et al., 
2004). Hence, in type 2 diabetes, insulin resistance or insensitivity is the major reason why 
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actively respiring cell like muscle cells do not respond to insulin signaling to take up glucose, 
causing impaired glucose tolerance and persistent hyperglycaemia (Dedoussis et al., 2007). 
Myoinositol is known to be involved in glucose metabolism, especially in insulin-mediated 
glucose uptake via its metabolites such as P-type inositol phosphoglycans (Saltiel, 1990; Kunjara 
et al., 1999; McLean et al., 2008; Facchinetti et al., 2015). Accordingly, dietary myo-inositol has 
been reported to be associated with the improvement of biomarkers of insulin sensitivity in 
individuals with diabetes related abnormalities (Maeba et al., 2008; Giordano et al., 2011) and 
translocation of Glut-4 to cell membranes in vitro (Yap et al., 2007) and in vivo (Dang et al., 
2010). 
Since improved insulin sensitivity mainly translates into the modulation of cellular 
glucose uptake, we investigated the effect of myo-inositol on glucose uptake in isolated rat psoas 
muscle (with or without insulin) as an index to further ascertain the ability of dietary myoinositol 
to improve insulin sensitivity in diabetic condition. Interestingly, our data showed that myo-
inositol (with or without insulin) markedly increased muscle glucose uptake at ex vivo condition 
in a concentration-dependent manner relative to the control (Fig. 4.2 and Table 4.1). This 
observation could suggest, at least in ex vivo condition, that myo-inositol may potentiate an 
insulin-mediated glucose uptake in muscles. However, it is also worthy to note that the 
interpretation of this observation or effect of myo-inositol is only limited to an ex vivo context 
and does not directly translate into an in vivo glucose uptake effect, but further supports the 
potential usefulness of myo-inositol supplementation in improvement of insulin sensitivity in the 
skeletal muscles (Dang et al., 2010; Facchinetti et al., 2015). Thus, further in depth studies are 
needed to adequately elucidate and confirm this ex vivo muscle glucose uptake potential of myo-
inositol at in vivo condition. 
On the other hand, the absorption of dietary glucose varies across the different segments 
of the small intestine. It was previously suggested that the proximal to mid-small intestine (part 
of the duodenum and jejunum) is responsible for the absorption of the majority of dietary 
glucose (Rider et al., 1967; Riesenfeld et al., 1980); hence, tissue from this segment was used to 
study glucose absorption in the ex vivo part of this study. According to the results from our ex 
vivo study, myo-inositol caused a concentration-dependent decrease in jejunal glucose absorption 
(Fig. 4.1) which suggests the potential of myo-inositol to impede postprandial blood glucose rise. 
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Interestingly, this was further confirmed in the in vivo section of our study where myo-inositol 
significantly reduced (p < 0.05) glucose absorption index (GAI) in the 1st qtr of the small 
intestine of normal and diabetic rats (Fig. 4.4), which may have translated into the lower blood 
glucose increase observed in myo-inositol fed rats, particularly in the diabetic group (Fig. 4.5). 
Indeed, the observed potent action of the dietary myo-inositol in the 1st qtr of the small intestine 
of animals is noteworthy because it is the site with relatively high glucose absorption capacity 
(Rider et al., 1967). Thus, suggesting that myo-inositol may have the potentials to inhibit the 
absorption of an appreciable portion of glucose obtained from the breakdown of starch and other 
complex carbohydrates. 
Additionally, gastric emptying and digesta transit rates of GIT content largely influence 
the absorption of nutrient from the small intestine. Previous studies have reported that delayed 
gastric emptying and accelerated digesta transit can contribute to reduce intestinal nutrient 
absorption as well as food intake (Salminen et al., 1984; Shafer et al., 1987), which has been 
hypothesized to be a mode of action of acarbose in controlling postprandial blood glucose rise in 
diabetic patients (Ranganath et al., 1998). Data from our present study showed that gastric 
emptying rate was significantly increased in animals after the induction of diabetes (Fig. 4.3), 
which depicts the clinical presentation of gastric emptying in most type 2 diabetic states (Phillips 
et al., 1991; Horowitz et al., 1996). Our study also revealed that dietary myo-inositol 
significantly delayed the diabetes-induced elevation of gastric emptying time in rats (Fig. 4.3) 
and concomitantly increased small intestinal and colonic digesta transit rates in normal and 
diabetic rats (Table 4.2), both of which might largely contribute to the reduced intestinal glucose 
absorption in normal or diabetic animals treated with myo-inositol. Based on the above 
observations, it is possible to hypothesize that myo-inositol may perhaps act via a competitive 
inhibition mechanism as a result of its mild structural resemblance with glucose. However, 
further study is needed to confirm this hypothesis. 
In summary, results from our study showed that myoinositol inhibited jejunal glucose 
absorption and increased muscle glucose uptake in an ex vivo condition. Our in vivo data 
demonstrated the inhibitory effect of orally administered myo-inositol on proximal small 
intestinal glucose absorption, which may be partly due to the observed delayed gastric emptying 
and accelerated digesta transit. Although our in vivo data also showed lower postprandial blood 
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glucose increase in myo-inositol fed animals, particularly in the diabetic group, it cannot be 
confirmed from our study whether the inhibition of intestinal glucose absorption was solely 
responsible for this effect or not. It could be hypothesized that myoinositol also influenced 
postprandial blood glucose increase by exerting muscle glucose uptake effect as seen in our ex 
vivo study. However, this hypothesis can only be confirmed following further in depth studies, 
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Previous studies have suggested that sorbitol, a known polyol sweetener possesses glycemic 
control potentials. However, the effect of sorbitol on intestinal glucose absorption and muscle 
glucose uptake still remains elusive. The present study investigated the effects of sorbitol on 
intestinal glucose absorption and muscle glucose uptake as possible anti-hyperglycemic or 
glycemic control potentials using ex vivo and in vivo experimental models. Sorbitol (2.5% to 
20%) inhibited glucose absorption in isolated rat jejuna (IC50 = 14.6± 4.6%) and increased 
glucose uptake in isolated rat psoas muscle with (GU50 = 3.5 ± 1.6%) or without insulin (GU50 = 
7.0 ± 0.5%) in a concentration-dependent manner. Furthermore, sorbitol significantly delayed 
gastric emptying, accelerated digesta transit, inhibited intestinal glucose absorption and reduced 
blood glucose increase in both normoglycemic and type 2 diabetic rats after 1 h of co-ingestion 
with glucose. Data of this study suggest that sorbitol exhibited anti-hyperglycemic potentials, 
possibly via increasing muscle glucose uptake ex vivoand reducing intestinal glucose absorption 




Diabetes is one of the major global public health problems and its prevalence is rapidly 
increasing in all over the world, particularly in the developing nations. According to the 
International Diabetes Federation, about 415 million people have diabetes worldwide and this 
figure is likely to become 642 million by 2040 (International Diabetes Federation, 2015). Among 
two major types of diabetes, type 2 diabetes (T2D) is the most prevalent one, which accounts for 
more than 90% of all diabetic cases (Loghmani, 2005). T2D is a heterogeneous disorder 
characterized by insulin resistance followed by partial pancreatic beta-cell dysfunction (Partley, 
2013). It is strongly influenced by sedentary life style, high fat and high calorie diet intake as 
well as routine consumption of refined and simple carbohydrates e.g. sucrose, fructose and so on 
(Uusitupa, 2002; Hu, 2003; Montonen et al., 2007; Stanhope et al., 2011). Excessive dietary 
intake of sucrose- and fructose-containing foods and food products has been consistently 
associated with detrimental health outcomes, such as elevated food intake, weight gain,visceral 
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adiposity, reduced insulin sensitivity, lipid dysregulation and the risk of developing T2D 
(Thorburnet al., 1989; Astrup et al., 2002; Elliott et al., 2002; Stanhope et al., 2011). Hence, 
there has been an upsurge on the use of alternative sweetening agents, such as sugar alcohols. 
Sugar alcohol is one of the classes of sugar substitute that have gained great popularity, 
especially for overweight, obese and diabetic individuals due to their sweetening ability with 
lesser undesired calories compared to sucrose (Islam and Indrajit, 2012). Additionally, apart 
from their minimal effect on the integrated blood glucose level compared to sucrose (Talbot and 
Fisher, 1978; Livesey, 2003), most commonly used sugar alcohols have demonstrated oral health 
care usefulness (Mäkinen, 2010; Gupta et al., 2013). Sorbitol is one of the widely used sugar 
alcohols. Several studies have reported that sorbitol possesses glycemic control effects, but may 
also possess anti-hyperglycemic effects (Brunzell, 1978; Livesey, 2003). In a previous study, it 
has been reported that a 35 g of orally administered sorbitol caused significantly lower increment 
in plasma glucose compared to sucrose or fructose in both normal and diabetic human subjects 
(Akgün and Ertel, 1980). In a recent study, it has been reported that some commonly used sugar 
alcohols including sorbitol exhibited in vitro alphaglucosidase, alpha amylase and sucrase 
inhibitory activities (Kang et al., 2014). Additionally, after the evaluation of several studies, the 
Joint FAO/WHO Expert Committee on Food Additives (JECFA) in a final comment or remark 
reported that sorbitol may inhibit glucose absorption as well (WHO, 1987). 
Although some previous and recent studies suggested the glycemic control or anti-
hyperglycemic potentials of sorbitol in vivo and alpha glucosidase, alpha amylase and sucrase 
inhibitory activities in vitro, the effect of sorbitol on intestinal glucose absorption and muscle 
glucose uptake still remains unknown. Hence, the present study was conducted to examine the 
effects of sorbitol on intestinal glucose absorption and gastric emptying as well as muscle 
glucose uptake as possible anti-hyperglycemic mode of actions by using some ex vivo and in vivo 
experimental models. 
 
5.3 Materials and methods 
Please refer to chapter 2, sub-sections 2.2.1 and 2.2.2, pages 66-74 for detailed material and 




5.4.1 Ex vivo study (experiment 1) 
Effects of sorbitol on intestinal glucose absorption and muscle glucose uptake 
Data for the effects of sorbitol on intestinal glucose absorption and muscle glucose uptake are 
presented in Fig. 5.1 and5.2 as well as Table 5.1. The data showed a concentration-dependent 
effect of sorbitol on jejunal glucose absorption ex vivo (Fig. 5.1). Incubation of jejunal tissue in 
5%, 10% and 20% sorbitol significantly reduced glucose absorption (p<0.05) compared to the 
control, when no significant difference was observed between the control and 2.5% sorbitol 
containing sample. Additionally, no significant difference was observed between the 5%, 10% 
and 20% sorbitol containing samples, while glucose absorption at 20% sorbitol concentration 
was significantly reduced (p<0.05) compared to glucose absorption at 2.5% sorbitol 
concentration (Fig. 5.1). 
 
 
Figure 5.1: Effect of sorbitol on glucose absorption in isolated rat jejunum. Data are presented 
as mean ± SD of five replicates of analysis. abcDifferent letters presented above the bars are 
significantly different from each other (p < 0.05; Tukey’s HSD multiple range post-hoc test, 








































Sorbitol (2.5% to 20%) increased dose-dependent glucose uptake in the isolated rat psoas 
muscle with (GU50 = 3.53 ± 1.61%) or without (GU50 = 7.02 ± 0.46%) insulin. Glucose uptake at 
10% and 20% concentrations of sorbitol was significantly higher (p<0.05) than the control and 
2.5% sorbitol containing sample. No significant difference in glucose uptake was observed 
between the 5% and 20% sorbitol containing samples with or without insulin (Fig. 5.2). A 
2mg/mL metforminsignificantly increasedmuscle glucose uptake than all sorbitol containing 
samples with or without insulin, while incubation with insulin significantly influenced (p<0.05) 
the glucose uptake effect of sorbitol (Table 5.1). Similar effects of metformin were found in the 
previous studies as well (Turban et al., 2012; Kristensen et al., 2014). 
 
 
Figure 5.2: Effect of sorbitol on glucose uptake with or without insulin in isolated rat psoas 
muscle. Data are presented as mean ±SD of triplicate analysis. a-c or x-z Different letters presented 
above the bars for with or without insulin are significantly different from each other (p < 0.05; 
Tukey’s HSD multiple range post-hoc test, IBM, SPSS version 21). 
 
Additionally, muscle tissue viability studies confirmed that 1 h incubation of psoas 
muscle tissue did not significantly affect the viability of the tissue (Please refer to Table 3.2 in 
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Table 5.1: Percentage GU50 values of glucose uptake increase of sorbitol in isolated psoas 
muscle, with and without insulin 
 With insulin [200mU/mL] Without insulin 
GU50 [%]* 3.53 ± 1.61
a 7.02 ± 0.46b 
Data are presented as mean ± SD of triplicate analysis. abValues with different superscript letters are significantly 
different from each other (p < 0.05; Tukey’s HSD multiple range post-hoctest, IBM, SPSS version 21). *GU50: 
Concentration (% as w/v) of sorbitol required to cause 50% increase of muscle glucose uptake. 
 
5.4.2 In vivo intestinal glucoseabsorption study (experiment 2) 
Effects of sorbitol on gastric emptying, glucose absorption index, digesta transit and blood 
glucose level 
The data for the effects of myo-inositol on gastric emptying, glucose absorption index and blood 
glucose level are presented in Fig. 5.3 to 5.5 and Table 5.2. Gastric emptying significantly 
increased (p<0.05) after the induction of diabetes but significantly decreased (p<0.05) after the 
treatment with either sorbitol or acarbose (Fig. 5.3). Significantly slower gastric emptying of 
diabetic animals was observed in the acarbose ingested group compared to the sorbitol ingested 
groups. Treatment with sorbitol did not significantly affect gastric emptying in normal animals 
(Fig. 5.3). 
Furthermore, administration of either sorbitol or acarbose significantly influenced GAI in 
the different intestinal segments of both normal and diabetic animals (Fig. 5.4). Ingestion of 
sorbitol significantly reduced (p<0.05) GAI in the 1st and 2nd qtrs of the small intestine in both 
normal and diabetic animals, while ingestion of acarbose significantly reduced (p<0.05) GAI in 
the 1stqtr of the small intestine of diabetic animals. In the proximal colon sorbitol and acarbose 
treatment significantly reduced (p<0.05) GAI in normal and diabetic animals respectively, while 






Figure 5.3: Effect of sorbitol on gastric emptying in different animal groups at the end of a 1 h 
experimental period. Data are presented as mean ± SD of 5–6 animals. abcDifferent letters 
presented above the bars are significantly different from each other group of animals, 
*significantly different from NC group and #significantly different from DBC group (p<0.05; 
Tukey’s HSD post-hoc test, IBM, SPSS version 21).NC, normal control; NSO, normal sorbitol; 




Figure 5.4: Effect of sorbitol on glucose absorption index (GAI) in the different GIT segments 
of different animal groups at the end of a 1 h experimental period. Data are presented as mean ± 
SD of five to six animals. abDifferent letters presented above the bars for a given segment are 
significantly different from each other group of animals, *significantly different from NC group 
and #significantly different from DBC group (p<0.05; Tukey’s HSD post-hoc test, IBM, SPSS 
version 21). NC, normal control; NSO, normal sorbitol; DBC, diabetic control; DSO, diabetic 
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The single oral dose of sorbitol and acarbose co-ingested with glucose significantly 
reduced (p>0.05) blood glucose increase 1 h after the dose administration in diabetic animals, 
although the results were not significantly different for normal animals (Fig. 5.5). 
 
 
Figure 5.5: Effects of sorbitol on final blood glucose concentrations and blood glucose increase 
in animals after 1 h of the dose administration. Data are presented as mean ± SD of six animals. 
a-d & x-zDifferent letters presented above the bars are significantly different from each other group 
of animals, *significantly different from NC group and #significantly different from DBC group 
(p<0.05; Tukey’s HSD multiple range post-hoc test, IBM, SPSS version 21). NC, normal 
control; NMI, normal myo-inositol; DBC, diabetic control; DMI, diabetic myo-inositol; DBA, 
diabetic acarbose. 
 
On the other hand sorbitol treatments significantly increased (p<0.05) digesta transit from 
the 3rd qtr of the small intestine up to proximal colon in normal rats (Table 5.2). In diabetic 
animals however, sorbitol and acarbose treatment only significantly increased (p<0.05) digesta 
transit in the cecum and proximal colon, while no significant difference was observed in the 
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Table 5.2: Effect of sorbitol ondigesta transit in the different segments of the intestinal tract 
during 1 h experimental period 
Group 1stqtr 2ndqtr 3rdqtr 4thqtr Cecum Prox. Colon 
 Small Intestine  Large Intestine 
  Digesta Transit [%]   
NC 95.26 ± 4.01ab 89.36 ± 4.58 70.27 ± 12.07a 48.53 ± 4.10a 23.68 ± 5.63a 36.81  ± 9.21a 
NSO 96.46 ± 1.74a 90.67 ± 1.34 82.68 ± 3.70b* 73.93 ±2.20b* 61.61± 4.69b* 68.16 ±2.16b* 
DBC 90.97 ± 0.08b 87.86 ± 1.59 76.55  ± 5.16ab 72.01 ±7.04b* 37.56 ± 3.58c* 49.69  ± 0.90c* 
DSO 95.89 ± 1.20ab 87.37 ± 3.88 78.43 ± 3.56ab 73.04±5.52b 45.98 ± 5.41d# 62.98  ± 2.59b# 
DBA 93.85 ± 4.72ab 87.01 ± 5.29 79.48  ± 6.09ab 71.76 ±5.38b 65.26 ± 5.25b# 87.63  ± 3.07d# 
Data are presented as mean ± SD of five to six animals. abcdDifferent superscript letters presented in each column for 
a given segment are significantly different from each other group of animals, *significantly different from NC group 
and #significantly different from DBC group (p < 0.05; Tukey’s HSD post-hoc test, IBM, SPSS, version 21). GRP, 




Sugar alcohols are known for their lower caloric value compared to sucrose when sorbitol is 
widely used due to its number of beneficial effects on health (Hayes, 2001; Livesey, 2003). It has 
been speculated that sorbitol may inhibit intestinal glucose absorption (WHO, 1987). A previous 
report suggested that sorbitol may be useful for glycemic control in normoglycemic and diabetic 
subjects (Akgün and Ertel, 1980), when a recent study reported that sorbitol possesses inhibitory 
effect on carbohydrate digesting enzyme activities in vitro (Kang et al., 2014). However, none of 
these previous studies investigated the effect of sorbitol on intestinal glucose absorption and 
muscle glucose uptake. Hence, the present study investigated the effects of sorbitol on intestinal 
glucose absorption and muscle glucose uptake to further understand the mechanisms behind the 
effects of sorbitol on dietary glucose absorption and uptake. 
Dietary glucose is actively absorbed from the intestine, contributing to blood glucose rise, 
but absorption capacity of glucose varies from one intestinal segment to another. However, it has 
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been reported that majority of dietary glucose is likely to be absorbed from the proximal to mid 
small intestine (part of the duodenum and jejunum) (Bogner et al., 1963; Rider et al., 1967; 
Lavin, 1976), and for the same reason intestinal tissue from this section was used for the ex-vivo 
glucose absorption study. In our ex vivostudy, the amount of glucose absorbed by the jejunal 
segments of rats reached a peak value of 5.20 ± 072 mg/cm jejunum after 2 hour incubation 
period in a glucose solution without sorbitol (Fig. 5.1). However, this peak value was 
significantly reduced (p<0.05) to 3.53 ± 0.50 mg/cm jejunum in the presence of 5% sorbitol and 
reached as low as 2.87 ± 0.70 mg/cm jejunum in the presence of 20% sorbitol, which suggests 
the possible inhibitory effect of sorbitol on intestinal glucose absorption. 
Previous studies have demonstrated that co-ingestion of glucose with sorbitol increased 
sorbitol absorption relative to ingestion of sorbitol alone (Beaugerie et al., 1995; Beaugerie et al., 
1996). Our in vivo data showed high glucose absorption index (GAI) across the different 
intestinal segments of rats (Fig. 5.4), which accounts for the complete and rapid intestinal 
absorption of glucose. However, the significantly reduced (p<0.05) GAI in the 1st and 2nd qtrs 
of the small intestine of normal and diabetic rats fed with sorbitol (Fig. 5.4) correspond to the 
results of our ex vivo glucose absorption study (Fig. 5.1) and further confirms the inhibitory 
potentials of sorbitol on intestinal glucose absorption. In fact, the observed inhibitory effect of 
sorbitol in the proximal small intestine is of particular interest, because the proximal small 
intestine is most likely the site where majority of glucose absorption occurs (Rider et al., 1967). 
In our study, sorbitol significantly inhibited the glucose absorption in this region of the small 
intestine, and the effect was comparable to that of a widely used anti-diabetic drug (acarbose) in 
both normal and diabetic animals (Fig. 5.4). Additionally, the reduced postprandial blood 
glucose increase observed in the sorbitol-fed animals (Fig. 5.5) may also be a reflection of the 
inhibitory effect of sorbitol on intestinal glucose absorption (Fig. 5.4). Based on the above 
discussions we hypothesize that the observed reduced intestinal glucose absorption in sorbitol-
fed rats (Fig. 5.4) might be due to the reported increased intestinal sorbitol absorption when co-
ingested with glucose (Beaugerie et al., 1995; Beaugerie et al., 1996). However, this hypothesis 
requires further investigation to elucidate the actual absorption-related interaction between 
sorbitol and glucose in the different sections of intestine. 
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Delayed gastric emptying and accelerated digesta transit can contribute to reduced 
intestinal nutrient absorption as well as food intake (Salminen et al., 1984; Shafer et al., 1987) 
and has been suggested to be partly involved in the mode of action of acarbose in reducing 
intestinal glucose absorption (Ranganath et al., 1998). In our study, the induction of diabetes 
significantly increased gastric emptying rate (Fig. 5.3), which depicts the clinical presentation of 
gastric emptying in most type 2 diabetic patients (Phillips et al., 1991; Horowitz et al., 1996. 
However, an oral bolus dose of sorbitol significantly reduced (p<0.05) gastric emptying in 
diabetic rats (Fig. 5.3) and increased the digesta and colonic transit in both normal and diabetic 
animals (Table 5.2). These data are in line with the results of previous studies in healthy human 
subjects (Hunt, 1963; Skoog et al., 2006) and may also contribute to the lower GAI in the 
proximal half of the small intestine (Fig. 5.4). 
Under physiological condition, the blood glucose homeostasis is constantly maintained 
by the action of two important hormones: insulin and glucagon. Among other functions, insulin 
promotes the clearance of circulating glucose for either storage or energy production in cells, 
thus prevent abnormal increment of blood glucose level (Aronoff et al., 2004). Previous studies 
have reported the glycogenic effects of oral or parenteral sorbitol administration in rats (Stetten 
and Stetten, 1951), which suggests possibilities of sorbitol to enhance clearance of circulating 
glucose towards glycogen synthesis. In our present study, sorbitol exhibited a concentration-
dependent increase in muscle glucose uptake with or without insulin compared to control (Fig. 
5.2). Insulin also significantly enhanced the muscle glucose uptake effect of sorbitol (Table 5.1), 
which has also been observed previously (Turban et al. 2012; Kristensen et al., 2014). These 
data suggest the potential of sorbitol in improving insulin-mediated muscle glucose uptake at 
least in ex vivo condition, but still requires further investigation at in vivo level. 
In summary, apart from the effects of sorbitol on enhancing muscle glucose uptake ex 
vivo (Fig. 5.2 and Table 5.1), the results of our present study suggest that sorbitol possesses 
inhibitory effects on intestinal glucose absorption ex vivo (Fig. 5.1) which have been further 
supported by the results of the in vivo study in normal and diabetic rats (Fig. 5.4 and 5.5). 
Additionally, our present study also revealed that the ingestion of sorbitol delayed gastric 
emptying (Fig. 5.3) and accelerated digesta transit (Table 5.2) in normal and diabetic rats, which 
might partly contribute to the observed in vivo inhibitory effects sorbitol on small intestinal 
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glucose absorption (Fig. 5.4). Hence, sorbitol may be further investigated as a potential anti-
hyperglycemic sweetener in diabetic foods and food products, which may ameliorate 
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The present report investigated the effects of erythritol on intestinal glucose absorption and 
muscle glucose uptake as possible underlying mechanisms behind its anti-hyperglycemic 
potentials. Experiment 1 examined the effects of increasing concentrations (2.5 – 20%) of 
erythritolon glucose absorption and uptake in isolated rat jejunum and psoas muscle respectively. 
Experiment 2 examined the effects of a bolus dose of erythritol (1 g/kg bw) on intestinal glucose 
absorption, gastric emptying and postprandial blood glucose increase in normal and type 2 
diabetic rats 1 h after the co-ingestion of erythritol with glucose (2 g/kg bw). Study 3 
investigated the effects of a bolus dose of erythritol (1 g/kg bw) on glucose tolerance, serum 
insulin level, muscle/liver hexokinase and liver glucose-6 phospahtase activities and mRNA 
expression of muscle Glut-4 and IRS-1 in normal and type 2 diabetic animals. Study 1 revealed 
that erythritol dose-dependently enhanced muscle glucose uptake with or without insulin. Study 
2 demonstrated that oral erythritol treatment delayed gastric emptying and reduced small 
intestinal glucose absorption as well as postprandial blood glucose rise, especially in diabetic 
animals. Study 3 showed that oral erythritol treatment improved glucose tolerance, insulin 
secretion, muscle/liver hexokinase and liver glucose-6 phospahtase activities and mRNA 
expression of muscle Glut-4 and IRS-1 in diabetic animals. Data of this study suggest that 
erythritol may exert anti-hyperglycemic effects not only via reducing small intestinal glucose 
absorption, but also by increasing muscle glucose uptake and improving glucose metabolic 
enzymes activity and Glut-4 and IRS-1 mRNA expression. Hence, erythritol may be a useful 
dietary supplement for managing hyperglycemia, particularly for type 2 diabetes (T2D). 
 
6.2 Introduction 
The increasing global socioeconomic threat caused by type 2 diabetes (T2D) has been linked to 
its higher prevalence compared to other types of diabetes. T2D accounts for more than 90% of 
total diabetes cases worldwide (Pratley, 2013) and currently one of the major threats to global 
public health (International Diabetes Federation, 2015). Unfortunately, almost 50% of people 
living with T2D are undiagnosed (Bahrami & Gerstein, 2016). T2D is described as a 
multifaceted and progressive disease that is linked to several metabolic defects and organ 
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malfunction or damage (Pratley, 2013). Insulin resistance and impairment of pancreatic beta cell 
function are the most prominent pathogenic features of T2D, which progressively results in 
defective insulin secretion and persistent hyperglycemia (Pratley & Weyer, 2001; Kahn, 2003). 
Insulin resistance in peripheral tissues, such as adipose and muscle tissues downregulates the 
signalling of cellular glucose uptake, which contributes to hyperglycemia in T2D (Pratley & 
Weyer, 2001; Kahn, 2003). 
Furthermore, there are several risk factors that strongly influence the pathogenesis and 
progression of T2D. Sedentary life style, routine consumption of high fat and high calorie diets 
as well as chronic consumption of refined and simple carbohydrates like sucrose and fructose 
have been reported to be among the most influential factors in the progression of T2D (Thorburn 
et al., 1989; Elliott et al., 2002; Astrup et al., 2002; Hu, 2003). In a previous study, it has been 
reported that 10 weeks consumption of sucrose equivalent to 28% of dietary energy increased 
food intake, body weight, body fat mass, and blood pressure compared to the consumption of 
non-sucrose sweeteners in overweight humans (Astrup et al., 2002). Furthermore, Thorburn et 
al. (1989) reported that the consumption of fructose equivalent to 35% of energy requirement 
reduced glucose disposal and insulin action in the liver and most peripheral tissues. Accordingly, 
dietary adjustments limiting the intake of added sugars, especially in diabetic individuals have 
been greatly encouraged (Amod et al., 2012). Consequently, sugar substitutes including non-
nutritive sweeteners such as saccharin, aspartame, stevia, sucralose, neotame etc and sugar 
alcohols such as xylitol, sorbitol, maltitol, erythritol, mannitoletc have become part of diabetic 
and non-diabetic diets, because of their minimal effect in increasing postprandial blood glucose 
and their lower caloric value compared to easily digestible simple carbohydrates such as glucose, 
sucrose and fructose (Livesey, 2003; Fitch & Keim, 2012). Sugar alcohols are known for their 
wide application, including oral health care application (Mäkinen, 2010) and erythritol is one of 
the popular sugar alcohols in the market. 
Erythritol, a four-carbon sugar alcohol, is a very unique sugar alcohol not only due to its 
zero caloric value and no glycemic effects, but also due to its minimal gastrointestinal side 
effects compared to other sugar alcohols (Livesey, 2003). Although it is well absorbed from the 
small intestine compared to other sugar alcohols (about 90% of ingested amount), it is not 
metabolized (Livesey, 2003) but completely excreted in the urine, thus does not contribute to the 
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systemic glucose pool. Apart fromthe zero caloric and glycemic effects, a number of studies have 
suggested the anti-hyperglycemic potentials of erythritol.  
In a previous study, Bornet et al. (1996) reported that the mean levels of plasma glucose 
and insulin in healthy humans remained unaffected up to 3 h after a single oral dose of 1 g/kg bw 
of erythritol (Bornet et al., 1996). In diabetic rats, 10 days oral administration of 100 to 400 
mg/kg bw of erythritol significantly reduced blood glucose level as well as oxidative stress 
markers like protein glycosylation and lipid peroxidation in the serum, liver and kidney 
(Yokozawa et al., 2002). Fourteen days oral administration of 20 g erythritol per day 
continuously reduced serum glucose and glycated hemoglobin (HbA1c) in human subjects with 
non-insulin dependent diabetes mellitus (Ishikawa et al., 1996). Furthermore, in a recent study, 
Flint et al. (2014) reported that short term (4 weeks) oral administration of erythritol (30 g/day) 
improved arterial endothelial function in type 2 diabetic subjects (Flint et al., 2014), which 
suggests that erythritol may be useful in the management of diabetes-related microvascular 
complications. In a most recent study, it was reported that a single dose of 75 g erythritol in 300 
ml of water, supplied via nasogastric tube modulated gut hormone (GPL-1) and also delayed 
gastric emptying in lean and obese normoglycemic subjects (Woelnerhanssen et al., 2016). 
Glucose tolerance was also not significantly affected in the erythritol fed group compared to 
control group (normal water feeding) of this study, which suggests that erythritol could be useful 
in the control of postprandial glucose elevation. 
Despite the above-mentioned anti-hyperglycemic potentials of erythritol in 
normoglycemic and diabetic conditions, further investigation are still required to understand the 
underlying mechanisms and mode of actions behind its anti-hyperglycemic effects. Hence, this 
study was conducted to investigate the effects of erythritol on intestinal glucose absorption, 
muscle glucose uptake and on the activities of related enzymes and expression of related genes 
using ex vivo and in vivo experimental models. 
 
6.3 Materials and methods 
Please refer to chapter 2, sub-sections 2.2.1 and 2.2.3 pages 66-83 for detailed material and 




6.4.1 Ex vivo study (experiment 1) 
Effects of erythritol on intestinal glucose absorption and muscle glucose uptake 
Data for the effects of erythritol on intestinal glucose absorption and muscle glucose uptake are 
presented in Fig. 6.1 and6.2 as well as Table 6.1. Erythritol did not significantly influence 
glucose absorption in isolated rat jejunum (Fig. 6.1). On the other hand, erythritol caused a 
concentration-dependent increase of glucose uptake in isolated psoas muscle with or without 
insulin (Fig. 6.2). Muscle glucose uptake of all concentrations of erythritol and 2 mg/ml 
metformin was significantly higher (p<0.05) than the control, while glucose uptake of 2 mg/ml 
metformin did not differ from glucose uptake of 10% and 20% erythritol (Fig. 6.2). Insulin 
significantly enhanced the muscle glucose uptake effect of erythritol; the computed GU50 of 
erythritol was 2.02 ± 1.24 % with insulin and 6.91 ± 2.03 % without insulin (Table 6.1). 
 
 
Figure 6.1: Effect of erythritol on glucose absorption in isolated rat jejunum. Data are presented 
as mean ± SD of five replicates of analysis (p < 0.05; Tukey’s HSD multiple range post-hoc test, 



















































Figure 6.2: Effect of erythritol on glucose uptake with or without insulin in isolated rat psoas 
muscle. Data are presented as mean ±SD of triplicate analysis. a-d or x-z Different letters presented 
above the bars for with or without insulin are significantly different from each other (p < 0.05; 
Tukey’s HSD multiple range post-hoc test, IBM, SPSS version 21). 
 
Table 6.1: Percentage GU50 values of glucose uptake increase of erythritol in isolated psoas 
muscle, with and without insulin 
 
With insulin (200mU/mL) Without insulin 
GU50 (%)* 2.02 ± 1.24
a 6.91 ± 2.03b 
Data are presented as mean ± SD of triplicate analysis. abValues with different superscript letters are significantly 
different from each other (p < 0.05; Tukey’s HSD multiple range post-hoctest, IBM, SPSS version 21). *GU50: 
Concentration (% as w/v) of erythritol required to cause 50% increase of muscle glucose uptake. 
 
Additionally, muscle tissue viability studies confirmed that 1 h incubation of psoas 
muscle tissue did not significantly affect the viability of the tissue (Please refer to Table 3.2 in 
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6.4.2 In vivo intestinal glucoseabsorption study (experiment 2) 
Effects of erythritol on gastric emptying, glucose absorption index and blood glucose level 
The data for the effects of erythritol on gastric emptying, glucose absorption index and blood 
glucose level are presented in Fig. 6.3 to 6.5. Erythritol significantly (p<0.05) delayed gastric 
emptying in normal animals (Fig. 6.3). Induction of diabetes significantly (p<0.05) accelerated 
gastric emptying, while erythritol and acarbose significantly reduced diabetes-induced 
accelerated gastric emptying with statistically similar capacity (Fig. 6.3). 
 
 
Figure 6.3: Effect of erythritol on gastric emptying in different animal groups at the end of a 1 h 
experimental period. Data are presented as mean ± SD of 5–6 animals. abcDifferent letters 
presented above the bars are significantly different from each other group of animals, 
*significantly different from NC group and #significantly different from DBC group (p<0.05; 
Tukey’s HSD post-hoc test, IBM, SPSS version 21).NC, normal control; NER, normal erythritol; 


































Furthermore, erythritol significantly reduced (p<0.05) GAI in the 1st qtr of the small 
intestine of normal and diabetic animals, while acarbose significantly reduced (p<0.05) GAI in 
the 1stqtr of the small intestine and also in the proximal colon of diabetic animals (Fig. 6.4). 
 
 
Figure 6.4: Effect of erythritol on glucose absorption index (GAI) in the different GIT segments 
of different animal groups at the end of a 1 h experimental period. Data are presented as mean ± 
SD of five to six animals. abDifferent letters presented above the bars for a given segment are 
significantly different from each other group of animals, *significantly different from NC group 
and #significantly different from DBC group (p<0.05; Tukey’s HSD post-hoc test, IBM, SPSS 
version 21).NC, normal control; NER, normal erythritol; DBC, diabetic control; DER, diabetic 
erythritol; DBA, diabetic acarbose. 
 
On the other hand, erythritol did not significantly influence blood glucose increase in 
normal animals, while in diabetic animals, erythritol and acarbose significantly prevented 
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Figure 6.5: Effect of erythritol on final blood glucose concentrations and blood glucose increase 
in animals after 1 h of the dose administration. Data are presented as mean ± SD of six animals. 
a-d & x-zDifferent letters presented above the bars are significantly different from each other group 
of animals, *significantly different from NC group and #significantly different from DBC group 
(p<0.05; Tukey’s HSD multiple range post-hoc test, IBM, SPSS version 21). NC, normal 
control; NER, normal erythritol; DBC, diabetic control; DER, diabetic erythritol; DBA, diabetic 
acarbose. 
 
6.4.3 In vivo muscle glucose uptake study (experiment 3) 
Effects of erythritol on oral glucose tolerance and serum insulin level 
The data for oral glucose tolerance test and serum insulin are presented in Fig. 6.6 and 6.7. 
Although erythritol did not significantly influence the glucose tolerance ability of normal 
animals, it significantly improved (p<0.05) the glucose tolerance ability of diabetic animals, 
especially at 30 and 60 min after the glucose ingestion (Fig. 6.6). On the other hand, erythritol 
did not significantly influence serum insulin levels in normal animals, but it appreciably 
increased (p = 0.178) diabetes-induced serum insulin depletion of diabetic animals, although the 
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Figure 6.6: Effect of erythritol onoral glucose tolerance. Data are presented as mean ± SD of 
four animals. “abc”Different letters presented above the bars are significantly different from each 
other group of animals,*significantly different from NC group and #significantly different from 
DBC group (p<0.05; Tukey’s HSD multiple range post-hoc test, IBM, SPSS version 23). NC, 
normal control; NER, normal erythritol; DBC, diabetic control; DER, diabetic erythritol. 
 
 
Figure 6.7: Effect of erythritol on serum insulin level. Data are presented as mean ± SD of four 
animals. “abc”Different letters presented above the bars are significantly different from each other 
group of animals,*significantly different from NC group and #significantly different from DBC 
group (p<0.05; Tukey’s HSD multiple range post-hoc test, IBM, SPSS version 23). NC, normal 
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Effects of erythritol on muscle hexokinase, liver glucokinase and liver glucose-6 phosphates 
activities 
The data for muscle hexokinase, liver glucokinase and liver glucose-6-phosphatase activities are 
presented in Fig. 6.8. Erythritol did not significantly influence the activities of muscle 
hexokinase (Fig. 6.8a), liver glucokinase (Fig. 6.8b) and liver glucose-6 phosphatase (Fig. 6.8c) 
in normal animals. Diabetes induction significantly reduced (p<0.05) muscle hexokinase and 
liver glucokinase activities and significantly increased (p<0.05) liver glucose-6 phosphates 
activity. While erythritol markedly improved diabetes-induced reduction of muscle hexokinase 
(p = 0.075) and liver glucokinase (p = 0.058) activities (Fig. 6.8a and 6.8b), it significantly 




                                   (a)                      (b)                                                 (c)  
 
Figure 6.8: Effects of erythritol on (a) muscle hexokinase,(b) liver glucokinase and (c) liver 
glucose-6 phosphatase activities.Data are presented as mean ± SD of four animals. “abc”Different 
letters presented above the bars are significantly different from each other group of 
animals,*significantly different from NC group and #significantly different from DBC group 
(p<0.05; Tukey’s HSD multiple range post-hoc test, IBM, SPSS version 23). NC, normal 























































































Effects of erythritol on mRNA expression of muscle Glut-4 and IRS-1 
The data for the mRNA expression muscle Glut-4 and IRS-1 are presented in Fig. 6.9. Gel image 
for β-Actin showed that there was no notable change in the mRNA expression of the reference 
gene across all animal groups (Fig. 6.9a and Supplementary data 6), hence it was suitable for 
normalizing the expression of our genes of interest. Erythritoltreatment did not significantly 
influence the mRNA expression of muscle Glut-4 and IRS-1 in normal animals (Fig. 6.9a and 
6.9b). Induction of diabetes decreased (p<0.05) the mRNA expression of muscle Glut-4 and IRS-
1 by10.39 ± 1.92 folds and 3.56 ± 0.61 folds, respectively (Fig. 6.9b). However, decreased Glut-
4 and IRS-1 mRNA expression of diabetic animals increased (p<0.05) by 16.14 ± 2.23 folds and 
4.80 ± 0.65 folds, respectively after erythritol treatment (Fig. 6.9b). 
 
 
        (a)                                                                                 (b) 
Figure 6.9: Effect of erythritol on Glut-4 and IRS-1 mRNA expression. (a) qPCR products of 
target genes subjected to a 2% agarose gel electrophoresis and product sizes estimated with a 1 
kb plus ladder (Refer to Supplementary data 6 for complete gel image with 1 kb plus ladder). 
NC, normal control; NER, normal erythritol; DBC, diabetic control; DER, diabetic erythritol. (b) 
Fold changes in mRNA expressions of Glut-4 and IRS-1 due to erythritol treatment in normal 
animals (NER:NC); due to induction of diabetes in normal animals (DBC:NC); and due to 
erythritol treatment in diabetic animals (DER:DBC). Data are presented as mean ± SD of n = 4.* 
and # different symbols means mRNA expression fold change of Glut-4 and IRS-1 are 










































The zero caloric as well as no glycemic effect of erythritol is a unique property compared to 
other sugar alcohols and a desirable quality for the management of T2D (Livesey, 2003). 
Additionally, erythritol has shown promising anti-hyperglycemic potentials in both 
normoglycemic (Bornet et al., 1996; Woelnerhanssen et al., 2016) and diabetic (Ishikawa et al., 
1996; Yokozawa et al., 2002) human subjects, which supports its effects on ameliorating several 
T2D-related metabolic defects (Ishikawa et al., 1996; Flint et al., 2014). Our present study 
revealed underlying mechanisms of action behind the anti-hyperglycemic effects of erythritol in 
normal and type 2 diabetic conditions. 
Postprandial glucose level is strongly influenced by the degree of glucose absorption in 
the small intestine, especially at the proximal region (jejunal and duodenal regions), which has 
been reported as the highest glucose absorption site of the small intestine (Rider et al., 1967; 
Riesenfeld et al., 1980). However, the rate of gastric emptying may also influence the extent of 
small intestinal nutrient absorption, including glucose absorption (Salminen et al., 1984), which 
can eventually influence postprandial glucose level (Aronoff et al., 2004). In fact, there are 
several evidences supporting the fact that accelerated gastric emptying could be one of the 
clinical metabolic defects contributing to hyperglycemia in diabetes subjects, especially type 2 
(Phillips et al., 1991; Horowitz et al., 1996; Aronoff et al., 2004); and that delaying of gastric 
emptying could be a mode of action to reduce postprandial glucose increase in diabetes subjects 
(Ranganath et al., 1998). Although in our ex vivo study (experiment 1), erythritol did not 
significantly reduce glucose absorption in isolated rat jejunum (Fig. 6.1), our in vivo absorption 
study (experiment 2) revealed that oral erythritol treatment significantly reduced glucose 
absorption in the 1st qtr of the small intestine (Fig. 6.4) and concomitantly delayed (p<0.05) 
gastric emptying (Fig. 6.3) of both normal and diabetic animals. These data suggest that the 
delayed gastric emptying effect of erythritol (Fig. 6.3), which has also been recently observed in 
normoglycemic human subjects (Woelnerhanssen et al., 2016) could be a major contributing 
factor in its ability to decrease small intestinal glucose absorption in normal and diabetic animals 
(Fig. 6.4). Furthermore, reduced postprandial glucose rise was also observed in the erythritol-
treated animals, especially in diabetic condition (p<0.05) (Fig. 6.5), which could be a reflection 
of the reduced small intestinal glucose absorption in similar group of animals (Fig. 6.4). These 
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results suggest the potency of erythtritol to improve or ameliorate hyperglycemia via inhibiting 
small intestinal glucose absorption. 
On the other hand, blood glucose homeostasis under normal physiological state is 
constantly maintained by the action of two important hormones: insulin and glucagon. Insulin is 
the major hormone that up regulates peripheral glucose uptake via a cascade of signaling 
components, which favours systemic glucose disappearance (Aronoff et al., 2004). Insulin binds 
to the extracellular α-subunit of membrane-bound insulin receptor molecule (glycoprotein), 
which causes the activation of tyrosine kinase of the intracellular β-subunit (catalytic domain) 
(Chang et al., 2004). Activated tyrosine kinase then phosphorylates the insulin receptor substrate 
family, especially IRS-1 and IRS-2, which causes them to display binding sites for numerous 
signaling partners, such as phosphoinositide 3-kinase (PI3-K) to bind (Chang et al., 2004; 
González-Sánchez & Serrano-Ríos, 2007). PI3-K plays a major role in metabolic functions such 
as stimulating glucose uptake in peripheral tissues, especially muscle and fat tissues via a 
downstream cascade of events that leads to the activation of Akt (a serine/threonine protein 
kinase identified as one of the downstream targets of activated PI3-K) (González-Sánchez & 
Serrano-Ríos, 2007). Activated Akt signals the translocation of Glut-4 to the plasma membrane 
as well as the cellular influx of circulating glucose for cellular metabolic functions (Chang et al., 
2004; González-Sánchez & Serrano-Ríos, 2007). A major cellular metabolic function of glucose 
is energy production via glycolysis-mediated metabolic pathways, especially in actively respiring 
cells of muscle tissues (Aronoff et al., 2004). Glycolytic pathway is initiated by a hexokinase-
catalyzed glucose phosphorylation, which confers a negative charge on glucose to prevent 
glucose molecules entering cells from exiting, and thus maintaining muscle glucose uptake and 
systemic glucose disappearance (Wu et al., 2005). 
Impaired muscle glucose uptake and systemic glucose disappearance during the 
development and progression of T2D are mainly associated with insulin resistance and 
subsequent impaired insulin secretion. This is caused by the dysfunction of cellular insulin 
signalling due to down regulation of major components of the insulin signalling pathway 
(Fröjdöet al., 2009; Boucher et al., 2014), including Glut-4 and IRS-1 (Carvalhoet al., 2001; 
Wang et al., 2009; Kampmannet al., 2011). Hence, we investigated the effect of erythritol on 
muscle glucose uptake as a possible anti-hyperglycemic mechanism of action. Interestingly, data 
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of our ex vivo study (experiment 1) showed that erythritol dose-dependently increased (p<0.05) 
glucose uptake in isolated rat psoas muscle with or without insulin (Fig. 6.2 and Table 6.1), 
which suggests that erythritol may potentiate insulin-mediated glucose uptake in muscles. This 
was further confirmed in the supporting data of our in vivo glucose uptake study (experiment 3), 
where acute oral erythritol treatment in diabetic animals appreciably improved Glut-4 and IRS-1 
mRNA expression (p<0.05) (Fig. 6.9a and 6.9b), serum insulin levels (p = 0.178) (Fig. 6.7) and 
oral glucose tolerance (p<0.05) (Fig. 6.6), which were initially reduced due to diabetes induction. 
Additionally, acute oral erythritol treatment concomitantly improved (p = 0.075) muscle 
hexokinase activities in diabetic animals (Fig. 6.8a), which demonstrates that erythritol improved 
glucose tolerance and metabolism via improving insulin secretion and modulating insulin-
mediated muscle glucose uptake; thus, ameliorated hyperglycemia. 
Furthermore, while insulin stimulates metabolic processes that favour systemic glucose 
disappearance, it also inhibits metabolic processes that can contribute to systemic glucose pool, 
especially when blood glucose rises above normal (Aronoff et al., 2004). This bi-functional role 
of insulin works in concert to ensure glucose homeostasis. Liver glycogenolysis is the major 
source of endogenous glucose contributing to systemic glucose pool, which is down regulated by 
insulin signalling when systemic glucose pool rises above normal (Aronoff et al., 2004). Liver 
glucose-6 phosphatase catalyzes the dephosphorylation of glucose-6 phosphate resulting from 
glycogenolysis, thus releasing glucose into circulation (Liu et al., 1994). On the other hand, liver 
glucokinase catalyzes the cellular phosphorylation of glucose, which helps to maintain the influx 
of glucose into hepatocytes for glycogen synthesis, thus enhancing systemic glucose 
disappearance (Lenzen, 2014). Both liver enzymes have been reported to be adversely affected 
during T2D, hence disrupting glucose homeostasis. In a previous study, it was reported that 
increased glucose-6 phosphatase activity and reduced glucokinase activity are major contributing 
factors of elevated endogenous glucose production in T2D (Clore et al., 2000). In another study, 
it was reported that induction of acute diabetes using streptozotocin significantly increased the 
activity and mRNA expression of hepatic microsomal glucose-6-phosphatase in young, juvenile 
and adult rats, aggravating hyperglycemia (Liu et al., 1994). In our present study, consistent 
trend was also observed, where induction of diabetes significantly increased liver glucose-6-
phosphatase activity (Fig. 6.8c) and significantly reduced liver glucokinase activity (Fig. 6.8b). 
However, acute oral treatment with erythritol appreciably reversed this trend in diabetic animals 
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(Fig. 6.8c and 6.8b), which suggests that erythritol possesses the potency to improve glucose 
metabolism in diabetic conditions via enhancing systemic glucose disappearance to ameliorate 
hyperglycemia. 
In summary, data from this study demonstrate the potency of erythritol in reducing small 
intestinal glucose absorption and enhancing insulin secretion and insulin-mediated muscle 
glucose uptake and metabolism via improving glucose metabolic enzyme activity and enhancing 
Glut-4 and IRS-1 mRNA expression, especially in diabetic animals. Although these anti-
hyperglycemic effects of erythritol were investigated separately in separate studies, we propose 
that the bi-functional anti-hyperglycemic potency of erythritol (impairment of small intestinal 
glucose absorption and enhancement insulin-mediated muscle glucose uptake and metabolism) 
may work in concert to improve glucose tolerance and ameliorate hyperglycemia, especially in 
diabetic animals. Hence erythritol may be a useful dietary supplement for managing 
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GENERAL DISCUSSIONS AND CONCLUSIONS 
7.1 General discussions 
The inadequate attention given to diabetes mellitus, especially type 2, coupled with the unhealthy 
eating habits of people have aided in the rapid increase in the prevalence of diabetes and related 
diseases globally, including Africa. From the results of a recent survey, it has been reported that 
among the IDF geographical regions, Africa will have the highest percentage increase (140.8%) 
of people living with diabetes by 2040 (IDF, 2015). Considering the mortality rate of diabetes 
and the enormous expenditure on healthcare for people with diabetes (IDF, 2015), this projection 
will aggravate socioeconomic problems in the continent. Unfortunately, the dietary habit and 
lifestyle of most people has continuously stimulated the increasing trend of T2D and related 
diseases like obesity. In South Africa for example, the consumption of sugar or sugar-sweetened 
products, especially among adolescents is continuously increasing (Steyn & Temple, 2012), 
despite the fact that this is major a player in the development of T2D, obesity and metabolic 
syndrome (Elliott et al., 2002; Astrup et al., 2002; Hu & Malik, 2010; Stanhope, 2012). As an 
intervention strategy, there has been a strong campaign to control sugar intake especially in 
diabetics (Amod et al., 2012; Steyn & Temple, 2012). In this light, sweeteners or sugar 
substitutes such as sugar alcohols, including xylitol, sorbitol, maltitol, myo-inositol and erythritol 
are increasingly gaining public endorsement because of their lower calorie content compared to 
regular table sugar without sacrificing the sweetening appetite of people (Talbot & Fisher, 1978; 
Fitch & Keim, 2012). Despite the low caloric nature of some of these sugar alcohols, several 
studies have shown that they possess anti-hyperglycemic or hypoglycemic potentials (Akgün and 
Ertel, 1980; Vessby et al., 1990; Ishikawa et al., 1996; Santamaria et al., 2012; Rahman & Islam, 
2014). Thus, this study was conducted to understand the mechanisms underlying the anti-
hyperglycemic potentials of some of these commonly used sugar alcohols, which includes 
maltitol, myo-inositol, sorbitol and erythritol. 
In order to achieve the set objectives, the afore-mentioned sugar alcohols were subjected 
to thorough ex vivo and in vivo investigations, examining their potency to exert glycemic control 
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via measuring their effects on intestinal glucose absorption or muscle glucose uptake. This is 
because intestinal absorption and muscle uptake of glucose are known therapeutic targets to 
ameliorate hyperglycemia in diabetics (Patel et al., 2012). 
 
Table 7.1: Summary of the ex vivo activities of tested sugar alcohols on the inhibition of 
intestinal glucose absorption and enhancement of muscle glucose uptake. 
Activity (% w/v) Sugar alcohols tested 
 Maltitol Myo-inositol Sorbitol Erythritol 
IC50 3.57 ± 1.18 28.30 ± 6.01 14.46 ± 4.60 55.90 ± 11.98 
GU50 with insulin 7.31 ± 2.08 2.68 ± 0.75 3.53 ± 1.61 2.02 ± 1.24 
GU50 without insulin 111.12 ± 19.36 8.61 ± 0.55 7.02 ± 0.46 6.91 ± 2.03 
Data are presented as mean ± SD of triplicate analysis. IC50: Concentration (% as w/v) of sugar alcohol required to 
cause 50% inhibition on intestinal glucose absorption.GU50: Concentration (% as w/v) of sugar alcohol required to 
cause 50% increase of muscle glucose uptake. 
 
Maltitol was the first and only disaccharide sugar alcohol under study, which exhibited 
the highest inhibitory activity on intestinal glucose absorption ex vivo, but did not show 
remarkable glucose uptake activity on isolated rat psoas muscle with or without insulin (Table 
7.1). In fact maltitol exhibited the least ex vivo muscle glucose uptake activity among all tested 
sugar alcohols (Table 7.1). These data suggest that maltitol may possess the potency to impair 
intestinal glucose absorption rather than enhancing muscle glucose uptake. In spite of this 
promising inhibitory activity of maltitol on intestinal glucose absorption ex vivo, bolus dose of 
maltitol (0.6 g/kg bw) did not affect intestinal glucose absorption or gastric emptying in both 
normal and diabetic animals (experiment 2). Accordingly, blood glucose level did not change 
significantly in both normal and diabetic animals after 1 h of a bolus maltitol feeding. Although 
these findings contradict our expectations, the poor intestinal glucose absorption inhibitory 
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activity of matitol under in vivo condition (experiment 2) compared to ex vivo condition 
(experiment 1) may be due to the disaccharide nature of this particular sugar alcohol. Due to its 
disaccharide nature, maltitol is hydrolysable by intestinal disaccharidases under in vivo condition 
(Kamoi 1975; Rennhard & Bianchine 1975; Lian-Loh et al., 1982), which may also affect its 
effects in vivo. These findings also seem to provide further explanations for the apparent 
discrepancy on the previously observed inhibitory effects of maltitol on alpha glucosidase and 
alpha amylase activities in vitro (Kang et al., 2014), which was not mimicked under in vivo 
experimental condition (Matsuo 2003). Based on the above discussions, it appears that maltitol 
may not be a useful dietary supplement to ameliorate hyperglycemia via reducing intestinal 
glucose absorption or enhancing muscle glucose uptake in either normal or diabetic condition. 
However, it may be useful for glycemic control compared to sucrose, due to its lower glycemic 
and caloric values. 
Myo-inositol, a six-carbon cyclic sugar alcohol was the second sugar alcohol under study. 
This sugar alcohol exhibited a notable inhibitory effect on intestinal glucose absorption under ex 
vivo condition (Table 7.1). The inhibitory activity of myo-inositol on intestinal glucose 
absorption was further confirmed in vivo (experiment 2), when dietary myo-inositol (1 g/kg bw) 
inhibited glucose absorption in the 1st qtr of the small intestine of normal and diabetic animals. 
This inhibitory activity of myo-inositol impaired postprandial blood glucose increase and was 
also comparable to that of acarbose, a known anti-diabetic drug. Myo-inositol also delayed 
gastric emptying in diabetic animals, which may also contribute to its inhibitory activity on 
intestinal glucose absorption (Salminen et al., 1984; Shafer et al., 1987). These data suggest that 
myo-inositol may be useful in the management of postprandial glycemia via inhibiting intestinal 
glucose absorption. On the other hand, the promising muscle glucose uptake effect of myo-
inositol observed in our ex-vivo study (experiment 1) (Table 7.1) again supports the 
involvement of myo-inositol in the improvement of glucose metabolism via insulin signaling 
(Dang et al., 2010; Santamaria et al., 2012), but still requires further investigations. Thus, dietary 
myo-inositol may be further investigated as an anti-hyperglycaemic supplement for diabetic 
foods and food products that may be useful in managing hyperglycemia possibly via inhibiting 
intestinal glucose absorption and enhancing muscle glucose uptake. 
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The next sugar alcohol under study was sorbitol, which also showed promising ex vivo 
inhibitory effect on intestinal glucose absorption that was even more remarkable than that of 
myo-inositol (Table 7.1). Although the inhibitory effect of sorbitol on intestinal glucose 
absorption has been previously hypothesized (WHO, 1987), our in vivo study (experiment 2) 
was able to confirm this hypothesis and also supports similar inhibitory activity of sorbitol 
observed in our ex vivo study (experiment 1). In fact, dietary sorbitol (0.4 g/kg bw) did not only 
inhibit glucose absorption in the first quarter of the small intestine of normal and diabetic 
animals, it also delayed gastric emptying and accelerated digesta transit, especially in diabetic 
animals, which possibly contributed to its inhibitory activity on intestinal glucose absorption 
(Salminen et al., 1984; Shafer et al., 1987). Like myo-inositol, the intestinal glucose absorption 
inhibitory effect of sorbitol was also comparable to acarbose, thus reducing posprandial glucose 
increase in diabetic animals. These data suggest that sorbitol may be useful in the management of 
postprandial hyperglycemia, especially in diabetics. On the other hand, our ex vivo study 
(experiment 1) is the first study to demonstrate the muscle glucose uptake potentials of sorbitol, 
which may be further investigated as a possible anti-hyperglycemic mode of action of sorbitol. 
At this point, it is important to note that although our in vivo absorption study 
(experiment 2) showed that a bolus dose of myo-inositol and sorbitol  impaired postprandial 
blood glucose increase in diabetic animals, it could not be confirmed from our study whether the 
inhibition of intestinal glucose absorption was solely responsible for this effect or not. It could be 
hypothesized that myo-inositol and sorbitol also influenced blood glucose increase by enhancing 
muscle glucose uptake as seen in our ex vivo study with both sugar alcohols. However, this 
hypothesis can only be confirmed following further in depth studies on both sugar alcohols, since 
our muscle glucose uptake study was limited to an ex vivo condition only, with respect to myo-
inositol and sorbitol. 
The last sugar alcohol under this study was erythritol, a four carbon sugar alcohol. This 
sugar alcohol is unique because it is the only sugar alcohol that is not metabolized in the body, 
thus has no glycemic and caloric effect (livesey, 2003). Although this sugar alcohol showed no 
significant inhibitory effect on intestinal glucose absorption ex vivo (experiment 1) (Table 7.1), 
it (1 g/kg bw erythritol) surprisingly inhibited (p < 0.05) glucose absorption in the 1st quarter of 
the small intestine and concomitantly delayed (p < 0.05) gastric emptying in both normal 
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diabetic animals (experiment 2). Considering the trend of these data (from ex vivo to in vivo), 
we can suggest that the delayed gastric emptying might be a major influencing factor for the 
intestinal glucose absorption inhibitory effect of erythritol in vivo (Salminenet al., 1984; Shafer 
et al., 1987). On the other hand our ex vivo study (experiment 1) also revealed that erythritol 
exhibited the highest muscle glucose uptake activity among all sugar alcohols tested with or 
without insulin (Table 7.1), which suggests that erythritol might improve muscle glucose uptake 
via improving some factors in insulin signaling pathway. In order to verify this, erythritol was 
subjected to an in vivo muscle glucose uptake study (experiment 3). Data from this study 
revealed that a bolus dose of erythritol appreciably improved glucose tolerance, insulin secretion, 
mRNA expression of muscle Glut-4 and IRS-1 as well as the activities of muscle and liver 
hexokinase, but suppressed the hepatic release of glucose in diabetic animals. These results 
support the data of our ex vivo glucose uptake study (experiment 1) on erythriol and also suggest 
the potency of erythritol to improve glucose tolerance and metabolism via improving insulin 
secretion and modulating insulin-mediated muscle glucose uptake, thus ameliorate 
hyperglycemia. Although the inhibitory (experiment 2) and glucose uptake (experiment 3) 
effects of erythritol were observed separately in two separate in vivo studies, we propose that this 
bi-functional anti-hyperglycemic potency of erythritol (inhibition of small intestinal glucose 
absorption and enhancement insulin-mediated muscle glucose uptake and metabolism) may work 
in concert to improve glucose tolerance and ameliorate hyperglycemia, especially in diabetic 
animals. Hence, erythritol may be a useful dietary supplement for managing hyperglycemia in 
diabetic individuals, especially type 2. 
 
7.2 General conclusions 
In summary, four sugar alcohols were investigated in this study. Three of these sugar alcohols 
(myo-inositol, sorbitol and erythritol) demonstrated remarkable inhibitory effects on intestinal 
glucose absorption in normal and diabetic rats and were also able to appreciably enhance muscle 
glucose uptake ex vivo (Fig. 7.1 and 7.2). Erythritol had the most potent muscle glucose uptake 
activity, which was further confirmed in vivo as a possible modulator of insulin-mediated muscle 
glucose uptake, especially in diabetics (Fig. 7.2). This study has identified possible mode of 
actions through which some commonly used sugar alcohols can exert anti-hyperglycemic effect 
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in diabetic conditions (Fig. 7.1 and 7.2). Thus, these sugar alcohols may be further investigated 
as potential anti-hyperglycemic supplements that may be useful not only as sweeteners but also 
in the management of diabetes, especially type 2. 
 
 
Figure 7.1: Schematic diagram showing the possible anti-hyperglycemic mechanisms of action 
of sorbitol, myo-inositol and maltitol. Sorbitol myo-inositol, and matitol inhibits intestinal 
glucose absorption and enhances insulin-mediated muscle glucose uptake ex vivo (1, 2 & 3). 
Sorbitol and myo-inositol reduced intestinal glucose absorption in vivo (4 & 5), which may 
partly be due to delaying gastric emptying (6) and accelerating degista transit (7). Maltitol did 
not significantly influence intestinal glucose absorption and gastric emptying in vivo (8), possible 




Figure 7.2: Schematic diagram showing the possible anti-hyperglycemic mechanisms of action 
of erythritol.  Erythritol inhibited intestinal glucose absorption (3), possibly via delaying gastric 
emptying (1 & 2). Erythritol also enhanced insulin-mediated glucose uptake (5), possibly via 
improving insulin secretion (4), mRNA expression of muscle Glut-4 (9) and IRS-1 (10) as well 
as the activities of muscle hexokinase (8) and liver glucokinase (6), while suppressing the 
hepatic glucose release or glucose-6 phosphatase activity (7). 
 
7.3 Recommendations 
We recommend that more resources should be channeled into thorough investigations on the 
potential usefulness of most of these sugar alcohols, specifically for their possible clinical 
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relevance in the management of diabetes, especially type 2. Considering the affordability and 
safety concerns of most synthetic anti-diabetic drugs, the use of sugar alcohol may be a safer 
option to improve the therapeutic value and effectiveness of already existing therapies for the 
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The present study investigated the anti-oxidative effects of xylitol both in vitro and in vivo in 
normal and type 2 diabetes (T2D) rat model. Free radical scavenging and ferric reducing 
potentials of different concentrations of xylitol were investigatedin vitro. For in vivo study, six 
weeks old male Sprague-Dawley rats were divided into four groups, namely: Normal Control 
(NC), Diabetic Control (DBC), Normal Xylitol (NXYL) and Diabetic Xylitol (DXYL).  T2D 
was induced in the DBC and DXYL groups. After the confirmation of diabetes, a 10% xylitol 
solution was supplied instead of drinking water to NXYL and DXYL, while normal drinking 
water was supplied NC and DBC ad libitum. After five weeks intervention period, the animals 
were sacrificed and thiobarbituric acid reactive substances (TBARS) and reduced glutathione 
(GSH) concentrations as well as superoxide dismutase, catalase glutathione reductase and 
glutathione peroxidase activities were determined in the liver, heart, kidney, pancreatic tissues 
and serum samples. Xylitol exhibited significant (p<0.05) in vitro nitric oxide and hydroxyl 
radical scavenging and ferric reducing activities. In vivo study revealed significant (p<0.05) 
reduction in TBARS concentrations in the xylitol consuming groups compared to their respective 
controls. Significant (p<0.05) increase in GSH levels and antioxidant enzyme activities were 
observed in analyzed tissues and serum of xylitol-fed animals compared to their respective 
controls. Results of this study indicate that xylitol has strong anti-oxidative potential against 
T2D-associated oxidative stress. Hence, xylitol can be used as a potential supplement in diabetic 
foods and food products. 
 









SUPPLEMENTARY DATA OF THIS THESIS 
 
Supplementary data 1: Screen shots images showing the in slico determination of primer 






Supplementary data2: Screen shots images showing the in slico determination of primer 






Supplementary data3: Screen shots images showing the in slico determination of primer 









Supplementary data 4: Standard curve for determining qPCR efficiencies of the reference gene 
(β-Actin) and genes of interest (Glut-4 and IRS-1). Mean Cq values of technical replicate (mean 
±SD; n=2) was plotted against the log of the corresponding cDNA input (ng) and the 




































Log of cDNA  input (ng) 
β-Actin (Slope = -3.480;     R^2 = 0.989;     E = 1.94;     %E = 93.8%)
Glut-4 (Slope = -3.396;     R^2 = 0.995;     E = 1.97;     %E = 97.0%)




(a)                                                  (b) 
 
                                              
      (c) 
Supplementary data 5: qPCR melt curves of the different cDNA samples for (a) β-Actin, (b) 






Supplementary data 6: qPCR products of target genes (β-Actin, Glut-4 and IRS-1) subjected to 
a 2% agarose gel electrophoresis and product sizes estimated with a 1 kb plus ladder. NC, normal 
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